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ABSTRACT
Kainic acid has been used widely as an effective model of excitotoxic 
neurodegeneration. Using both the intraperitoneal and intrahippocampal routes of 
injection, we have shown that kainate selectively damages discrete populations of 
cells in the hippocampus. Following intraperitoneal administration, the A2A agonists 
2-p-(2-carboxyethyl)phenethylamino-5 ’-A-ethylcarboxamidoadenosine hydrochloride 
(CGS 21680) and A/6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine 
(DPMA), protected against kainate-induced cell death. Protection by CGS 21680 
was slightly moderated by the Ai receptor antagonist 8-cyclopentyl-l,3- 
dipropylxanthine (CPX), but substantially reduced by the addition of the peripherally 
acting adenosine antagonist 8-(p-sulphophenyltheophylline) (8-PST). The 
administration o f a selective A2A antagonist 4-(2-[7-amino-2-{2-furyl} {l,2,4}triazolo 
{2,3-a}{l,3,5}triazin-5-yl-amino]ethyl)phenol (ZM 241385) also protected the 
hippocampus against kainate toxicity. This protection was reversed when ZM 
241385 was co-administered with CPX.
After intrahippocampal injections of kainate, neither CGS 21680, R- 
phenylisopropyladenosine (R-PIA) nor adenosine were protective in the CA3a region 
of the hippocmpus. ZM 241385 decreased kainate-induced neuronal death, as did the 
addition of the NMD A receptor antagonist, (+)-5-methyl-10,11 -dihydro-5 H-dibenzo- 
[a,d]-cycloheptene-5,10-imine maleate (MK-801).
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Abstract
Combined results from both intrahippocampal and intraperitoneal studies, suggested 
that protection by the A2A agonist was mediated mostly from the periphery and not 
from receptors localised within the hippocampus. Evidence also suggested that 
stimulation of A2A receptors resulted in an inhibition of the A\ subtype. Importantly, 
this study questioned the previous assumption that adenosine, released endogenously 
during cerebral insults, mediates protection.
The nitric oxide synthesis inhibitors AG-nitro-L-arginine methyl ester (L-NAME) and 
7-nitroindazole (7-NI), also protected against intraperitoneally administered kainate. 
This suggested that inhibition of neuronally (and not endothelially) produced nitric 
oxide was beneficial.
Studies using the TdT-mediated dUTP-biotin nick end labelling (TUNEL) method 
for identifying apoptotic cells showed that following intraperitoneal kainate 
administration, apoptosis was localised to the CA1 region of the hippocampus. 
Expression of the brain-derived neurotrophic factor (BDNF) protein was 
investigated, and a possible link between the mechanism of cell death and the 
inflammatory response also examined.
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INTRODUCTION
EXCITO TO XICITY AND ISCHAEM IA
Brain damage can be observed in patients suffering from head trauma, certain types 
of epilepsy, cerebral infarcts (such as stroke) and in infants as a consequence of a 
hypoxic birth. Due to its prevalence in society, it is crucial to understand further the 
basic mechanisms in order to design more effective therapies to eliminate or reduce 
the damage associated with these conditions. A confusingly large number of both in 
vivo and in vitro models for cerebral ischaemia and excitotoxicity have been devised 
over the years. The models include the direct injection in live animals of compounds 
designed to induce excitotoxicity and ischaemia, the occlusion of specific blood 
vessels using an array of mechanical and chemical procedures and a number of 
models utilising cultured cells.
While none of the models mentioned above, nor the different assortment of cerebral 
insults are identical, there is a large proportion of common ground. Excitotoxic and 
ischaemic insults follow a similar physiological pathway, but have different points of 
origin. For ischaemia, the event at the peak of the cascade is a decrease in cerebral 
blood pressure below a critical threshold (Siesjo, 1992a). The reduction in blood- 
borne adenosine triphosphate (ATP) results in the breakdown of energy-dependent 
ion transport across neuronal membranes within the compromised brain (Siesjo, 
1992a). Due to the number and variety of ATP-dependent ion channels situated 
within the plasma membrane of neurones, any large fluctuation from the normal 
homeostatic ATP levels would result in alterations in ion flow and subsequent
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elec trochem ica l gradients. T he  loss o f  K h from the cell and the C a 1' influx
(N icho lson  et. a l ., 1977), coup led  with distorted  N a + and C l '  hom eos tas is  (I lo ssm ann  
ct. a l., 1977; Hansen, 1985; H ansen  & Zeuthen, 1981), leads to the generalised 
co llapse  o f  the ce llu lar m em b ran e ,  tissue acidosis  (N ords trom  et. a l. , 1978; Siesjo,
1985; C harlton  et. a l., 1993) and neuronal depolarisa tion . T he  influx o f  N a f and Cl" 
induces the cell to take up w ate r  via o sm osis  (N icholson  et. a l ., 1977), causing cell 
sw elling  and osm oly tic  dam age.
In ischaem ia, the depo lar isa tion  o f  the presynaptic  cell fo llow ing  calc ium  influx leads 
to the release o f  large am o u n ts  o f  the excita tory  am ino  acid  (B A A ) transm itters  
g lu tam ate  and  aspartate  (B enven is te  et. a l . , 1984), v ia  the reversal o f  the sodium - 
dependen t  transport  system  (R oettger & Lipton, 1996). In ep ilepsy  this release o f  
BAA transm itte rs  is triggered by a spontaneous, not insult  induced , depolar isa tion  o f  
neurones. O nce  released into the synaptic cleft, g lu tam ate  either b inds to and 
activates specific receptors, or is rapidly rem oved  by neuronal and glial uptake 
systems. Both the ionotropic  kainic acid and a -am in o -3 -hydroxy l-5 -m e thy l-  
isoxazo le -4 -prop ion ic  acid (A M P A ) subtypes o f  g lu tam ate  receptors  are initially 
activated by g lu tam ate, increasing  the influx o f  sod ium  (and to a lesser degree 
ca lc ium ) into the cell. T h is  postsynaptic  m em brane  depo lar isa tion  alters the 
d irection  o f  ionic flow, a llow ing  the m ag n es iu m  block o f  the TV-methyl-D-aspartate 
(N M D A ) type o f  g lu tam ate  receptor to be reversed (M ayer  et. <7 / . ,  1984; N ow ak  et. 
a l., 1984). S ubsequen t N M D A  receptor ac tivation  results in further ca lc ium  entry 
into the cell w hich, co m b in ed  with calc ium  release from in tracellu lar stores and 
d isrupted  ex trusion, leads to cell death (Choi, 1988a; Choi, 1988b; Siesjo, 1988).
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CALCIUM -ASSOCIATED CELL DEATH  
Introduction
Calcium-associated delayed cell death occurs through a number of mechanisms and 
is most likely a result of a combination of factors rather than a single event. Protease 
activation by calcium may be of significant importance as actions of the proteases 
include severing the anchoring connection between the plasma membrane and the 
cytoskeleton as well as breaking down components of the cytoskeleton itself (Choi, 
1988a; Cafe et. al., 1993). This would further disrupt the integrity of the membrane 
and ion flow across it, hastening cell death. Inhibition of the calcium-activated 
protease calpain protects against vascular occlusion-associated brain damage (Bartus 
et. al., 1994).
Energy failure, the rise in free intracellular calcium coupled with receptor 
stimulation, results in increased activity of phospholipase A2 (Kontos et. al., 1980), 
phospholipase C (Lynch & Bliss, 1986) and protein kinase (Conor et. al., 1988). 
Phospholipase Ai (PLA2) hydrolyses phospholipids to lysophospholipids and free 
fatty acids, including arachidonic acid (AA), while phospholipase C (PLC) initiates 
the inositol pathway (and further release of calcium from intracellular stores) and 
also leads to the production of AA and other free fatty acids (Bruno et. al., 1993).
Arachidonic Acid
While AA mediates actions of its own (e.g. leakage of molecules across the blood 
brain barrier; Unterberg et. al., 1987), its metabolism to prostaglandins (PGs),
5
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leukotrienes (LTs) and thromboxanes (TXs), leads to the formation of highly reactive 
free radicals. However, when the production of free radicals from this pathway was 
prevented using aspirin (which inhibits cyclooxygenase, preventing PG and LT 
formation) or BW 775C (a lipoxygenase inhibitor which blocks LT production), no 
significant protection was observed in high density cortical neurone cultures from 
kainate induced cytotoxicity (Cheng & Sun, 1994). This does not rule out the 
importance of the AA pathway in excitotoxicity. The enzyme prostacyclin synthase 
is inhibited by free radicals in vivo, which in turn results in an overactivation of the 
alternate enzyme in the AA cascade, thromboxane synthase (Siesjo, 1992b). This 
could exacerbate brain damage through TX-mediated effects on vasoconstriction and 
platelet aggregation. This effect on blood vessels would not occur within in vitro 
systems and may explain why no effect was noted with aspirin in culture (Cheng & 
Sun, 1994). In agreement with this suggestion of a TX-mediated increase in 
neuronal death, cyclooxygenase inhibitors have been shown to decrease damage in 
the hippocampus of gerbils in vivo (Nakagomi et. al., 1989).
O'Regan et. al. (1995), suggested that the cleavage of membrane phospholipids by 
PLA:, to form arachidonic acid, could alter membrane integrity allowing for the 
diffusion of charged molecules (including calcium and the excitotoxic amino acids) 
along their respective concentration gradients, increasing associated damage. Aside 
from the free radical-related detrimental effects another action of AA is the inhibition 
of glutamate uptake by neurones (Yu et. al., 1987). Due to most of the uptake of 
glutamate being the responsibility of glial cells, this inhibition of the neuronal uptake 
system may not represent a major route of toxicity. AA also inhibits the production
6
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of ATP from the mitochondrial respiratory chain (Takeuchi et. a l,  1991), further 
exacerbating cellular stress.
Alteration in M itochondrial Function
The mitochondrial respiratory complex, essential for ATP production by oxidative 
phosphorylation, consists of proteins transcribed from both nuclear and 
mitochondrial DNA (mtDNA). The ability of the mitochondria to take up calcium 
renders the structure vulnerable during occasions of high intracellular calcium 
concentrations (e.g. during excitotoxicity or ischaemia). Alterations in mitochondrial 
membrane potential and subsequent disruption to the intramitochondrial electron 
chain by increased levels of calcium, results in the formation and release of free 
radicals (Piantadosi et. al., 1996; Park et. a l, 1996). These radicals may themselves 
cause point mutations within the mitochondrial DNA, impairing respiration further 
and increasing the formation of reactive oxygen species (Attardi, 1981). This process 
is made more likely by mitochondrial susceptibility to DNA damage coupled with 
limited repair mechanisms (Brandy & Davidson, 1990). In keeping with this theory, 
the CA1 region of the hippocampus (an area known to be sensitive to glutamate 
toxicity), shows a selective decrease in mtDNA expression during certain 
experimental ischaemia models. Levels of mRNA and activity of cyclooxygenase-I 
(COX-I; one of the mitochondrial DNA encoded protein subunits forming part of the 
electron transport system) and motor proteins such as microtubule-associated protein 
lc (MAPlc) and kinesin (responsible for converting energy from ATP hydrolysis to 
mechanical work and moving organelles such as mitochondria along microtubules),
7
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are all shown to be sensitive to ischaemia (Abe et. a l, 1993). Indeed, it has been 
shown that during glutamate toxicity, the ability to restore mitochondrial membrane 
potential is crucial in determining the final outcome of a cell (necrosis or apoptosis - 
see later; Ankarcrona, 1995). The time for protein synthesis to show disruptive 
effects (provided the initial calcium overload does not kill the cell) may, in part, 
explain the phenomenon of delayed cell death. Another factor contributing to the 
susceptibility of mitochondria to cerebral insults may be the direct inhibitory action 
of arachidonic acid on ATP production mentioned earlier (Takeuchi et. a l, 1991).
FREE RADICALS AND M ECHANISM S OF TOXICITY  
Origins of Free Radical M olecules
The case for the involvement of free radicals in both excitotoxic and ischaemic 
neuronal damage has increased in recent years (Kogure et. a l,  1985; Bondy & Lee, 
1993; Coyle & Puttfarken, 1993). Free radicals are molecules or atoms containing a 
single unpaired electron. This electron generally confers an extremely high chemical 
reactivity onto the molecule, leading to very rapid reactions with neighbouring 
substances and therefore a short half life. Although free radicals are produced 
naturally within cells by a number of different mechanisms, a large increase in 
reactive oxygen species has been noted in the brain shortly after cerebral insult 
(Bondy & Lee, 1993; Keidrowski et. a l, 1992; Sun et. a l, 1992). These free radicals 
most probably arise during cerebral insults from a multitude of sources. Arachidonic 
acid liberated by calcium-activated PLA2 leads to the production of lipid 
hydroperoxidases and oxygen radicals (although as stated above, this pathway may
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be only of limited importance). Another possible supply of radicals is xanthine 
oxidase (XO). Under normal conditions xanthines are oxidised by a dehydrogenase 
enzyme that transfers electrons to the nicotinamide adenine dinucleotide cation 
(NAD+). Tissue disruption and calcium influx can convert xanthine dehydrogenase 
into the oxidase form. This uses oxygen as an electron acceptor, liberating superoxide 
radicals upon both the conversion of hypoxanthine to xanthine and xanthine to uric 
acid (Halliwell & Gutteridge, 1989; Coyle & Puttfarcken, 1993, Atlante et. al 
1997). Superoxide radicals could also be formed by the co-oxidation of xanthine 
oxidase with arachidonic acid (Fridovich & Porter, 1981). The role of xanthine 
oxidase is once again controversial with some reports showing protective effects of 
calpain inhibitor I (inhibits calpain-induced xanthine oxidase production) and 
allopurinol (Cheng & Sun, 1994), while Betz et. al. (1991), showed that a protective 
effect was only observed at a dose where allopurinol was acting as a free radical 
scavenger.
As stated above, disruption to mitochondria may also result in the release of a large 
concentration of free radicals.
Nitric oxide (NO), which is released naturally under normal conditions and in higher
concentrations during ischaemia, reacts rapidly with superoxide radicals (*0 2 -) to
form the peroxynitrite anion (ONOO") which decomposes to the hydroxyl radical 
(•OH) (Beckman et. a l,  1990). This pathway may be a major source of damaging 
free radicals produced during excitotoxicity and ischaemia as a number of studies 
have shown that prevention of NO formation is protective in experimental models 
(see page 16).
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Neither the superoxide radical nor hydrogen peroxidase (H2O2) are reactive enough to 
generate any significant degree of damage (and certainly not that amount associated 
with ischaemia), but can by way of the Haber-Weiss and Fenton reactions be 
converted to the highly reactive *OH radical (see reactions below).
2*02“ + 2H+  ► H2O2 + O2
•02“ + Mn+  ► + O2
•O2- + H2O2  ► O2 + -OH + OH"
H2O2 +  ► Mn+ + -OH + OH"
Where M is usually the transition metal iron or copper.
The resultant hydroxyl radical formed by the above reactions results in oxidative 
stress, which is a shift in the pro-oxidant/anti-oxidant balance towards the pro­
oxidant state. This can result in severe metabolic dysfunction including peroxidation 
of lipid membranes, depletion in nicotidamide nucleotides, rises in intracellular 
calcium, cytoskeleton disruption and DNA strand breakage (Halliwell & Chirico, 
1993).
Free Radical-Associated Damage 
L ip id  p e r o x id a t io n
Biological material contains a wide variety of unsaturated lipid material, particularly 
in the form of membranes. The unpaired electron of the free radicals reacts with and 
removes a hydrogen atom from an unsaturated carbon within these unsaturated fatty
10
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acid chains (Gutteridge & Halliwell, 1990). The removal of hydrogen leaves the 
resultant carbon chain as a free radical able to bind molecular oxygen to form a lipid 
peroxide radical. This peroxy radical will then form a hydroperoxide by abstracting a 
hydrogen from another unsaturated fatty acid, continuing the chain reaction of events 
(Gutteridge & Halliwell, 1990).
This process of lipid peroxidation, which has been shown to occur in excitotoxicity 
(Ueda et. al., 1997) and ischaemia (Hall et. al., 1993), can lead to extensive damage 
to the finely organised structure of biological membranes that are rich in unsaturated 
carbon bonds (e.g. the cellular and the mitochondrial membrane; Watson, 1993). 
This in turn can cause a loss in the specialised function of the membrane.
D e s t r u c t i o n  o f  t h io l s
Thiol groups are found throughout the cell including within enzymes responsible for 
removing free radicals (free radical scavengers). Many important cellular proteins 
and enzymes (e.g. the structural protein actin or ATPase enzymes involved in the 
transport of calcium in mitochondria) also depend on thiol groups for functional 
activity. The oxidation of these thiol enzymes by free radicals can lead to drastic 
changes in their activity, resulting in effects such as alteration of cellular membrane 
structure or perturbation of cellular calcium homeostasis (Comporti et. al., 1991). It 
is probable that this modification of a large number of diverse molecules within the 
cell may be the initial event that ultimately leads to free radical-associated cell 
necrosis.
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Relevance of Free Radicals in Cerebral Insults
C oupled  w ith  the above ev idence that exc ito toxicity  and ischaem ia result in the 
produc tion  o f  large am oun ts  o f  reactive m olecules, the brain itse lf  appears to be at 
particu lar risk from  free radical dam age. Peroxid izable  po lyunsaturated  fatty acids 
are a m ajo r  consti tuen t o f  brain cell m em branes. In addition iron, which prom otes  
cy to toxic  radical form ation, is found in relatively high concentra tions  in certain brain 
regions (F loyd  &  Carney, 1992), a lthough m ostly  in bound form (Cafe et. a l., 1993). 
System ic  cells  are subjected  constantly  to free radicals from both extracellu lar 
sources  as well as from  intracellular m etabolism , requiring  the evolution o f  num erous 
defence sys tem s (C oyle & Puttfarcken, 1993). T hese  defences  include antioxidant 
enzym es (such  as superox ide  d isn iu tase  (SO D ) and glu ta th ione peroxidase),  low 
m olecu la r  m ass  an tiox idants  (e.g. a - to co p h ero l  and ascorb ic  acid) and proteins which 
bind transition  m etals  in a form that disables them  from  partak ing  in free radical 
reactions (C oyle  &  Puttfarcken, 1993). Free radical toxicity to the cell only occurs 
w hen  these m ech an ism s  are overloaded. In the brain, levels o f  these co m p o u n d s  are 
relatively low  and therefore easily saturated. This  defic iency in protective 
m ech an ism s  and high relative concentra tion  o f  iron, m ay m ake brain cells much 
m ore suscep tib le  to d am ag e  by free radicals.
Free radicals  appear  to play a significant part in exc ito tox ic /ischaem ic  brain dam age, 
as show n by the large num ber o f  studies using free radical scavengers which 
dem onstra te  at least a partial protective effect (e.g. B runo et. al. 1994; M acG regor et. 
al., 1996b; O 'N eill  et. a l ., 1994; Saija et. a l., 1994; T rue love  et. a l.. 1994; Zhao  et. 
al.. 1994). T h e ir  exact role and im portance (w he ther free radical formation is the
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d e te rm in an t  in d ictating  the fate o f  the cell, or just a com ponen t  o f  a com plex  which 
over loads  the cell on a num ber o f  d ifferent fronts) has still to be resolved.
REACTIVE GLIOSIS
G liosis  occu rs  under cond itions  o f  insult within the central nervous system (CN S). 
w here  cells o f  the im m une  system  (e.g. m icroglia), as well as astrocytes and 
fibroblasts ,  undergo  m orphological  changes and p roduce  m olecules  such as laminin 
(I.icsi et. a l., 1983), m icro tubu le  associa ted  protein 2 (M A P 2; Gciscrt et. a l ., 1990), 
basic fibroblast g row th  factor (bFG F; Frautschy et. a l., 1991), transfo rm ing  growth 
factor-fR ( T G F - p l ;  M organ  et. a l., 1993) and p-am ylo id  precursor protein (API*: 
K aw arabayash i et. a l., 1991). T he gliotic response  varies depend ing  on the insult. 
For ex am p le  isom orph ic  gliosis, caused  by neuro toxic  agents  w here  no dam age 
occurs  to the b lood  brain barrier, is considered  to be distinct from the anisom orphic  
g liotic response  w here  there is d isruption. After in traventricular injections o f  A M P A  
or kainate  a gliotic response  was observed  in selective regions o f  the h ippocam pus  
shortly  after the exc ito toxic  insult (A raujo  & W andosell ,  1996).
Due to the rapid inflam m atory  response to certain  cerebral insults (e.g. M orioka et. 
a l . 1991), it has been suggested that while  degenera tion  o f  neurones may not be the 
signal w hich initially triggers the gliotic response, a lthough neurodcgcneration  may 
be involved in shap ing  the specific response by release o f  m olecules  (e.g. p roducts  o f  
ce llu lar  b reakdow n) after glial ac tivation (Jorgensen  et. a l . , 1993). In exc ito toxicity / 
ischaem ia  the h ighest concentration  o f  reactive astrocytes was observed  in the 
dam ag e-sen s i t iv e  CA1 and C A 3-4  regions o f  the h ip p o cam p u s  (A raujo  & W andosell,
13
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1996), while microglia were more diffuse and generalised (Marty et. al., 1991). In 
the first two weeks after central kainate injection, microglia and macrophages appear 
predominant but, with their decline in number, astrocytes, which remain for a period 
of months, become the dominant cell type (Dusart et. al., 1991; Marty et. al., 1991).
The inflammatory response consists of a number of different cell types. Neutrophils, 
which undergo a complex interaction with the endothelial layer of blood vessels, 
migrate from the circulation. Macrophage, monocytes and mast cells also form part 
t of the interconnecting cascade. Mast cells, via the release of histamine, encourage 
the binding of neutrophils to the endothelium (by releasing P-selectin). Activated 
macrophages and monocytes secrete cytokines which in turn induce the further 
release of P-selectin, as well as priming neutrophils (see Cronstein, 1994).
As well as this release of cytokines, the inflammatory response produces toxic 
molecules to assimilate cells. While these compounds include enzymes (such as 
collagenase), it is the generation of toxic oxygen metabolites (e.g. superoxide radicals 
and H2O2) that may be of more importance in increasing local neuronal toxicity. 
While these latter molecules are produced within vacuoles, there is a degree of 
leakage into the extracellular space.
Due to the variety of molecules produced by the inflammatory response the benefits 
versus detriment of reactive gliosis have yet to be determined. The release of bFGF 
and TGF-p by activated microglia is believed to be protective and important in 
promoting tissue repair (Rothwell & Relton, 1993; Mattson & Rychlik, 1990). 
Overproduction of cytokines (e.g. interleukine) may be more harmful (Relton & 
Rothwell, 1992), by increasing the production and secretion of molecules such as
14
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arachidonic acid and nitric oxide from microglia (Hartung et. al., 1992). Astroglial 
transport systems are the main source of glutamate removal from the synaptic cleft 
(Hertz & Schousboe, 1980) and inhibition of these transporters results in pathology 
similar to that of excitotoxicity (Rothstein et. al., 1996). Conversely, the removal by 
astrocytes of y-aminobutyric acid (GABA) from the synaptic cleft (Yu & Hertz, 
1982) could be detrimental by increasing the possibility of epileptic seizures 
(Ravindran et. al., 1994). Glutamate depolarises glial cells directly, by activation of 
non-NMDA receptors (Muller et. al., 1992), initiating a calcium wave which passes 
along an astrocytic network, implicating a more complicated role for astrocytes 
within the neuronal network (e.g. modulation of neuronal activity; Smith, 1992). 
More importantly the influx of calcium can itself result in the release of glutamate 
from astrocytes (Parpura et. al., 1994). The complete role of astrocytes within 
neurological pathophysiology has yet to be fully elucidated and may be much more 
significant during cerebral insults than was previously assumed.
APOPTOSIS
There is accumulating evidence that while necrosis plays a large and important part 
of excitotoxic cell death, apoptosis may also account for a proportion of neuronal 
death (Choi 1996; Chopp, 1996; Weiss et. al., 1996; Honkaniemi et. al., 1996). 
Apoptosis is an active process, characterised by cell shrinkage, organelle 
relocalisation and compaction, chromatin condensation and formation of apoptotic 
bodies (Kerr, 1971; Majno & Joris, 1995). The co-existence of necrosis with 
apoptosis (Choi, 1996) can make the determination of the predominant mechanism of
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cell death difficult. Further complication arises from the observation that even 
during apoptosis, secondary necrosis can occur. This would most likely only arise on 
occasions where a large population of cells undergoes apoptosis, overloading the 
phagocytic removal system. DNA fragmentation, a diagnostic feature of apoptosis 
(although controversially not always apparent; Ankarcrona et. al., 1995), has been 
observed in a number of ischaemic models (Filipkowski et. al., 1994; Hill et. a l, 
1995; Li et. al., 1995; Pollard et. al., 1994). Glutamate or glutamate analogue 
exposure to neuronal culture systems has been shown to alter the expression of 
immediate-early genes such as c-fos (Kasof et. al., 1995, Lerea et. al., 1992), 
believed to be a reliable marker for apoptosis (Smeyne et. al., 1993), and induces 
both rapid necrosis and delayed-onset apoptosis (Ankarcrona et. al., 1995). Death by 
necrosis or apoptosis was correlated to mitochondrial function. A large number of 
cells died early after glutamate application, via necrosis. In contrast, Ankarcrona et. 
al. (1995), showed that cells which underwent and subsequently recovered from the 
initial mitochondrial dysfunction died from an apoptotic mechanism.
NITRIC OXIDE
Nitric oxide is a simple gas that has recently been shown to have an important role 
within human physiology and pharmacology in such diverse functions as 
vasodilatation (as the endothelial derived releasing factor or EDRF, NO increases 
arterial diameter; (Moncada et. al., 1991a), platelet aggregation, neurotransmission 
and cytotoxicity (Dawson, 1994; Dawson & Snyder, 1994)). These effects are either 
mediated directly by NO itself, or indirectly via soluble guanylate cyclase activation
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leading to an elevation of cyclic guanosine monophosphate (cGMP) levels (Moncada 
et. al., 1991a).
The conversion of L-arginine to L-citrulline by nitric oxide synthase (NOS) enzymes 
results in the generation of NO. The conversion is an oxidative-reductive process, 
requiring nicotidamide adenine dinucleotide phosphate (NADPH), oxygen, calcium 
and calmodulin (Bredt & Snyder, 1994).
Three discrete forms of NOS have been identified: Type I, II, III (Xie et. al., 1992; 
Bredt et. al., 1991). Type I (neuronal or nNOS) and type III (epithelial or eNOS) are 
constitutive enzymes and calcium-calmodulin dependent. Inducible NOS, type II, 
does not require calcium after it’s initial expression. Although hippocampal cells 
show limited immunostaining to nNOS, there is a larger amount of reactivity to 
eNOS, especially within the CA1 neurones (Dawson & Dawson, 1995). .
Nitric oxide has been targeted as a possible mediator of glutamate-induced 
neurotoxicity due to both an increase in NO levels after ischaemia (Balcioglu & 
Mather, 1993; Miilsch et. al., 1994) and excitotoxicity (Faraci et. al., 1994), and an 
apparent upregulation of nNOS and nNOS mRNA during ischaemia (Zhang et. al., 
1994b). The excitotoxic/ischaemic-associated calcium influx activates both 
constitutive forms of NOS, elevating the levels of NO.
Nitric oxide has a number of actions relevant to excitotoxic/ischaemic insults which 
may be beneficial or detrimental to the neuronal population. Nitric oxide can 
decrease cellular calcium influx by inhibiting the opening of the NMDA-associated 
calcium channel (Manzoni et. al., 1992), or increase the availability of EAAs by 
stimulating the release of both glutamate and aspartate and inhibiting glutamate
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uptake (Lawrence & Jarrett, 1993; Pogun & Kahur, 1993). Nitric oxide has also been 
shown to facilitate a feedback loop by interacting with the haem moiety of NOS 
(Moncada et. al., 1991a). Apart from toxic free radical actions of NO mentioned 
earlier, Dawson & Dawson (1995) speculated that NO may also inhibit the 
ribonucleotide reductase enzyme and thereby DNA synthesis, due to it’s ability to 
bind to certain non-haem iron complexes. Nitric oxide has further effects on iron 
metabolism release (e.g. activation of iron regulatory factor; Drapier et. al., 1994), 
which may be significant in the formation of free radicals via the Fenton reaction.
Nitric oxide activated cGMP exerts a number of effects on calcium levels, by acting 
on a variety of receptors. cGMP itself inhibits L-type calcium channels, via cGMP- 
dependent protein kinases or by cGMP stimulated cyclic adenosine monophosphate- 
(cAMP-) phosphodiesterases. Alterations in Ca2+/Mg2+-dependent ATPase activity 
by cGMP also affect calcium flux across the cellular membrane and from 
intracellular stores (see Milbourne & Bygrave, 1995).
A further possible indirect route by which NO may cause damage is by the depletion 
of the toxic molecule scavenger glutathione, through the formation of intracellular S- 
nitrosoglutathione (Clancy et. al., 1994), although Wink et al. (1993) reported that 
NO itself is a free radical scavenger. NO has been shown to result in increased 
release of dopamine within the global temporary cerebral ischaemia model (Kahn et. 
al., 1995). Dopamine itself has been shown to be toxic to neuronal populations 
(Filloux & Townsend, 1993).
The evidence for the role of NO in the glutamate neurotoxicity cascade is strong 
since it has been shown that NOS inhibitors such as A^-nitro-L-arginine (L-NA), NG-
18
Introduction
monomethyl-L-arginine (L-NMMA), vVG-nitro-L-arginine methyl ester (L-NAME) 
inhibited and sodium nitroprusside (SNP-a nitric oxide donor) mimicked the damage 
in cortical hippocampal or striatal cell cultures (Corasaniti et. al., 1992; Tryiletti, 
1992; Dawson et. al., 1993; Dawson & Snyder, 1994; Dalkara et. al., 1994; Kolleger 
et. al., 1993). SNP has also been shown to posses anti-convulsant effects mediated 
through NO, while L-NA prolonged seizure duration (Dawson et. al., 1991; 
Marangoz et. al., 1994). Many other experiments that reduce the action of NO by 
various methods (e.g. by preventing its formation, or inhibiting its activity) have also 
resulted in attenuation of NMD A neurotoxicity (see Dawson, 1994). However, in 
contrast, other investigators have found no benefit with the addition of inhibitors 
(Pauwels & Leysen, 1992), and no detrimental effects of NO donors (Garthwaite & 
Garthwaite, 1994). Some have found opposite effects (Zhang & Iadecola, 1993; 
Shapira et. al., 1994), with NO inhibitors increasing neuronal damage. NO itself has 
been shown to be a pro- or anti-convulsant dependent on the dose of the NOS 
inhibitor.
The above evidence lead to the speculation that low doses of NOS inhibitor are 
neuroprotective, whereas high doses are ineffective or detrimental, implying that 
partial inhibition of NOS is sufficient to achieve the optimal effect. The higher dose 
could adversely affect the feed-back loop or prevent the beneficial vascular effect of 
nitric oxide on increasing cerebral blood flow. This leads to further speculation that 
NO production in the brain may be a defence response to decrease EAA toxicity in 
ischaemia.
The discrepancy in results could also be explained by the existence of two forms of 
NO (Lipton et. a l, 1993; Dawson, 1994). The nitrosonium ion (NO+) is
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neuroprotective by nitrosylating the NMDA receptor modulatory site, while the free
radical form (NO*) interacts with superoxide forming the peroxynitrite ion (ONOCT), 
which is neurotoxic (Lipton et. al., 1993; Dawson & Dawson, 1995). Differences in 
results may therefore arise from altered respective concentrations of each form (e.g. 
this may occur in vitro following the addition of the reducing agent cysteine which 
promotes NO’ formation; Dawson, 1994).
7-nitroindazole (7-NI), which is capable of penetrating the blood brain barrier, has 
been proposed as a potent and competitive selective inhibitor of the neuronal NOS 
isoform in vivo (Babbedge et. al., 1993). Dalkara et. al. (1994) showed a decrease in 
infarct size in focal cerebral ischaemia after systemic injection of 7-NI. This, 
together with evidence that 7-NI attenuated seizure activity and decreased NO 
formation in vivo after kainate injection (Miilsch et. al., 1994), indicates a possible 
role for neuronal NOS in ischaemic injury which is masked when using the non- 
selective inhibitors. 7-NI could, therefore, inhibit the toxic release of NO by the 
neuronal isoform of NOS, while still preserving the beneficial vasodilatory effects of 
the endothelial released NO, and has indeed been shown to be protective in global 
cerebral ischaemia (O’Neill et. al., 1996).
THE HIPPOCAM PUS
The frequent use of the hippocampus as an area of observation is due not only to the 
specific damage associated with a number of conditions (e.g. excitotoxicity, 
ischaemia, epilepsy and schizophrenia), its involvement in normal brain function 
(e.g. long-term potentiation; Bliss & Collingridge, 1993), but also as the
20
Introduction
hippocampus is regarded as a source of a relatively homogeneous neuronal 
population (pyramidal neurones are prevalent at 80-95 %) which is representative of 
the CNS in general (Banker and Goslin, 1991). The pyramidal cell layer also has the 
advantage of being a well defined structure that is clearly visible under a light 
microscope. The hippocampus is known to contain populations of all of the 
glutamate receptor types (Monaghan et. al., 1983), as well as other groups of 
receptors thought to be important during cerebral insults, such as those of the 
adenosine subfamily.
The hippocampus is an arched structure of the brain which displays a large 
proportion of structural homology between rats, mice, gerbils and humans. The 
structure itself consists of the dentate gyrus, cornu ammonis and subiculum, and is 
divided into a number of layers. From the dorsal position the layers run in the order 
of the ependyma, alveus, stratum oriens, stratum pyramidale, stratum radiatum, 
stratum lacunosum-moleculare (Cajal, 1911). Three cell types constitute the majority 
of the hippocampus. The cornu ammonis (CA) contains bipolar pyramidal cells with 
'bushy’ dendrites protruding both top and bottom. The cells form a prominent, 
clearly visible layer of a few cells thick, which is sub-divided into five regions, the 
CA1, CA2, CA3a, CA3b and CA4. The densely packed unipolar granule cells of the 
dentate gyrus and interneurones make up the majority of the remaining cells 
(Isaacson, 1982).
Input to the hippocampus arrives through the perforant pathway innervating dentate 
granule cells from the entorhinal cortex. Mossy fibres from the dentate gyrus 
subsequently innervate CA3 pyramidal cells, which in turn innervate the ipsilateral
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CA1 pryamidal cells via the Schaffer collaterals and the contralateral CA1 pyramidal 
cells via the commissural fibres (Isaacson, 1982).
KAINIC ACID AS A TOOL FOR THE STUDY OF ISCHAEM IA  
Introduction
Kainic acid, originally isolated from a Japanese seaweed as an ascaricide, has been 
used extensively in neurobiological research for the past several years. Initially, the 
drug was found to excite neurones when applied iontophoretically to rat cortical 
neurones (Shinozaki & Konishi, 1970). Subsequently, it was reported that injections 
of kainate into the brain destroyed specific populations of neurones while sparing 
axons and synaptic terminals (Schwarcz et. al., 1978; Schwob et. a l,  1980). Data 
have since shown that kainate preferentially activates seizures in the limbic system, 
particularly the hippocampus (Lothman & Collins, 1981), resulting in the efflux of 
excitatory amino acids into the extracellular space (Connick & Stone, 1986). Due to 
the specific pattern of neuronal damage (see below), kainate administration is now 
considered a good experimental model for temporal lobe epilepsy and global 
ischaemia (Heggli et. a l,  1981; Lothman & Collins, 1981; Sperk, 1994). More 
recently the kainate model has been suggested to show characteristics similar to 
schizophrenia(Bardgett et. a l,  1995).
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Kainic Acid-Induced Cerebral Damage
The mechanism of kainate toxicity is similar to that of excitotoxic/ischaemic damage 
described above. Kainate has both a pre- and post-synaptic action. Post-synaptically 
kainate acts on both kainate and AMPA receptors, depolarising the cells, while pre- 
synaptically inducing the release of glutamate (Ferkany et. al., 1982; Connick & 
Stone; 1986), resulting in the activation of the remaining glutamate receptors. The 
following excitotoxicity is as previously described. Kainate has also been shown to 
dilate cerebral arterioles via an increased production of nitric oxide (Faraci et. al., 
1994).
Kainate produces a slightly different distribution of hippocampal damage depending 
on its route of introduction. Following intracerebroventricular injection of kainate, 
preferential damage of pyramidal neurones occurs in the CA3 region of the 
hippocampus (Nadler et. al., 1978; Magloczky & Freund, 1993). The CA1 and CA4 
regions also displayed some damage, while the CA2 area showed little evidence of 
kainate toxicity. Bardgett et. al. (1995), showed that neuronal damage following 
bilateral intracerebroventricular administration of kainate was dependant on dose. 
Injection of 1.5 nmol of kainate damaged the CA3 region to nearly 100 %, while 
leaving the CA1 region untouched. Higher concentrations of 4.5 and 6 . 6  nmol 
produced 50 % and 75 % damage within the CA1, and showed damage progressing 
from the CA3 to the CA4.
Systemic injections of kainic acid produce more widespread damage throughout the 
hippocampus, including the CA1 and CA3-4 regions (Schwob et. al., 1980; Ben-Ari 
et. a l 1981) This pyramidal cell death is believed to be a direct result of the binding
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of kainate to the high-affinity kainate receptors (the highest percentage of which are 
found in the CA3 region). Damage to the CA1 region was delayed and occurred up 
to four days after the initial injection (Liu et. al., 1996). Distal damage to the 
amygdala, entorhinal cortex and medial thalamic nuclei is more likely to be caused 
by hyperactivity in afferent excitatory pathways (Schwob et. al., 1980), as might be 
some of the damage in the CA1 region of the hippocampus which is innervated by 
the Schaffer collaterals from the CA3 region (Magloczky & Freund, 1993). 
Differences between routes of administration are even more apparent in the immature 
rabbit where intraperitoneal injections of kainate damaged the hippocampus with a 
pattern similar to that described above, but intraventricular administration was found 
not to be toxic (although progressive susceptibility was observed in animals over two 
months old; Franck & Schwartzkronin, 1984).
Injections of kainate usually cause a sequence of stereotypical events of staring 
spells, wet dog shakes, mild and severe limbic convulsions, rearing, falling and 
salivation (Lothman & Collins, 1981). Some reports suggest that damage to the 
hippocampus is dependant on seizures and that preventing the seizures themselves 
would dramatically decrease the extent of neuronal death (Ferkany et. al., 1982; 
Lehmann et. al., 1983). This theory is disputed by Franck and Schwartzkroin (1984), 
who showed that the immature rabbit hippocampus was relatively insensitive to 
intraventricular injections o f kainate, even though seizures were observed. Evidence 
with anticonvulsant compounds suggests that seizures are more likely to be a 
consequence of, rather than an initiator of, excitotoxicity or ischaemia. The 
anticonvulsant chlormethiazole was protective at a dose below that required to 
prevent global ischaemically-induced epileptic activity (Cross et. al., 1995). In
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contrast, clonazepam abolished seizures without a respective decrease in 
hippocampal damage (MacGregor et. al., 1996b).
As well as causing neuronal cell death by necrosis, kainic acid has also been found to 
lead to distinctive morphological and biochemical features associated with apoptosis 
(Filpikowski et. al., 1994; Pollard et. al., 1994). As mentioned earlier, DNA 
fragmentation, a feature of apoptosis, has been noted in rats at 18 and 72 hour 
following kainate injection in the hippocampus, entorhinal and sensory cortex 
(Filpkowski et. al., 1994). Pollard et al. (1994), examining apoptosis in the 
amygdala and hippocampus using morphological and silver staining techniques, 
showed that within the hippocampus, pyramidal cells of the CA3a region were 
preferentially stained, followed by neurones of the CA3c and CA4 which only 
showed scattered staining. Kainate has also been shown to induce the expression of 
immediate-early genes (Kasof et. al., 1995a, Willoughby et. al., 1997), believed by 
many to be necessary for apoptosis (Smeyne et. al., 1993), as well as the expression 
of target ‘effector genes’ (Konopka et. al., 1995). Willoughby et. al. (1997) showed 
two phases of c-fos induction, an initial induction within the hippocampus followed 
by a more widespread general event. The mechanism by which kainate induces this 
expression is not fully determined. Bading et. al. (1995), utilising hippocampal 
neuronal cultures suggested c-fos expression was a result of indirect activation of 
NMDA receptors, whereas evidence with rat cortical cultures suggests L-type 
voltage-sensitive calcium channel involvement (Murphy et. al., 1991).
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Kainate Receptor Localisation
Ligand binding and recombinant experiments show that five genes encode the 
kainate (high affinity) receptor subunits (GluR5/-6/-7, KA1/-2), while GluRl/-2/-3/-4 
encode those of the AMPA receptor (low affinity kainate receptor). The two 
receptors can be separated by their order of both binding affinities and agonist 
potency. For AMPA receptors, AMPA binds with much higher affinity than kainate, 
but kainate does show a degree of receptor stimulation (albeit much lower than that 
of AMPA itself). AMPA does not display a high degree of binding or agonist 
potency against the high affinity kainate receptor (see Bettler & Mulle, 1995). 
Kainate receptors show a rapid desensitisation in the presence of kainate or 
glutamate, whereas AMPA subunits display desensitisation only in the presence of 
glutamate or AMPA itself (Fedele & Raiteri, 1996). mRNA for the KA-1 high 
affinity kainate receptor subunit is localised to the CA3 region of the hippocampus, 
dentate gyrus (high density), inner cortical layers, cerebellar Purkinje cells and white 
matter (low density), while the KA-2 subunit mRNA is more diverse. GluR-5 
mRNA is found in cingulate and pyriform cortex, subiculum, septal nuclei and 
Purkinje cells; GluR- 6  in cerebellar granule cells, caudate-putamen and 
hippocampus; GluR-7 in the inner cortical layers, cingulate cortex, subiculum, 
caudate-putamen, reticular thalamus and stellate/basket cells of the cerebellum 
(Wisden & Seeburg, 1993).
Autoradiographic studies have localised the kainate receptors to a number of regions 
in the rat brain including the neocortex, corpus striatum, the CA3 region of the 
hippocampus, the supragranular layer of the dentate fascia and the granule layer of
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the cerebellum (Unnerstall & Wamsley, 1983; Lunn et. al., 1996). Kainate binding 
sites have been localised to mossy fibre terminals and the soma of CA3 pyramidal 
cells of the hippocampus (Foster et. al., 1981), suggesting that kainate stimulates the 
mossy fibre CA3 synapses both post- and pre-synaptically. A decrease in sensitivity 
of CA3 cells towards kainate-induced neuronal degeneration after mossy fibre lesions 
(Okazaki & Nadler, 1988) suggests that this presynaptic action, which results in the 
release of excitatory transmitters glutamate and aspatate from nerve terminals, is 
important in the excitotoxic effects of kainate. It remains unclear whether this 
release is mediated by kainate or AMPA receptors. AMPA receptor localisation 
almost overlaps that of kainate, although the highest concentration is in the dendritic 
fields of the CA1 (Olsen et. al., 1987; Rainbow et. al., 1984). NMDA receptors are 
more abundant in the hippocampus, neocortex, amygdala, septal nuclei and striatum 
(Monaghan et. al., 1983).
ROLE OF ADENOSINE IN CEREBRAL INSULTS
During periods of excitotoxicity, ischaemia and hypoxia, the concentration of 
adenosine in the extracellular space increases dramatically from a basal level of 0.05- 
2 pM suggesting the possibility of adenosine as an endogenous protective agent 
during cerebral insults (Zetterstrom et, al,, 1982; Hagberg et, al., 1987). The 
adenosine levels increase at a cerebral blood flow level (25 ml. 100 g"1. min'1) above 
that required for the rise in glutamate (20 ml. 100 g '1. m in'1; Matsumoto et. a l,  1992) 
indicating a possible, but time limited protective action of adenosine against 
glutamate toxicity. This release is also observed within the kainate model of
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excitotoxicity, where extracellular adenosine concentration follows a ‘bell’ shaped 
pattern, with the peak at 2 0 0  minutes after kainate perfusion through a microdialysis 
probe (Carswell et. al., 1997). Similar release of adenosine has been noted with the 
introduction of NMD A (Chen et. al., 1992), although the peak occurs earlier, 2 hours 
prior to that seen after kainate perfusion.
Adenosine receptors have been separated into three major subclasses, Ai, A2 and A3 . 
All are linked to a G-protein coupled receptor, Ai and A3 receptors to a Gi protein 
inhibiting adenylate cyclase, while A2 activates the enzyme via a Gs-protein (Marala 
& Mustafa, 1993). Ai and A3 receptors also activate phospholipase C. Ai receptors 
reportedly stimulate phosphoinositide metabolism as well as affecting both potassium 
and calcium flux. Binding studies have further classified adenosine A2 receptors into 
two distinct subtypes, A2A and A2B (Bruns et. al., 1986). While the low affinity A2B 
subtype is distributed throughout the brain, the high affinity A2A receptors are more 
localised. Autoradiographic and in situ hybridisation studies identified A2A receptors 
within the neostriatum and to a lesser extent the globus pallidus (Jarvis & Williams, 
1989). More recent developments have characterised A2A receptors within the 
hippocampus and cerebral cortex (Cunha et. al., 1994), although these receptors 
appear to differ pharmacologically from the typical striatal population (Cunha et. al., 
1994). 2-p-(2-carboxyethyl)phenethylamino-5 ’-A-ethylcarboxamidoadenosine
hydrochloride (CGS 21680), which binds at namomolar concentrations to striatal A2A 
receptors, displayed an affinity for the A2A agonist at the hippocampal and cortex 
receptors that was a third of the striatal receptors, and a slightly lower maximal 
binding (Cunha et. al., 1996).
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Analogues of the natural compound adenosine are able to prevent neuronal damage 
due to kainate. Connick & Stone (1989) showed that direct administration of the 
stable adenosine analogue phenylisopropyladenosine (R-PIA) into the brain, could 
protect against the neurodegeneration produced by the NMDA-receptor agonist 
quinolinic acid. Even at low doses (10 pg. kg '1) systemically injected R-PIA 
prevented hippocampal damage produced by kainate (Macgregor & Stone, 1993). R- 
PIA is an effective protectant when given up to 2 hours after kainic acid. Treatment 
with other Aj adenosine agonists has been proven to protect cells in a number of 
different models (Arvin et. a l, 1989; Daval et. al., 1989; Evans et. al., 1987, Von 
Lubitz et. al., 1988), while antagonism of A] receptors results in enhancement of 
damage (Phillis, 1995). In contrast antagonists of the A2 adenosine receptor, which 
has opposing effects on the levels of cAMP to Ai receptors, have been shown to 
protect the hippocampus (Phillis, 1995; Von Lubitz et. al., 1995). Increasing the 
availability of adenosine with the addition of adenosine kinase inhibitors (Jiang et. 
al., 1997a) or upregulation of A] receptors by caffeine (Rudolphi et. al., 1989), also 
protects against cerebral insults.
There are several ways in which adenosine may be protective. Adenosine inhibits the 
release of many neurotransmitters, including glutamate (Poli et. al., 1991). This 
effect is mediated by presynaptic Ai receptors linked via G-proteins to both calcium 
and potassium ion channels. In the postsynaptic neurone, adenosine helps to 
maintain the intracellular calcium homeostasis, possibly by preventing the 
depolarisation associated with an influx of ions (Rudolphi et. al., 1992). This would 
prevent the removal of the Mg NMDA blockade and the reversal of the glutamate 
uptake systems in glial and neuronal cells. This stabilisation of the intracellular
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environment is achieved by increasing potassium permeability, hyperpolarising the 
neurone (Rudolphi et. al., 1992). In addition, there are a number of effects mediated 
by adenosine acting on A2 receptors which may be either beneficial or detrimental.
In the striatum A2A receptor stimulation increases the release of the excitotoxic amino 
acids aspartate and glutamate (O’Regan et. al., 1992, Popoli et. al., 1995) and 
acetylcholine (Cunha et. al., 1995) but inhibits the release of GABA (Kirk & 
Richardson, 1994). A2A antagonists, which inhibit the further release of glutamate, 
have repeatedly been shown to increase neuronal survival within ischaemic models 
(Phillis, 1995; Von Lubitz et. al., 1995). Activation of the adenosine A2A receptor 
also increases cerebral blood flow (Stella et. al., 1996; Torregrossa et. al., 1990) via 
endothelial-derived nitric oxide synthesis (Sobrevia et. al., 1997), and inhibits 
platelet aggregation (Dionisotti et. al., 1992), although the latter effect may not be via 
conventional cAMP and subsequent adenylate cyclase activation (Cristalli et. al.,
1994). Both effects increase blood and nutrient supply to any ischaemically 
compromised area of the brain. CGS 21680, an A2A selective agonist (Jarvis et. al., 
1989), depresses cerebral glucose utilisation in a large number of brain regions, 
including the hippocampus (Nehlig et. al., 1994), an effect which may be 
advantageous to neurones by decreasing the requirement for a depleted nutrient 
during ischaemia. 2-[(2-aminoethylamino)-carbonylethylphenylethylamino]-5’-N-
ethylcarboxoamido adenosine (APEC), a centrally acting A2A agonist, increases 
cerebral blood flow and with chronic exposure and increases neuronal preservation in 
the hippocampus during forebrain ischaemia (Von Lubitz et. al., 1995). More 
recently, CGS 21680 has been shown to protect neurones against forebrain ischaemia 
in gerbils (Sheardown & Knutsen, 1996). A2 receptors decrease superoxide anion
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production in neutrophils (Cronstein et. al., 1985), reducing the possibility of free 
radical-associated neuronal death which has been implicated in excitotoxic/ischaemic 
damage (Cheng & Sun, 1994; Kitawaga et. a l ,  1990; MacGregor et. al., 1996b; 
O’Neill et. al., 1994). A2A receptor stimulation, therefore, provides a mixture of 
possible beneficial and detrimental effects, presenting a more confusing picture than 
that of the Ai receptor. The present study reports the effects in rats of the A2A 
agonists CGS 21680 and A^-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)- 
ethyl] adenosine (DMPA) on excitotoxic neuronal damage induced by kainic acid, 
and the effects of antagonists selective for Ai and A2 receptors.
NEUROTROPHIC FACTORS
Neurotrophins, a family of structurally related polypeptides originally thought to be 
mainly influential for neuronal survival, differentiation and plasticity during 
embryonic and early postnatal development, have been shown to possess a significant 
role within the adult CNS (Hefti et. al., 1993). The neurotrophin family includes 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 
3 (NT-3), NT-4/5 and NT - 6  (found in non-mammals only), and which mediate their 
actions via structurally distinct tyrosine kinase receptors. NGF activates the TrkA 
receptor (Kaplan et. al., 1991), BDNF and NT-4/5 the TrkB receptor (Klein et. al., 
1991; Klein et. al., 1992) and NT-3 the TrkC receptor (Lamballe et. al., 1991). As 
with all tyrosine kinase receptors their mode of action is a two step process of ligand 
binding followed by autophosphorylation of their ligand residues (Jing et. al., 1992). 
These molecules subsequently bind a downstream constituent (e.g. PLCy).
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Within the CNS the TrkA receptor is localised mainly to cholinergic neurones of the 
basal forebrain and striatum, and less densely in the thalamus and brainstem 
(Vasquez & Ebendal, 1991; Merlio et. al., 1992; Steininger et. al., 1993; Venero & 
Hefti, 1993). TrkB is more widespread, but is found in high amounts in the cortical 
layers of the cerebellum, thalamus and hippocampus (Klein et. a l, 1990; Merlio et. 
al., 1992) . The hippocampus itself contains high levels of BDNF and NGF mRNA, 
as well as NT-3 and NT-4/5 mRNA (Korsching et. al., 1985, Hofer et. al., 1990, 
Enfors et. al., 1990; Timmusk et. al., 1993). While protein levels for NGF display a 
degree of overlapping to areas stained for NGF mRNA, there were areas where 
protein was found without the presence of mRNA (Connor & Varon, 1992). This 
was suggested to be due to retrograde transport and accumulation of the protein. 
Similar accumulation was observed with BDNF protein (Yan et. al., 1997), with 
discrete areas containing protein, but no mRNA (Yan et. a l,  1997; Conner et. al., 
1997).
Glutamate and other transmitters are known to influence neurotrophins. After 
intrahippocampal injection, kainate has been shown to induce BDNF mRNA, in both 
the ipsilateral and contralateral hippocampus, cortex, amygdala, claustrum and 
hypothalamus (Ballarin et. al., 1991). This increase was due to both an increase in 
the number of neurones expressing BDNF and the amount being expressed, and 
remained high (up to 40-fold) for at least 7 hours. An increase in NGF was also 
observed, but it displayed shorter term effects with levels decreasing to basal by 7 
hours. Evidence from cortical cultures suggests that while this effect is observed by 
the addition of glutamate analogues (kainate, AMPA, NMDA and quisqualate) it is
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not seen with glutamate per se and may be regulated by metabotropic glutamate 
receptors (Bessho et. a l, 1993).
Kokaia et. al. (1996), has shown similar results after transient forebrain ischaemia. 
BDNF protein levels were highest in dentate gyrus and CA3 region of the 
hippocampus and lowest in the CA1 region and neocortex, while mRNA levels were 
similar (although less comparatively in the CA3 area compared with the dentate 
gyrus). Using the dentate gyrus-hilar lesion model, Lindvall et. al. (1994), showed an 
increase of NGF and BDNF, both peaking at 8  hours, but with BDNF at a much 
higher level. It was also suggested that this phenomenon was only observed in mild 
insults, with the suppression of transcription and/or translation of both BDNF and 
TrkB genes in severe insults. None of the other neurotrophic factors appear to be 
upregulated during excitotoxicity/ischaemia.
All the above studies focus on the short-term increases of neurotrophin mRNA or 
protein. When observed for a longer period a more complex tri-phasic pattern 
emerges, with a peak after a few hours (-125 % of pre-insult control levels) before a 
return to basal levels. A larger subsequent peak (-275 %) after seven days was 
followed by a lower sustained peak sixty days after the original injection of kainic 
acid (Suzuki et. al., 1995). The levels of BDNF did not return to normal for at least 
six months.
These alterations in neurotrophin gene expression are probably triggered by calcium 
influx, and are probably another mechanism by which the brain protects itself against 
such cerebral insults. The protective ability of neurotrophic factors has been shown 
in countless studies (e.g. Pringle et. al., 1996; Kubo et. al., 1995, Nakao et. al.,
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1995), although BDNF can increase glutamate toxicity in pre-treated cerebellar 
neurones (Fernandez-Sanchez, 1995) or cortical cultures exposed to a free radical 
generator (Gwag et. al., 1995; Koh et. al., 1995)
The protection observed with neurotrophic factors is probably mediated a number of 
different mechanisms, one of the most important being the stabilisation of calcium 
homeostasis, which may be via the upregulation of calcium binding proteins. Genes 
coding for calmodulin show an altered pattern of expression after systemic kainate 
administration (Sola et. al., 1997). Cell adhesion molecule I (CAM I) mRNA 
showed an increase five hours after the injection, while CAM II declined over 24 
hours. CAM III remained unaltered. Whether these changes were mediated by 
neurotrophins or other factors was not investigated. BDNF suppresses calcium
94 *accumulation by activating Ca pumps decreasing cellular calcium levels or a 
protein kinase which phosphorylates calcium channels, limiting uptake (Jiang et. al., 
1997b). BDNF also increases activity of glutathione peroxidase, which scavenges 
metabolically produced electrophiles. BDNF blocks NOS expression in spinal motor 
neurones after ventral root avulsion (Novikov et. al., 1995), which as stated earlier 
may be beneficial to the compromised brain. A further effect of BDNF is the 
increase of neuropeptide Y (NPY) mRNA within NPY-releasing neurones (Takei et. 
al., 1997), which may be beneficial due to the observation that NPY-deficient mice 
are more susceptible to spontaneous and evoked seizures (Erickson et. a l , 1996). A 
detrimental effect of BDNF is that it has been shown to increase the depolarisation- 
induced (high K+) release of glutamate from cultured cortical neurones (although no 
apparent effect was noted on basal release; Takei et. al., 1997). This may help 
explain observations of a pre-synaptic enhancement of glutamatergic synaptic
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transmission (Lessmann et. al., 1994), which may in turn explain the conflicting 
views of it’s ability to attenuate or exacerbate excitotoxic/ischaemic neuronal 
damage.
OBJECTIVES
The aims of this project were to further explore excitotoxic cell death, as well as the 
role of adenosine as a possible endogenous neuroprotective agent. Focusing in part 
on the role of the neurotrophin BDNF and apoptosis, this study examines the 
mechanisms of both kainate-induced damage to the hippocampus and the protection 
provided by a number of compounds.
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INTRAPERITONEAL INJECTIONS
Male Wistar rats of weight 190-250 g were used in all intraperitoneal injection 
experiments. All animals were purchased from Harlan Olac and allowed to settle in 
the animal house for at least a week under standard conditions ( 1 2  hour lighting 
cycles and both food and water available ad libitum) before use.
All injections were administered at a volume no greater than 3 ml. kg '1. Kainate, 
CGS 21680 and L-NAME were dissolved in saline, DPMA in methanol, 8 -(p- 
sulphophenyltheophylline) (8 -PST) in distilled water, 8-cyclopentyl-l,3- 
dipropylxanthine (CPX) in ethanol, 4-(2-[7-amino-2-{2-furyl}{l,2,4}triazolo{2,3- 
a} {1,3,5}triazin-5-yl-amino]ethyl)phenol (ZM 241385) in polyethylene glycol 300/ 
0.1M NaOH (1:1 v/v), R-PIA in methanol and 7-NI in saline/tween 80 (3:1 v/v - a 
few drops of NaOH were added to lower the pH value to 8 ), to provide solutions of 
the correct concentration for injection. The drugs, when added, were all injected 10 
minutes prior to the injection of kainate, which was administered at a standard dose 
of 10 mg. kg’1. The animals were left for seven days under standard conditions.
To ensure that the kainate injected was entering the brain (and not having been 
injected into an organ such as the bladder and rapidly excreted), animals were 
monitored for epileptic activity. In all animals (except those where only saline or 
vehicle were administered) some kainate-associated activity was observed. This 
usually comprised of wet dog shakes, Straub tail, although in some cases seizures 
were apparent.
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INTRAHIPPOCAMPAL INJECTIONS
For this surgical procedure male Wistar rats of weight 270-310 g, were anaesthetised 
with equithesin (3 mg. kg'1). A small area of the head was shaved before the animal 
was placed into a stereotaxic frame. A rectal probe and a heating blanket were used 
to maintain a normothermic temperature throughout the experimental procedure. The 
co-ordinates for the injections and the position of the tooth bar (-3.5 mm from 
interaural) were obtained from Paxinos and Watson (1986). The skin over the skull 
was cut and the exposed area cleared of membranous tissue. The bregma was located 
and ventral, lateral and anterior co-ordinates were taken. For the injection into the 
hippocampal structure, the co-ordinates used were -0.36 mm (anteroposterior), -0.32 
mm (dorsoventral) and +0.32 mm (lateral) from the bregma (fig. 1). The skull was 
bored with a drill at the point ventral to the injection site. Bone fragments were 
removed and the dura gently broken.
The needle was pre-washed with saline and filled with an amount ( -0 .5  ml) of the 
compound(s) to be injected. The needle (29G) was lowered slowly to the correct 
ventral position and left for 1 minute, before the drug(s) were infused. A syringe 
pump (Sage instruments) was used to ensure a constant rate of injection over 3.5 
minutes. The injection volume was 1 pi. With the exception of ZM 241385 all co­
injected compounds were administered in the same solution. Due to the 
immiscibility of the A2A antagonist with saline, simultaneous injection of ZM 241385
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with kainate was unrealisable. ZM 241385 was therefore administered just prior to 
the kainate injection. Injection volume and time were modified such that the total 
volume and time remained constant (i.e. each compound was administered in a 
volume o f 0.5 pi over 1.75 minutes).
The needle was left for 2 minutes after drug administration, to allow diffusion away 
from the injection site, before slow removal. The cut was stitched using a Mersilk 
thread (Ethicon Ltd.) and needle. To prevent dehydration, two i.p. injections of 2 ml 
saline were administered post-operatively, 30 minutes apart. Animals were then left 
to recover under standard conditions for either two or seven days.
In the above experiments, kainate, CGS 21680, adenosine and (+)-5-methyl-10,l 1- 
dihydro-5H-dibenzo-[a,d]-cycloheptene-5,10-imine maleate (MK-801) were 
dissolved in saline, R-PIA was dissolved in methanol, with subsequent dilutions in 
saline (such that the final methanol concentration was 0.02 %) and ZM 241385 in 
polyethylene glycol 300/ O.IMNaOH (1:1 v/v).
PERFUSION AND TISSUE SLICING
After recovery from either of the above experimental protocols, the rats were 
anaesthetised with sodium pentobarbitone (60 mg. kg*1). The method of perfusion 
first described by Brown & Brierley (1972) was used, in which the animal was placed 
into a supine position and the heart exposed. 50 ml of physiological medium with 
12.5 % xylocaine was then perfused through a cannula placed into the left ventricle at 
mean arterial blood pressure before fixation by 250 ml of FAM (40 % formaldehyde, 
glacial acetic acid, methanol in the ratio 1:1:8 v/v). The fixative was perfused over a
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period of 20 minutes. The animals were decapitated and the heads stored at 4 °C in 
fixative for up to a week. The brain was subsequently removed and the left 
hemisphere marked with Indian ink.
The brain was dissected laterally into five 2 mm sections, before placing into a 
Histokinette (Reichert-Jung) processor for the duration of the 24 hour automated 
cycle. Processing consisted of dehydration through a series of alcohols (70 %, 90 %, 
absolute + 2  % celloiden (to soften the tissue), absolute alone and amyl acetate 
(which removes the alcohol)) and wax (Tissue Tek II; Sakurq Fine Technical Ltd.), to 
impregnate the tissue with wax. To ensure complete infusion of the wax throughout 
the tissue, the brain slices were left in heated wax in a vacuum for 2 0  minutes or until 
air was no longer being drawn from the tissue. The slices were then embedded in 
wax which is allowed to set on a cold plate. The section of brain was then cut into 
sections of 6  pm using a microtome (American Optical Company).
Sections were then stretched in warm water and mounted on glass slides pre-coated 
with an adhesive (albumin). The slides were then allowed to dry at 37 °C.
At two points during the above protocol codes were used to ensure that the observer 
was blind to the origin of the sections under examination.
HAEM ATOXYLIN AND EOSIN STAINING
The slides were first dewaxed in xylene (this was later changed to the less toxic 
alternative, Histoclear; Raymond Lamb Laboratory Supplies) and run through 
descending ethanol concentrations (absolute (x 2), 90 % and 70 %) before washing in
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water. The slides were then immersed in Mayer’s haematoxylin for 5 - 6  minutes. 
After washing in water the slides were placed into Scott’s solution (an alkali which 
changes the acidic haematoxylin pigment red to blue). The section was then 
examined and restained (if the colour was too light) or dipped into acid alcohol for 5 
seconds if the staining was too intense. The sections were subsequently washed, 
immersed into eosin for 45 seconds - 3 minutes and then washed again. Again re­
immersion in eosin would increase the staining if required. The slides were then 
washed along an alcohol gradient (the time spent in 70 % alcohol was dependent on 
the strength of the eosin staining as it leaches the stain) to either xylene or Histoclear. 
After 10 minutes the sections were removed and a coverslip, pre-coated in 
Histamount (Hughes & Hughes Ltd.), was placed over the brain sections.
QUANTITATIVE ANALYSIS
Sections were examined under a light microscope by observers who as stated above, 
were unaware of the drug treatment received. The haematoxylin stained cell nuclei 
blue, while eosin stained the remaining tissues varying shades of pink. With 
neurones which were damaged, the eosin staining was more intense, staining the cell 
a deeper shade of pink than the surrounding. Pink damaged neurones were therefore 
easily distinguished from viable blue stained cells. The left (marked) hippocampus 
was examined and areas CA1, CA2, CA3a CA3b and CA4 regions scored for 
damage (fig. 2). The method of determining cell damage was based on a cell count 
combined with observation and knowledge of the hippocampal structure. As the 
pyramidal cell layer is a discrete, easily discernible structure, it is possible to observe
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areas within a cell layer which are devoid of cells 7 days post-trealment. In order to 
compensate for these gaps, an estimate was made of the percentage area where dead 
or dying cells had been removed. Cells still present were then counted to obtain a 
viable cell count of the remaining neurones. These values were then combined to 
obtain a semi-quantitative value of total damage. For example, if 50 % of the 
observable hippocampal cells are stained deep pink in a region where a proportion of 
the cell layer equivalent to 50 % of the total area is devoid of cells, then damage is 
recorded at 75 %. Figure 3 correlates this method with the straight forward viable 
cell count (r = 0.8845).
Other areas on the same plane of section (e.g. the pyriform) were examined in the 
same way as above.
TUN EL M ETHOD FOR STAINING APOPTOTIC CELLS
Early experiments used the propidium iodide method to determine the presence of 
apoptotic cells. Due to the known problems with this protocol in discriminating 
apoptotic from non-apoptotic cells, the TUNEL method was employed as a more 
selective substitute. The protocol below was amalgamated from a number of sources 
(e.g. Gavrieli el. al., 1992; Suzuki et. al., 1996).
As the increased levels of protein in the nucleus decrease the ability of DNA break 
labelling by the TUNEL method (Kerrigan et. al., 1987), the initial step of the 
protocol was an attempt to lower the protein content. Originally, incubation of the 
dewaxed brain sections in proteinase K (20 pg. ml' 1 for 15 minutes) was used, but 
following a study discussing the effectiveness of various pre-treatment protocols 
(Negoescu et. al., 1996), this was altered to microwave irradiation. The sections
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were heated in 0.01 M citrate buffer (pH 6 ) to a temperature of ~85 °C, followed by 
rapid cooling in citrate buffer and then in double strength phosphate buffer solution 
(PBS). This method was shown by Negoescu et. a l (1996) to double the sensitivity 
for the TUNEL method without altering the selectivity. The study also showed that 
the use of formaldehyde as a fixative retained selectivity and sensitivity.
The sections were then washed in both distilled water (four times) and 2 % hydrogen 
peroxide (to inactivate endogenous peroxidase), before immersion into terminal 
deoxynucleotidyl transferase (TdT) buffer (5 minutes). Bovine serum albumin 
(BSA) within the buffer prevented non-specific binding. The slides were 
subsequently incubated at 37 °C for 1 hour with the TUNEL reagents (0.3 units of 
TdT (Sigma) and 2 nmol of biotin-16-dUTP (Boehringer Mannheim) per section, 
dissolved in TdT buffer).
After 1 hour the reaction was halted by soaking the slides for 15 minutes in TB 
buffer. The slides were subsequently washed in distilled water then PBS twice each. 
The original staining protocol used aminoethyl carbazole (AEC). Once washed 
sections were incubated with extravidin peroxidase (1 : 1000 in PBS) for 30 minutes 
at 37 °C. Washing in distilled water then PBS (both twice) preceded staining the 
sections with AEC for 30 minutes at 37 °C. Due to the leaching of the stain from 
sections in alcohol, dehydration and mounting with Histamount was not possible. 
Sections were instead mounted in aqueous glycine. While this method did highlight 
apoptotic stained cells, due to the likeness in colour of the stain (brown) and the 
background glycine (yellow), an alternative was sought. This substitute to the AEC 
stain was dimethylaminbenzidine (DAB), which was not leached to any significant 
degree during dehydration. After incubation in TB buffer slides were washed in PBS
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three times. Extravidin peroxidase was replaced with incubation of the sections with 
avidin/biotinylated enzyme complex (ABC; Vectastain, Vector Laboratories) 
complex for 60 minutes. Subsequent washing was in PBS (twice) and then 
phosphate buffer (PB), before staining with 0.05 % DAB solution until colour 
developed (5 minutes). The slides were then dehydrated and mounted in Histamount 
in the same manner as described above for haematoxylin and eosin staining.
In negative controls incubation with the TUNEL reagents was replaced with TdT 
buffer (under similar conditions).
A small number of slides were counterstained with eosin (45 seconds - 3 minutes) 
after DAB staining. These were subsequently dehydrated and mounted as above.
BDNF-PRO TEIN STAINING
The procedure used for identifying BDNF protein on brain sections was the standard 
immunocytochemical protocol. Three washes in PBS preceded incubation in 
blocking serum (20 % goat serum in 0.3 % Triton/PBS) for 60 minutes. Excess 
blocking serum was removed before the addition of the primary antibody (rabbit anti- 
BDNF polyclonal antibody; Chemicon Int. Ltd.). Original experiments using 1 in 
1000, 2000 and 3000 dilutions of the BDNF antibody revealed that 1 in 2000 dilution 
resulted in specific staining without excess background. This concentration, diluted 
into blocking serum was used in the remaining experiments. The primary antibody 
was left covering the sections for ~16 hours.
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The antibody was removed by washing three times in PBS before the addition of the 
biotinylated secondary antibody (anti-rabbit IgG; 1:200 in 0.3 % Triton/PBS) for 60 
minutes. The remainder of the protocol followed that used in the revised latter 
portion of the apoptosis experiments. Briefly the sections were washed in PBS, 
incubated with the ABC complex, washed in PBS and PB and stained with DAB. 
The slides were then dehydrated and mounted.
STATISTIC AL ANALYSIS
All values given are mean ± standard error of the mean. ANOVA was used to
compare each value with each and with controls. Any observed statistical
significance was investigated by the use Student Newman Keiil's t-test, where a 
value for p less than 0.05 was considered significant.
SO LU TIO NS AND M ATERIALS
1NTRAH1PPOCAMPAL INJECTIONS 
EQUITHESIN
16.2 ml Sodium Pentobarbital 
4.25 g Chloral hydrate
2.12 g M gS 04
39.6 g Propelyne glycol
10 ml Ethanol
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HEMATOXYLIN AND EOSIN STAINING 
MAYER’S HEMATOXYLIN
I g Haematoxylin
50 g Potassium alum
1 g Citric acid
50 g Chloral hydrate
0.2 g Sodium iodate
1 I dH20
EOSIN
Stock
1 g Eosin Y (Raymond Lamb Laboratory Supplies)
20 ml dH20
80 ml 95 % Alcohol
Working Solution 
100 ml 
300 ml
2 ml
SCOTTS SOLUTION
80 g
14 g 
2 I
TUNEL STAINING 
TdT BUFFER 
3.36 g 
75 ml
37.5 mg BSA 
89 mg 
75 ml
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Stock
80 % Alcohol 
Glacial acetic acid
M gS04
Sodium bicarbonate 
dH20
Sodium cocodylate 
Tris-HCl
Cobalt chloride 
dH20
Materials & Methods
TRIS-HCI
125 ml 0.2 M Tris
225 ml 0 . 1MHC1
150 ml dH20
pH to 7.2 with 0.1 M HC1
TB BUFFER
8.75 g Sodium chloride
4.4 g Sodium citrate
500 ml dH20
CITRATE BUFFER (0.01 M)
A: 1.47 g Sodium citrate in 500 ml dH 20
B: 0.21 gCitric acid in 100 ml dH 20  
For pH 6.0 add solution B to A
PB (0.2 M)
A: 8.72 g NaH2P 0 4 in 600 ml dH20
B: 42.45 g Na2H P 04 in 1500 dH20
560 ml Solution A + 1440 Solution B, pH 7.2 
PBS
200 ml 0.2 M PB
36 g NaCl
1800 ml dH20
AEC
10 g 3-amino-9-ethylcarbazole
2.5 ml N,N, dimethyl formamide
37.5 ml 0.05 M Acetate buffer (pH 5.0)
7.5 pi 3% H20 2
Acetate buffer (pH 5.0)
A: 1.2 ml Glacial acetic acid in 100 ml dH20
B: 1.64 g Sodium acetate in 100 ml dH20
37 ml A + 88 ml B, made up to 500 ml with dH20
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NEURONAL DAM AGE  
H aem atoxylin and eosin:
S a l in e /v e h ic l e  c o n t r o l s
In both intraperitoneal (i.p.) and intrahippocampal (i.h.) models of kainate 
excitotoxicity, control injections of saline or drug vehicles, did not induce any 
noticeable damage in any region of the brain examined (including the hippocampus) 
compared with untreated animal brains (see fig. 5 & 6  and fig. 23 for 
photomicrographs of i.p. and i.h. experiments respectively). In central experiments, 
the insertion of the needle did result in a visible tract through the cortex and CA1 
region. This tract was surrounded by small dark cells, which corresponded to the 
description of glial cells. The presence of these cells did not extend beyond 100 pm 
in any direction. Damage values in the hippocampal regions were not affected 
outside this sphere and not at the plane of section used in examining hippocampal 
damage.
Intraperitoneal injections 
K a i n a t e
Kainate, injected systemically at a dose of 10 mg. kg-1 resulted in significant damage 
in three of the five regions of the hippocampus when compared with results observed
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with saline (which showed no damage in any region; fig. 4). The highest degree of 
neuronal damage as assessed by haematoxylin and eosin staining was observed in the 
CA1 region (48.4 % ± 7.4, p < 0.001, n = 16; fig. 7). The CA3a region displayed 
slightly less damage, 38.1 % ± 7.0 (p < 0.001; fig. 8 ), whilst the CA2 region 
exhibited a moderate amount, 22.2 % ± 6.4 (p < 0.01). The CA3b and the CA4 
regions did not display any degree of damage significantly different from the saline 
controls.
A d e n o s i n e  A 2A r e c e p t o r  a g o n i s t s
CGS 21680
The selective A2A agonist CGS 21680 was administered ten minutes prior to the 
injection of kainate via the intraperitoneal route at three concentrations, 0 . 1  mg. kg-1, 
0.01 mg. kg-1 and 2 pg. kg-1. All three regions significantly damaged by kainate were 
protected by 0.1 mg. kg' 1 CGS 21680 (p < 0.001 for the CA1 and CA3a regions, < 
0.01 for the CA2 region; fig. 4, 9 & 10). Neuronal damage was assessed as 6.9 % ±
4.4 in the CA1, 3.5 % ± 3.5 in the CA2 and 5.0 % ± 2.4 in the CA3a region (n = 13), 
approaching the levels observed with saline controls. No increase in damage was 
noted in the CA3b (0.76 % ± 0.76) or CA4 regions (0.38 % ± 0.38), which were 
unaffected by kainate alone. Percentage damage with the introduction of 0.01 mg. 
kg' 1 CGS 21680 prior to kainate, was similar to that seen with 0.1 mg. kg' 1 CGS 
21680 in the CA1 and CA2 regions of the hippocampus (7.0 % ± 4.4, p < 0.001 and
4.5 % ± 1.9, p < 0.01, respectively, n = 10). A lower, but still significant, amount of 
protection was observed in the CA3a region (damage was 16.5 % ± 7.7, p < 0.05).
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Again there was no significant neuronal death in the CA3b or CA4 regions (1.0 % 
±0.7 and 0.56 % ± 0.56, respectively). The lowest concentration of CGS 21680, 2 
pg. kg-1, displayed only a very limited degree of protection against kainate. In the 
CA1 region the value of damage (27.0 % ± 9.8, n = 10) was both significantly 
different from both saline controls (p < 0.05) and kainic acid (p < 0.05). Near 
complete protection was again observed in the CA2 region (damage was 5.0 % ± 1.9, 
p < 0.01), while in the CA3a region the damage observed (25.0 % ± 8.7) was not 
significant against kainate, but was significantly greater than the saline control (p < 
0.05). No significant damage was observed in either the CA3b or CA4 regions (3.5 
% ±1.7 and 2.0 % ± 2.0, respectively). In view of these results, CGS 21680 in 
subsequent further studies was injected at an intraperitoneal dose of 0 . 1  mg. kg-1.
DPMA
Another A2A agonist, DPMA was used at two intraperitoneal injection 
concentrations, 0.1 mg. kg-1 and 1.0 mg. kg '1. Concentrating on only those areas of 
the hippocampus damaged by kainate (fig. 11), DPMA, when injected at the higher 
dose, showed protective effects in both the CA1 and CA2 regions of the 
haematoxylin and eosin stained hippocampal section (p < 0.01 and < 0.05 
respectively, n = 4). Damage was recorded as 5.0 % ± 3.5 in the CA1 and 1.25 % ± 
1.25 in the CA2. No significant neuronal preservation was observed in the CA3a 
region (27.5 % damage ± 16.4). While no significant change in percentage cell death 
occurred in either the CA3b or CA4 regions (18.8 % ±17.1  and 22.5 % ± 22.5, 
respectively), one animal did show a degree of damage in both areas. Results
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Fig.  4 P r o t e c t i o n  by t h e  A2A r e c e p t o r  a g o n i s t  CGS 2 1 6 8 0 ,  a g a i n s t  
k a i n a t e  —i n d u c e d  h i p p o c a m p a l  cel l  d e a t h .  *** p < 0 . 0 0 1 ,  ** 
p < 0 . 0 1 ,  * p < 0 . 0 5  v e r s u s  k a i n a t e  a l o n e ;  + + - +  p <  0 . 0 0 1 ,
+  +  p <  0 . 0 1 ,  +  p < 0 . 0 5  a g a i n s t  s a l i n e  c o n t r o l s .
6 0  -i
5 0  -
4 0  -
3 0  -
20  -
10  -
0
CA1 CA2 CA3a CA3b CA4
1 0 m g . k g 1 K a i n a t e , n  = 16 
l/VQ 0.1 m g . k g ' 1 CGS 2 1 6 8 0  + 1 O m g . k g -1 k a i n a t e ,  n = 1 3 
[ \ \ J  0 . 0 1  m g . k g ' 1 CGS 2 1 6 8 0  + 1 O m g . k g " 1 k a i n a t e ,  n = 1 0 
LXJXJ 2 / ^ g . k g " 1 CGS 2 1 6 8 0  + 1 O m g . k g  " 1k a i n a t e ,  n = 10
Fig. 5
Fig. 6
A «
/
Haematoxylin and eosin stained CA1 region o f  the hippocampus after i.p. injection o f saline 
(1 ml). All the cells appear viable and are stained blue with haematoxylin, with no evidence 
o f neurones taking up the deep pink eosin stain. 20 mm : 40 pm.
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M k r n m r .
C A 3a region o f  the hippocam pus stained for haematoxylin and eosin following i.p. saline 
administration. As for the CA1 region, the cells display a healthy m orphology  seven days 
after the initial injection. 20 mm : 40  pm.
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Haematoxylin  and eosin stained CA1 region seven days after i.p. injection o f  
kainate. N eurones after kainate administration contrast markedly with those 
control.  N ote examples o f  dam aged cells (arrows), stained heavily with eosin. 
pm.
10 mg. k g '1 
after saline 
20 mm : 40
Damaged C A 3a  region following i.p. injection o f  10 mg. k g '1 kainate. Selective neuronal 
dam age is widely apparent throughout this region (arrows indicate non-viable  cells). 20 mm :
arj
r
Fig. 9 Protection against kainate toxicity after the i.p. administration o f  the A 2a agonist CGS 21680 
in the CA1 region. 0.1 mg. k g '1 CGS 21680, injected 10 minutes after 10 mg. kg '1 kainate, 
results in neuronal morphology approaching that o f  saline controls. 20 mm : 40 pm.
Fig. 10 Kainate toxicity in the C A 3a region is prevented by C G S 21680. As for the CA1 region, 0.1 
mg. kg’1 C G S  21680 prevented the appearance o f  non-viable cells, when injected 10 minutes 
after 10 mg. kg’1 kainate. 20 mm : 40 pm.
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obtained with the lower concentration of DPMA showed no significant reduction in 
kainate-induced toxicity.
C G S  2 1 6 8 0  a n d  a d e n o s i n e  a n t a g o n i s t s
To help elucidate the mechanism of protection afforded by CGS 21680, this 
compound was administered in conjunction with an Ai receptor antagonist, CPX, or 
a peripherally acting general adenosine antagonist, 8 -PST (fig. 12)
CPX at 50 pg. kg' 1 did not induce any significant change in protection observed with 
CGS 21680 alone in the CA1 and CA2 regions (damage was 5.0 % ± 5 .0  and 0 % ± 
0, respectively, n = 3; fig. 13 for photomicrograph of the CA1 region). Due to the 
low number of animals treated with this combination, these values were not 
significantly different from those values obtained for kainate (although they did not 
represent a significant increase in damage from saline controls levels either). In the 
CA3a region of the rat hippocampus, CPX did appear to moderate the protective 
effects of CGS 21680 as damage increased from 5.0 % ± 2.4 (CGS 21680 alone) to
15.0 % ± 12.6 (fig. 14). This value, while not significantly different from CGS 
21680 alone, did not represent a statistically significant protection from kainate 
induced toxicity.
At 20 mg. kg' 1 the peripheral antagonist 8 -PST, negated a proportion of the beneficial 
effects of the adenosine A2A agonist in the CA1 and the CA3a regions (n = 5; fig. 
12). Damage increased in the CA1 region to 28.0 % ± 18.3 (fig. 15) and in the CA3a 
to 28.0 % ±13.1 (fig. 16). No such augmentation was noted in the CA2 region (1.0
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Fig.  1 1 P r o t e c t i o n  o b s e r v e d  wi th t h e  A2A a d e n o s i n e  r e c e p t o r  a g o n i s t  
DPMA.  DPMA p r o t e c t e d  a g a i n s t  k a i n a t e  —i n d u c e d  n e u r o n a l  
d a m a g e  in t h e  r a t  h i p p o c a m p u s  a t  1 . 0  b u t  n o t  0.1 m g .  kg ~1 
** p < 0 . 0 1 ,  * p < 0 . 0 5  v e r s u s  k a i n a t e  a l o n e .
CA1 CA2 CA3a
H  1 O m g . k g ~ 1 K a i n a t e ,  n = 9
l/Q /J  1 . O m g . k g - 1 DPMA + 1 O m g . k g -1 k a i n a t e , n  = 4 
[ \ \ J  0.1 m g . k g -1 DPMA +  1 O m g . k g -1 k a i n a t e , n  = 3
D
A
M
A
G
E
Fig.  12  E f f e c t s  of  t h e  a d d i t i o n  of  t h e  c e n t r a l l y  a c t i n g  A1 a n t a g o n i s t  
CPX,  a n d  t h e  p e r i p h e r a l l y  a c t i n g  a d e n o s i n e  a n t a g o n i s t  8 —PST,  
on  CGS 21 6 8 0  —m e d i a t e d  p r o t e c t i o n  a g a i n s t  k a i n a t e  t ox i c i t y .
** p < 0 . 0 1 ,  * p < 0 . 0 5  v e r s u s  k a i n a t e  a l o n e .
6 0
5 0  -
CA3a
1 0 m g . k g - i  K a i n a t e ,  n = 1 6
l/V O  0.1 m g . k g  ~1 CGS 2 1 6 8 0  +  1 0 m g . k g ~ 1 k a i n a t e ,  n = 13
E \X ] 0.1 m g . k g -1 CGS 2 1 6 8 0  +  5 0 / ^ g . k g - 1 CPX
+ 1 O m g . k g -1 k a i n a t e ,  n = 3 
[XX3 0.1 m g . k g - 1 CGS 2 1 6 8 0  +  2 0 m g . k g - 1 8 - P S T
+  1 O m g . k g -1 k a i n a t e , n  = 5
Fig. 13 C A 1 region following the i.p. administration o f  C G S 21680 + C PX  + kainate. While a slight 
increase in the num ber o f  non-viable cells is apparent in the above photomicragraph (arrows 
indicate dam aged  cells), overall protection by 0.1 mg. k g '1 C G S  21680 was net decreased 
following the addition o f  50 pg. k g '1 CPX. 20 mm : 40 pm.
Fig. 14 C A 3a region sh ow s a decrease in A 2A-m ediated protection fo llo w in g  the adm inistration o f  
C PX . A larger num ber o f  non -v iab le  c e lls  are apparent w ith the in c lu sion  o f  50 pg. k g '1
C P X  com pared to 0.1 mg. k g '1 CGS 21680 + 10 mg. k g '1 kainate. 20 mm : 40 pm.
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Fig. 15 Substantial dam age to the CA1 region after i.p. administration o f  C G S 21680, kainate and 
the peripheral antagonist, 8-PST. Levels o f  cellular damage approach those o f  kainate alone, 
following the injection o f  0.1 mg. k g '1 CGS 21680 with 20 mg. k g '1 8-PST. 20 m m  : 40 pm.
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Fig. 16 Damaged C A 3 a  region after i.p. injection o f  C G S 21680, 8-PST and kainate. The large 
number o f  non-viable  cells highlights the reversal o f  protection by 0.1 mg. kg' CGS 21680 
with the administration o f  20 mg. k g '1 8-PST. 20 mm : 40 pm.
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% ± 1.0). Due to the variability between experiments, these increases were neither 
significant from kainate nor CGS 21680 (0.1 mg. kg"!) + kainate levels.
Adenosine A2a antagonist, ZM 241385
The properties of the selective antagonist of the adenosine A2a receptor, ZM 241385, 
were studied within this model of kainate excitotoxicity (fig. 17). When given alone 
ten minutes prior to the initial injection of kainate, ZM 241385, at an i.p. dose of 10 
mg. kg '1, displayed significant protection against kainate-induced toxicity in the 
CA3a areas of the hippocampus (4.3 % ± 2.8, p < 0.05, n = 7; fig. 19). A reduction 
in damage to 0.71 % ± 0.71 was observed in the CA2 region, although due to the 
lower amount of kainate-induced damage in this region, this reduction was not 
significantly different. In the CA1 region damage decreased non-significantly to 19.3 
% ± 12.6 (fig. 18).
This protection of the CA3a region by ZM 241385 was not apparent after the further 
addition of 50 pg. kg '1 CPX, where damage at 27.5 % ± 20.1 (n = 4; fig. 20), was not 
significantly different from kainate alone. Damage in the CA1 region was observed 
at 33.8%  ±20.8 (fig. 21).
The A2a antagonist compound was also injected in conjunction with the A2a agonist 
CGS 21680. At 10 mg. kg'1 ZM 241385 administered with 0.1 mg. kg '1 CGS 21680 
displayed total protection against kainate. In none of the animals studied (n = 5) was 
any neuronal damage noted in any region of the hippocampus. While this was 
significant in the CA1 (p <0.01) and the CA3a (p < 0.05), this was not significantly 
different from kainate in the CA2 region.
62
D
A
M
A
G
E
Fig.  17  P r o t e c t i o n  a g a i n s t  k a i n a t e - i n d u c e d  n e u r o t o x i c i t y  by i .p.
i n j e c t i o n  of  t h e  A2A r e c e p t o r  a n t a g o n i s t  ZM 2 4 1 3 8 5 .  ** 
p < 0 . 0 1 ,  * p < 0 . 0 5  v e r s u s  k a i n a t e .
60 -i
50  -
40  -
30  -
20  -
10  -
0
CA1 CA2 CA3a
H  1 0 m g . k g 1 K a i n a t e ,  n = 16 
l/V O  l O m g . k g -1 ZM 2 4 1 3 8 5  4- 1 O m g .  k g -1 k a i n a t e ,  n = 7 
[XX3 1 O m g . kg-1 ZM 2 4 1 3 8 5  +  5 0 / u g . k g  -1 CPX
+ 1 O m g . k g -1 k a i n a t e , n  = 4 
XXI l O m g . k g - 1 ZM 2 4 1 3 8 5  +  0 . 1 m g . k g -1 CGS 2 1 6 8 0
+ l O m g . k g -1 k a i n a t e , n  = 5
18 CA1 region following i.p. administration o f  ZM 241385  and kainate. While the above 
photom icrograph does not show the presence o f  dam aged  neurones, overall,  the level o f  
neuronal death observed with 10 mg. k g '1 ZM 241385 + 10 mg. k g '1 kainate did not differ
from that o f  kainate alone. 20 mm : 40 pm. 
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19 Protection against kainate-mediated excitotoxicity by ZM 241385  (i.p.) in the C A 3a  region. 
The lack o f  damage above is representative o f  the group as a whole (n=7), with levels o f  
damage seven days after the injection o f  10 mg. k g '1 Z M 2 41 38 5  +  10 mg. k g '1 kainate 
approaching those o f  kainate alone. 20 mm : 40 pm.
•  %
#
f c .
*
V s -  ' .»  -
i t  I,* ..■'. • * • «• +r
%•
Fig. 20 C A I region following the i.p. administration o f  ZM 214385, kainate and the A| antagonist 
C PX . A large num ber o f  eosin stained neurones are apparent with the co-administration o f  
50 pg. m g’1 C PX  with 0.1 mg. k g '1 ZM 241385 and 10 mg. k g '1 kainate. The level o f  
excitotoxicity is similar to that observed after kainate alone. 20 mm : 40 pm
Fig. 21 Lack o f  protection by ZM 241385 in the C A 3a  region following co-administration o f  CPX 
(i.p.). As for the C A I region above, a large num ber o f  non-viable cells are observed 
following 50 pg. k g '1 CPX  + 10 mg. k g '1 Z M 241385  + 10 mg. k g '1 kainate. SCALE
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Intrahippocam pal injections 
K a i n a t e
Alongside studies using systemic administration, intrahippocampal injections were 
also utilised. Two early experiments in which an infusion of 10 nmol kainate in lpl 
was made, revealed an ipsilateral pattern of complete neuronal degradation in almost 
all regions of the hippocampus (only the CA2 region had damage less than 100 % in 
both experiments, where in one study the damage was recorded as 80 %). 
Subsequent studies used lower concentrations of 1 and 0.25 nmol. Animals were 
killed and perfused at either two or seven days after the initial injection (fig. 22).
Experiments with 1 nmol kainate revealed the greatest amount of damage in the 
CA3a region of the hippocampus. In the CA3a region, the levels of damage were
90.0 % ± 6.7 after two days (p < 0.01 compared to saline controls, n = 3) and 100 % 
± 0 after seven days (p < 0.01, n = 4). In the CA3b region, damage was assessed as 
73.3 % ± 14.5 after two days, but this declined to a level of 25.0 % ± 25.0 after seven 
days. No significant damage occurred in the CAI,  CA2 or CA4 regions.
Studies using the lower, 0.25 nmol, concentration of kainate were also terminated 
after either two or seven days. Similar results were observed between two and seven 
days. As for 1 nmol kainate, the highest degree of damage was noted in the CA3a 
region of the hippocampus after 0.25 nmol injection. After two days damage was 
96.7 % ± 3.3 (p < 0.001 compared with saline controls, n = 3), and 93.4 % ± 2.7 (p < 
0.001, n = 10) after seven days. Values for the CA3b region are also similar between 
regimens (56.7 % ± 23.3 for two days and 50.0 % ± 8.0 for seven; see fig 24 for 
photomicrograph of CA3 region of animal injected with 0.25 nmol kainate, killed
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after seven days). Again, while small amounts of damage were noted in the 
remaining regions of the hippocampus, none were significantly different from saline 
control levels.
In the remaining experiments kainate was used at the lower concentration of 0.25 
nmol to provide a model of near complete neurodegeneration of the CA3a region by 
excitotoxic mechanisms.
A d e n o s i n e  A 2A a g o n i s t ,  C G S  2 1 6 8 0
CGS 21680 was administered with 0.25 nmol kainate at concentrations of 0.01, 0.1, 
0.25 and 2.5 nmol (fig. 25). When compared to kainate alone, none of the 
concentrations alleviated excitotoxic effects. In the CA3a region, CGS 21680 at a 
concentration of 0.01 nmol produced damage of 75.0 % ± 25.0 (n = 4), 0.1 nmol 
resulted in 85.0 % ± 10.2 damage (n = 4), 0.25 nmol in 95.0 % ± 2.9 and 2.5 nmol in 
100 % ± 0 (fig. 26).
In the CA3b region the highest amount of damage was found with the lowest 
concentration (71.3 % ± 23.8), closely followed by the largest concentration used 
(68.3 % ± 8.8). The two intermediate doses (0.1 and 0.25 nmol) induced less damage 
than the two extreme concentrations, but still offered no significant protection over 
kainate (28.8 % ± 10.9 and 36.7 % ± 31.8). No significant damage was noted in any 
of the remaining hippocampal regions.
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Fig.  2 2  Ex c i t o t o x i c  d a m a g e  t o  t h e  CA3a a n d  CA3b r e g i o n s  of  t h e
h i p p o c a m p u s  a f t e r  c e n t r a l  i n j e c t i o n  of  k a i n a t e .  A n i ma l s  we r e  
ki l led t wo or  s e v e n  d a y s  a f t e r  t h e  ini t ial  i n j e c t i o n .  +  +  + 
p < 0 . 0 0 1  v e r s u s  s a l i n e  c o n t r o l s .
1 0 0  n
8 0  -
60  -
40  -
20  -
CA3a CA3b
1 nmol  Ka i n a t e ,  2 Day,  n = 3 
i/V"] 1 nmol  Ka i n a t e ,  7 Day,  n = 4 
[ \ \ |  0 . 2 5 n m o l  Ka i n a t e ,  2 Day,  n = 3 
IXXl 0 . 2 5 n m o l  Ka i n a t e ,  7 Day,  n=l O
CA3a CA3b CA3a CA3b CA3a CA3b
Fig. 23 Photom icrograph o f  the C A3a region following intrahippocampal injection o f  saline. The 
neurones show similar m orphology to those after i.p. saline, and do not display any 
indications o f  neuronal degradation. 20 mm : 40 pm
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Fig. 24 D am aged  neurones o f  the C A 3a region seven days after i.h. injection o f  0.25 nmol kainate.
The photom icrograph, in contrast to the saline control above, shows very few viable 
neurones (thick arrows) as well as a num ber o f  eosin stained dying cells (thin arrows). The 
presence o f  small darkly stained glial is also prominent. Importantly there are also areas o f  
the C A 3 a  region where there is a complete  lack o f  neurones (e.g. see bracketed region). 20 
mm : 40  pm
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Fig.  2 5  No p r o t e c t i o n  of  t h e  h i p p o c a m p u s  f r o m  k a i n a t e  t ox i c i t y  a f t e r  
i n t r a h i p p o c a m p a l  a d m i n i s t r a t i o n  of  CGS 2 1 6 8 0 .  +  + -F p < 0 . 0 0 1  
v e r s u s  s a l i n e  c o n t r o l  l evel s .
CA3a CA3b CA3a CA3b CA3a CA3b CA3a CA3b CA3a CA3b
8 H  0 . 2 5 n m o l  Ka i n a t e ,  n = l0
IXXJ 0 . 0 1 n m o l  CGS 2 1 6 8 0  + 0 . 2 5 n m o l  K a i n a t e ,  n =  4
P \ \ l  O . I n mo l M CGS 2 1 6 8 0  + 0 . 2 5 n m o l  K a i n a t e ,  n =  4
[XXI 0 . 2 5 n m o l  CGS 2 1 6 8 0  + 0 . 2 5 n m o l  Ka i n a t e ,  n = 3
| | 2 . 5 n m o l  CGS 2 1 6 8 0  + 0 . 2 5 n m o l  Ka i n a t e ,  n = 3
$ ^  ^
Fig. 26 Lack o f  protection by the A2A agonist CGS 21680. The photom icrograph o f  2.5 nmol CGS 
21680  + 0.25 nmol kainate closely resembles that o f  kainate alone. Almost complete 
degradation o f  the region is apparent. As for kainate alone, areas void o f  neurones can be 
discerned, as well as an increase in glial cells above that seen in the saline control. 20 mm : 
40 pm
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A d e n o s i n e
The effects of adenosine itself were also examined within the intrahippocampal 
kainate injection model of excitotoxicity. Adenosine was administered in 
conjunction with kainate, at three concentrations, 0.01, 0.25 and 2.5 nmol (fig. 27). 
Although all three reduced the mean level of neuronal damage in the CA3a region, 
none modified damage to a level which was significantly different from kainate 
alone. In the CA3a region, adenosine at 2.5 nmol reduced damage to a value of 66.7 
% ± 19.6 (n = 6 ; fig. 31), 0.25 nmol to 75.0 % ± 13.3 (n = 7) and 0.01 nmol to 70.6 
% ± 12.6 (n = 8 ). The kainate-associated damage observed after adenosine 
administration in the CA3b was 28.3 % ± 16.0 for the highest concentration, 38.6 % 
± 14.6 for 0.25 nmol and 41.3 % ± 13.1 for 0.01 nmol. Again, even though the 
values obtained for damage in the CA3b after kainate administration were lower in 
the presence of adenosine, none of the concentrations used induced a significantly 
different amount of damage. No significant increase in damage was observed in the 
CAI, CA2 or CA4 region.
A i a d e n o s i n e  r e c e p t o r  a g o n i s t ,  R - P I A
The adenosine Aj receptor agonist, R-PIA, was investigated at concentrations of 0.01 
and 0.25 nmol (n = 3 for both; fig 28). R-PIA was infused via an intrahippocampal 
injection with 0.25 nmol kainic acid. The purine agonist did not protect the CA3a 
region of the hippocampus to any degree. Values of 96.7 % ± 3.3 and 88.3 % ± 6.0 
were obtained for damage after R-PIA administration at 0.25 (fig. 32) and 0.01 nmol 
respectively. Differences in damage appeared in the CA3b region. 0.01 nmol
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adenosine significantly reduced damage to 13.3 % ± 8 . 8  (p < 0.05), while 0.25 nmol 
adenosine tended to increase kainate damage (80.0 % ± 5.8). As with kainate alone, 
neither R-PIA at 0.1 nor 0.25 nmol resulted in significant damage in the CAI, CA2 
or CA4 regions.
A d e n o s i n e  A 2A -s e le c tiv e  a n t a g o n i s t ,  Z M  2 4 1 3 8 5
The selective A2A receptor antagonist compound ZM 214385 wa^ administered as an 
intrahippocampal injection at concentrations of 0.05, 0.25 and 2.5 nmol (fig. 29). At 
2.5 nmol ZM 241385 significantly protected both the CA3a and CA3b regions of the 
hippocampus (32.9 % ± 15.8 and 9.3 % ± 4.7, respectively, n = 7) against 0.25 nmol 
kainate (p < 0.01; fig. 33). While both 0.25 nmol and 0.05 nmol tended to show a 
decrease in damage to the CA3a region (65.7 % ± 17.6, n = 6  and 88.3 % ± 1.7, n = 
3, respectively), neither was significantly different from kainate alone. No reduction 
was observed with either of the two lower concentrations in the CA3b region (42.1 % 
± 12.4 for 0.25 nmol and 58.3 % ± 8.3 for 0.05 nmol dose). No neuronal damage 
was noted in any other hippocampal areas, with any concentration.
N M D A - a n t a g o n i s t  M K - 8 0 1
By far the greatest effect of any drug used in alleviating kainate excitotoxic damage 
was the NMDA receptor antagonist MK-801 (fig. 30). MK-801 was given at both a 
high (2.5 nmol) and a low (0.01 nmol) dose in conjunction with kainate. Both doses 
were extremely significant (p < 0.001) in reducing CA3a neurodegeneration (3.3 % ±
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3.3 for the 2.5 nmol dose (fig. 34) and 10.0 % ± 5.8 for the 0.01 nmol dose). While 
both doses displayed a reduction in CA3b damage (3.3 % ± 3.3 for the 2.5 nmol dose 
and 20 % ±11.5 for 0.01 nmol MK-801), only 2.5 nmol MK-801 was significantly 
different from damage induced by kainate alone.
E x t r a h i p p o c a m p a l  d a m a g e
Other areas of the brain in the same plane of section as the hippocampus (-3.60 from 
bregma) were also examined for damage using haematoxylin and eosin staining after 
both i.p. and i.h. injections. Within the hippocampus itself, no other regions of 
damage were apparent after i.p. or i.h. injections, including the dentate gyrus which 
appeared to be resistant to all regimens and concentrations of kainate used.
I.p. administration of 10 mg. kg' 1 kainate proved neurotoxic to discrete populations 
of cells outwith the hippocampus. Cells within the distinct formation of the pyriform 
cortex and posterolateral and posteromedial cortical amygdala displayed degrees of 
damage ranging from 0 to 85 % (fig 35 & 36). Damage within the pyriform cortex 
displayed a significant linear relationship with that of the CA3a region (fig. 37; slope 
= 0.71; p = 0.0055) such that damage was only observed in the pyriform when there 
was a corresponding degree of neurodegeneration in the hippocampus. When 
examined after administration of kainate in conjunction with other compounds (e.g. 
CGS 21680) damage to this area was usually only apparent when there was an 
occurrence of neurotoxicity to the hippocampus. Protection of this region also 
occurred in parallel to the hippocampus. No compound showed selective preferential
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Fig.  2 7  La c k  of  p r o t e c t i o n  a g a i n s t  k a i n a t e  f o l l owi ng t h e  i n t r a  — 
h i p p o c a m p a l  i n j e c t i o n  of  a d e n o s i n e .  +  +  +  p C O . 0 0 1 ,  + + 
p < 0 . 0 1  v e r s u s  s a l i ne .
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[ \ \ |  0 . 2 5 n m o l  A d e n o s i n e  + 0 . 2 5 n m o l  K a i n a t e , n = 7 
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Fig.  2 8  P r o t e c t i o n  in t h e  CA3b r e g i o n  only by low i n t r a h i p p o c a m p a l  
c l os e s  of  t h e  A1 a g o n i s t  R —PIA. * p < 0 . 0 5  v e r s u s  k a i n a t e  
a l o n e .  +  +  + p < 0 . 0 0 1 ,  + +  p < 0 . 0 1 ,  +  p < 0 . 0 5  v e r s u s  s a l i ne  
c o n t r o l .
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P r o t e c t i o n  a g a i n s t  i n t r a h i p p o c a m p a l  k a i n a t e - i n d u c e d  n e u r o n a l  
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Fig.  3 0  I n t r a h i p p o c a m p a l  a d m i n i s t r a t i o n  of  t h e  NMDA a n t a g o n i s t  
MK —801  p r o t e c t e d  a g a i n s t  k a i n a t e - i n d u c e d  e x c i t o t o x i c i t y . 
*** p < 0 . 0 0 1 ,  * p < 0 . 0 5  a s  c o m p a r e d  wi th k a i n a t e ,  +  +  + 
p < 0 . 0 0 1  v e r s u s  s a l i ne .
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C A 3a  region following the i.h. administration o f  adenosine + kainate. A large num ber o f  
non-viable  cells are apparent throughout this region seven days after an injection o f  2.5 nmol 
adenosine + 0.25 nmol kainate. There is almost a complete  absence on blue stained viable 
cells, show ing a lack o f  protection by adenosine itself. 20 mm : 40 pm.
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Lack o f  protection in the C A 3a  region by the A, agonist R-PIA. 0.25 nmol R-PIA, co­
injected with 0.25 nmol kainate did not alter the m orphology associated with kainate 
excitotoxicity, with almost com plete  degradation o f  this area. 20 mm : 40 pm.
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Fig. 33 Protection  from kainate toxicity in the CA3a region following the in trahippocampal co­
administra tion  o f  ZM 214385. The above photomicrograph, shows that seven days after the 
i.h. injection o f  2.5 nmol ZM 241385 with 0.25 nmol kainate, there is no dam age to the 
C A 3 a  region. All o f  the above neurones appear viable and resemble those o f  the saline 
control. 20 mm : 40 pm.
Fig. 34 Photom icrograph o f  the C A 3a region protected by the co-injection o f  MK-801 with kainate 
(i.h.). MK-801 at 2.5 nmol prevented the appearance  o f  dam aged  neurones induced by 
kainate alone. The region closely resembles that o f  the saline controls. 20 mm : 40  pm.
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protection of either the hippocampus, the pyriform cortex or any other region 
selectively toxic to kainate.
The excitotoxic effects of kainate to the pyriform cortex or cortical amygdala were 
not observed after intrahippocampal injections. No other extrahippocampal, nor 
intrahippocampal areas (apart from those mentioned above) were sensitive to 
centrally administered kainate. The above figures for damage after intrahippocampal 
kainate, refer to damage on the ipsilateral hemisphere of the rat brain. Examination 
of the contralateral hemisphere revealed no damage in either the hippocampus or in 
any other region on the same plane of section.
Astrocytes in the brain after kainate injection
Due to the suggested importance of astrocytes in cerebral insults, the astrocytic 
population was observed after haematoxylin and eosin staining. No increase of 
astrocyte-typical cells (small, dark bodies under light microscopy) was observed after 
i.p. administration of kainate in the hippocampus compared with saline controls, 
except occasionally a small increase directly around areas o f  cell damage (see above 
photomicrographs). In i.h. studies, a larger number of cells were apparent around the 
CAS region in damaged brains (see fig. 24). None were observed in any regimen 
without corresponding damage. None of the compounds which proved protective 
increased the number of astrocytes without the presence of damaged neurones. When 
examining the extrahippocampal regions sensitive to kainate a large number of 
astrocytic-like cells were apparent when damage was observed. Again, no protective 
compound increased the number of astrocytic-like cells.
81
. 35 Photom icrograph  o f  the pyriform cortex from an animal injected with saline (i.p ). The 
haematoxylin  and eosine staining o f  the control pyriform region shows blue viable cells, 
w ithout the presence o f  compromised neurones. The morphology o f  cells in this region is 
similar to that o f  the control hippocampus. 20 mm : 40 pm.
36 Pyriform region following peripherally  injected kainate. In stark contrast to the control 
section above, the addition o f  10 mg. k g - 1 kainate induces widespread neuronal cell death. 
Very few viable cells are apparen t amonst the eosin stained com prom ised  neurones, and 
large gaps devoid  o f  cells can also be observed. 20 mm : 40 pm.
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Fig.  3 7  C o r r e l a t i o n  b e t w e e n  d a m a g e  of  t h e  p y r i f o r m  c o r t e x  wi th 
t h a t  of  t h e  CA 3a r e g i o n  of  t h e  h i p p o c a m p u s .  V a l u e s  a r e  
p e r c e n t a g e  d a m a g e  a s  a s s e s s e d  by h a e m a t o x y l i n  a n d  
e o s i n  s t a i n i n g .
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Results
TUNEL-POSITIVE CELLS 
Intraperitoneal injections
For a number ot sections previously stained with haematoxylin and eosin to 
determine damage, serial sections were stained with the TUNEL method to identify 
apoptotic cells (table 1). These serial sections were no more than 20 pm anterior or 
posterior to the haematoxylin and eosin stained section . For determining whether 10 
mg. kg"1 kainate induced apoptosis, four sections were used. As determined from 
haematoxylin and eosin studies, two of these sections were from a hippocampus 
which was highly damaged (90 % : 75 % and 60 % : 75 % damage for the CAI : 
CA3a regions in the two sections respectively) and two represented the hippocampus 
from an animal with moderate to low damage (50 % : 5 % and 25 % : 10 %). For 
comparison, fig. 39 & 40 and fig. 41 & 42 are the CAI and CA3a regions of TUNEL 
stained sections from a saline treated and a kainate treated animal.
TUNEL staining of brain sections from these animals revealed apoptotic cells only in 
the CAI region. This staining was observed only in the three animals where previous 
haematoxylin and eosin staining of serial sections had observed moderate to high 
levels of damage in the CAI region (50-90 %) and not in the animal with damage of 
25 %. No apoptotic cells were apparent in the CA3a region (or any other pyramidal 
region) in any of the kainate treated animals. This increase in TUNEL positive 
staining in the CAI region was not observed in animals treated with saline only.
Similarly, TUNEL staining experiments with CGS 21680 (0.1 mg. kg '1) + kainate (10 
mg. kg '1) and ZM 241385 (10 mg. kg'1) + kainate (10 mg. kg '1), were performed on a
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number of sections covering a range of damage levels. For CGS 21680 (0.1 mg. kg'1) 
+ ZM 241385 (10 mg. kg"1) + kainate (10 mg. kg '1) no animal displayed any 
hippocampal damage (from haematoxylin and eosin stained sections) and therefore 
TUNEL stained sections did not reflect this neurodegenerative range.
Only one of these sections stained for TUNEL displayed any apoptosis in the CAI 
region, and then the amount was low The amount of damage in this ZM 241385 (10 
mg. kg '1) + kainate(10 mg. kg '1) treated animal was 10 %. In the CA3a region the 
percentage of TUNEL positive cells correlated to damage (from haematoxylin and 
eosin stained sections).
In all the above experiments, a linear correlation between the percentage of apoptosis 
and damage was observed (fig. 43; p < 0.001, slope = 0.902 ), such that apoptosis 
increases proportionally with increased damage. In only one instance was the 
presence of TUNEL staining apparent without any correlating damage. This may 
represent an early stage of apoptosis which haematoxylin and eosin staining does not 
detect.
From the table therefore, it is apparent that none of the above regimens, protective or 
detrimental, exerts its effect by increasing or decreasing apoptotic cell death within 
the CAI above that expected (i.e. low or no damage associated with low or no 
TUNEL staining, and moderate to high damage with a higher presence of apoptotic 
neurones).
From sections counterstained with eosin after TUNEL staining, it is apparent that 
within the CAI, the TUNEL-positive cells were the same cells observed as damaged 
after haematoxylin and eosin staining (Fig. 44). While the majority of TUNEL-
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positive cells were counterstained with the deep pink colour not all of the pink cells 
in the CAI stained for apoptosis (10-20 % remained unstained for apoptosis). In 
agreement with the earlier studies above, there was the presence of pink damaged 
cells in the CA3a without any indication of TUNEL staining (Fig. 45).
In all the above experiments, TUNEL staining (when present) was localised in the 
dark nuclear matter within the cell, corresponding with the condensed chromatin 
feature of apoptosis.
Intrahippocampal injections
A different picture emerged after TUNEL staining of sections for intrahippocampally 
injected animals (table 2). After kainate injections (0.25 nmol), TUNEL-positive 
cells were noted only in areas of damage, including a large number along the 
injection tract. Damage in the CA3a region after kainate injection (0.25 nmol), 
observed from haematoxylin and eosin stained sections was near maximal in all 
animals studied (n = 3). Following TUNEL staining a large number of apoptotic 
cells were also apparent in the CA3a region. In the CAI region, TUNEL staining 
was positive only in the one animal which displayed damage (20 %). Similarly, 
animals injected with CGS 21680 (2.5 nmol) and kainate (0.25 nmol) exhibited 100 
% damage in the CA3a (n = 3) and a large number of apoptotic neurones. The only 
variation in this pattern of high damage, high TUNEL-positive staining, was 
observed in animals treated with ZM 241385 (2.5 nmol) with kainate (0.25 nmol), 
where no TUNEL-positive staining was noted in two of the three sections with 
previously observed CA3a neuronal damage (60-90 %).
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Table 1 Table correlating serial sections stained for either damage or apoptosis after i.p. injections 
Values are percentage damage (determined from haematoxylin and eosin staining) or 
percentage o f  positively stained neurones (obtained from T U N E L  experiments).
.
CA1 Damage CA1 TUNEL CA3a Damage CA3aTUNEL
Kainate 10 mg.kg-1
90 90 75 0
50 25 5 0
60 40 75 0
25 0 10 0
Saline
0 0 0 0
................... 0 0 0 0
■ ' 0 0 0 0
CGS21680 0.1 m3. kg-1 + Kainate 10 mg. kg-1
45 40 10 0
0 0 0 0
0 0 0 0
45 40 25 0
ZM241385 10mg. kg-1 + Kainate 10 mg. kg-1
0 0 0 0
60 60 15 10
0 0 0 0
0 0 0 0
75 70 15 0
CGS21680 0.1 mg. kg-1 + ZM241385 10 mg. kg-1 + Kainate 10 mg. kg-1
0 0 0 0
0 0 0 0
0 0 0 0
CGS21680 0.1 mq. kg-1 + 8-PST 20 mg. kg-1+ Kainate 10 mg. kg-1
50 50 25 0
90 80 65 0
0 0 0 0
Fig. 39 Lack o f  T U N E L  staining following i.p. injected saline in the CAI region. T he  above 
photom icrograph provides a control for the C A I region. N o staining of neuronal material 
can be discerned. 20 mm : 50 pm.
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Fig. 40 Control T U N E L  staining in the C A 3a region after i.p. saline injection. As for the CAI 
region, no staining o f  neurones o f  this region can be observed in control animals. 20 mm : 
50 pm.
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Fig. 41
Fig. 42
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Kainate-induced T U N E L  staining in the C A l region o f  the hippocampus. 10 ntg.kg 1 
kainate (i .p.) increasd the T U N E L  staining in the C A l region. As can be seen, the staining 
is localised to the compact material o f  the nucleus, with very little non-specific staining. In 
this photomicrograph most neurones have stained positive for the apoptotic  marker. 20 mm 
: 50 pm
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N o T U N E L  positive staining o f  neurones o f  the C A 3a region following kainate
administration. The C A 3 a  region o f  the same animal which produced the above picture ot 
T U N E L  staining in the C A l did not display similar staining for the C A 3a  region, although 
non-neuronal cells (e.g. glia) are positively stained. 20 mm : 50 pm
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Fig. 44 Eosin countersta ining o f  the C A l region following the T U N E L  method (i.p.). Cells stained
for apoptotsis  also take up the deep pink eosin (see th ick arrow), although not all o f  the non-
viable cells are positive for apoptosis (thin arrows). While this section is from an animal
injected with 2 pg. k g '1 CGS 21680 + 10 mg. kg 1 kainate, it is typical o f  the C A l region
following any dam aging regimen. 20 mm : 40  pm.
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Fig. 45 D am aged  C A 3a  region stained by both the T U N E L m eth o d  and eosin (i.p.). A lthough a 
num ber o f  dam aged  cells are apparent (see arrows), none are positive for apoptosis. Again 
this was representative o f  the C A 3a region where dam age occured after i.p. injections. 20 
mm : 40 pm.
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rable  2 Table correlating T U N E L  positive staining with haematoxylin and eosin assessed
dam age in the C A 3a  region o f  the hippocam pus after intrahippocampal injections. 
Values represent percentages for the respective experiments.
CA3a Damage CA3aTUNEL
V A AC___1
______________
. . .  '3  1 ;
2.5 nmol + Kainate 0.25 nmol
>—i
2.5 nmol + Kainate 0.25 nmol
Adenosine 2.5 nmol + Kainate 0.25 nmol
10 
95 
95
o
80
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Results
BRAIN-DERIVED NEUROTROPHIC FACTOR  
Intraperitoneal injections
Brain sections were examined immunohistochemically for the presence of BDNF 
protein (table 3). After i.p. injections of 10 mg. kg*1 kainate an induction of BDNF 
protein was observed compared with the saline control treated animals (fig. 48 & 51). 
The staining for the BDNF protein was observed diffused throughout the cytosol of 
the cell. Although there was an increase in BDNF induction throughout all regions 
of the hippocampus after kainate, the percentage of cells stained positive for BDNF 
did not correlate directly with damage observed from haematoxylin and eosin 
staining.
With the low amount of damage associated with CGS 21680 (10 mg. kg*1) + kainate 
(10 mg. kg*1), it was difficult to observe any increase or decrease in BDNF protein 
binding when compared with kainate alone (i.e. independent of damage). Evidence 
from the two damaged hippocampi following injection of the A2A agonist with the 
excitotoxin, suggests that BDNF protein is expressed only in the presence of cellular 
damage (although as suggested from experiments where kainate was injected alone, 
the level of induction does not directly correlate to that of damage).
While CGS 21680 0.1 mg. kg*1 with kainate 10 mg. kg*1 (n = 8 ) did not show any 
induction of BDNF staining in any section where damage was not observed, the 
further addition of ZM 241385 10 mg. kg*1, appeared to alter this pattern of induction 
as BDNF protein was observed in three of five sections where damage had not 
occurred. This was also apparent to a lesser extent with ZM 241385 10 mg. kg*1 and
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kainate 10 mg. kg'1. In complete contrast animals treated with the A\  agonist R-PIA 
(when given at 25 fig. kg '1, n = 5), did not display the kainate-associated induction of 
BDNF staining even though damage occurred in two of the sections.
Intrahippocam pal injections
Table 4 shows that effects similar to those seen with i.p. kainate were observed after 
central injection of 0.25 nmol kainate. BDNF staining was mostly localised to cells 
within areas of damage (CA3a and CA3b), but displayed no direct correlation 
between the extent of damage and degree of staining (fig 53 & 54 compares 
photomicrographs of the CA3a regions of animals treated with saline with kainate). 
At 2.5 nmol none of the combinations of CGS 21680, adenosine or ZM 241385 with 
kainate 0.25 nmol displayed this increase in BDNF staining, even though a 
proportion of animals with each regimen did exhibit damage within the CA3 region 
of individual experiments. A slight increase was noted at lower concentrations of the 
above compounds, although still less than the increase seen with kainate alone. In 
contrast 0.25 nmol R-PIA did not appear to affect the augmentation of BDNF 
staining by kainate.
NITRIC OXIDE SYNTHASE INHIBITORS
Nitric oxide synthase inhibitors, L-NAME and 7-nitroindazole, were injected 10 
minutes before the intraperitoneal injection of 10 mg. kg-1 kainate (Fig. 55). 
Subsequent haematoxylin and eosin staining revealed significant protection against
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able 3 Correlation o f  serial section stained for BDNF or damage after
intraperitoneal injections. Values represent percentage dam age (from 
haematoxylin and eosin staining) or percentage o f  cells expressing B D N F protein.
CA1 Damage CA1 BDNF-Ab CA3a Damage CA3a BDNF-Ab
Kainate 10 mg.kg-1
_____
.......... .
ig. 48 C omplete  absence o f  B D N F protein staining following i.p. saline injection. While the 
formation o f  the C A l can be discerned, there is an obvious lack o f  staining to any degree 
with the saline control.  20 mm : 40  pm.
ig. 49  Lack o f  B D N F  staining in the C A 3 a  region o f  control animals. As for the C A l region, the 
absence o f  B D N F  protein staining makes the C A 3 a  region barely perceptible. 20 mm : 40 
pm.
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Fig. 50 Kainate-induced B D N F protein staining in the C A F  C om pared with the near blank picture 
obtained with saline controls, 10 mg. k g '1 kainate (i.p.) increased BDNF protein throughout 
the C A l region. Noticeably, the staining is mostly localised to the neurones. Within the 
neurones themselves, staining appears to be found in discrete patches on the cellular 
membrane. 20 mm : 40 pm.
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Fig. 51 Kainate also increases the amount o f  positive staining for B N D F protein in the CA3a region.
A very similar picture is observed within the CA3a region after 10 mg. k g '1 kainate as for the 
C A l region, with most staining localised to patches on nuclear membranes. 20 mm : 40 pm.
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Table 4 Table correlating serial sections stained for BDN F protein or damage,
after intrahippocampal injections. Values represent percentage o f  
damaged cells or percentage o f  total cells stained positive for BDNF.
. . .
CAl Damage CA1 BDNF-Ab CA3a Damage CA3a BDNF-Ab
ii ..............— ■i..
■mm.
:____________ . '
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o 
o 
o 
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95 0 
100 15 
0 0 
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90 0 
95 0 
100 80
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O 
O 
O 
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90 10 
90 20
Adenosine 0.25 nmol + Kainate 0.25 nmol
0 0 
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90 0 
100 10 
80 20
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0 70 
100 60
100 85 
90 90 
30 0
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Fig. 53 No B D N F  protein-positive staining is apparent following intrahippocampal injection o f  
saline in the C A 3a  region. Similar to the picture observed after i.p. saline, a complete lack 
o f  staining for the protein was observed after the injection into the hippocampus o f  1 pi 
saline. 20 mm : 40 pm.
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Fig. 54 B D N F  staining in the C A 3a region following i.h. injection o f  kainate. A different pattern is 
observed  following i.h. kainate than for systemic administration. Due to the lack o f  
neurones in the C A 3a  region seven days after the initial injection, the lack of neuronal 
staining is not surprising. Positive staining o f  glial cells is apparent. 20 mm : 40  pm.
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kainate excitotoxicity in the hippocampus. L-NAME, administered at a dose of 5 
mg. kg"1, significantly reduced damage associated with kainate alone in the CAl 
(from 56.7 % ± 9.6 to 5.0 % ± 2.9) and CA3a region (51.1 % ± 9.0 to 10 % ± 5.8). 
Similar significant values were obtained for the i.p. injection of 7-NI in the kainate 
model. In the CAl region percentage damage was 2.5 % ± 2.5 and 5.0 % ± 5.0 for 
the CA3a area. Both regimens tended to reduce kainate-associated damage in the 
CA2 region of the hippocampus, but in both cases this decrease was not significant.
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DISCUSSION OF M ETHODS  
Routes o f Injection: Advantages and Disadvantages
In this study both intraperitoneal (i.p.) and intrahippocampal (i.h.) routes of kainate 
administration were used, in order to correlate data between the two and provide 
further insight into the mechanism of action of purines within the kainate model of 
excitotoxicity.
After systemic administration of kainate, < 1 % reaches the brain (Nadler et. al., 
1980; Berger et. a l, 1986). MacGregor (1994) calculated that for a 200 g rat (with 
an estimated brain weight of 3 g) an intraperitoneal injection of 10 mg. kg' 1 would 
result in an intracerebral concentration of < 1.75 nmol. Of course this value is an 
estimation, with variability between animals in physiology (e.g. pH, blood flow etc.), 
possibly affecting the concentration.
Another factor which may result in differences of kainate between individual 
experiments is the ability of kainic acid to cause dysfunction to the blood brain 
barrier. Saija et. al. (1992) noted that kainate increased permeability of the blood 
brain barrier to [,4C]GABA within the cortex, hippocampus and cerebellum, 
although this was not always constant with either an increase in neuronal injury or an 
alteration in glucose utilisation. The fact that such a small percentage of kainate 
reaches the CNS (and is therefore more susceptible to minor changes in
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environment), may help explain why kainate, when injected systemically alone, or in 
conjunction with other compounds, produces variation between experiments in the 
degree of damage (e.g. Balchen et. al., 1993; MacGregor & Stone, 1994), which is 
not observed in culture (e.g. Deupree et. al., 1996).
Even though the exact concentration of kainate within the CNS may not be known, 
systemic injections should result in a widespread (if not necessarily homogeneous) 
distribution of kainate throughout the brain regions. This is both advantageous, in 
that it provides an overall picture of effects mediated by kainate, as well as 
detrimental in studying the effects on specific localities (e.g. the hippocampus), as 
afferent pathways from one region may distort the picture in another. This may still 
happen after intrahippocampal administration due to diffusion of kainate, although 
with only a small volume of drug injected, this effect on afferent pathways is likely to 
be less significant. The i.h. route may represent a more accurate picture of 
excitotoxic damage to the hippocampus, since less afferent effects modulate the 
hippocampal response to kainate. Peripheral effects may also contribute to the 
overall picture after i.p. injections.
While injections into a specific region of the brain negate a large number of the 
problems associated with systemic injections (e.g. unknown concentrations, 
peripheral effects), intrahippocampal administration does possess it’s own 
complications. The process itself is more invasive, requiring the animal to undergo 
general anaesthesia. Apart from interference to the experiment by the anaesthetic 
itself (see later), the stress to the animal combined with a recovery period may exert 
unknown effects on the experiment. Some of the effects were compensated for: (a) 
Body temperature under anaesthesia was maintained by a thermal blanket coupled to
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a rectal probe, (b) The period for which the animals were maintained under 
anaesthetic was kept to a minimum ( ~ 1  hour), and (c) any fluid loss due to inability 
(or lack of inclination) to drink was corrected by two i.p. injections of 2-3 ml saline 
post-operatively. Other disadvantages of intrahippocampal injections include the 
disruption to the blood brain barrier by the insertion of a fine needle into the 
hippocampus and the possible influx of blood borne products (such as macrophages). 
The injection also produces a gradient of concentration of kainate away from the 
needle point. At the tip of the needle the concentration of the administered 
compounds would be that of the initial solution, but as the compound diffuses 
outwards, the concentration becomes more dilute.
To help overcome the disadvantages associated with both the i.p. and i.h. excitotoxic 
models, this study used both in an attempt to fully investigate protection observed 
with some compounds.
H aem atoxylin and Eosin Staining
One of the main problems with any study investigating any form of cellular death is 
how to determine accurately when a cell is classified as dead (or beyond the point 
from which it cannot recover). As both the necrotic and apoptotic cell death 
pathways share a degree of homology in their latter stages (such as ATP depletion, 
mitochondrial dysfunction and free radical production) the point at which a cell may 
be classed as dead may be similar. Within either process of cell death, there are 
known to be stages that are reversible (e.g. blebbing, macromolecular synthesis and 
chromatin condensation) and those beyond which the cell cannot recover (e.g.
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distortion of the cell membrane; Trump & Berezesky, 1995). There are a number of 
techniques which attempt to focus as close to the ‘point of no return’ as possible. 
Most prove ultimately to hold true in the majority of cases, but not universally, 
resulting in the acceptance that most techniques label markers that suggest and 
usually correlate with, but do not conclusively prove, cell death. Such techniques 
include labelling of the gliotic marker [3H]l-(2-chlorophenyl-V-methyl-V-(l- 
methylpropyl)-3-isoquinoline-carboxamide ([3H]-PK 11195) after neuronal insults 
(MacGregor & Stone, 1993) and measurement of protein synthesis (Karle et. al., 
1995) which correlates incompletely with cell viability during apoptosis (Mills et. al., 
1995). The result is that most studies resort to the older, simpler methods afforded 
by histology. Even within histology there is still variation in the stain used and the 
method of quantification. Stains used for models of cerebral insults are include 
haematoxylin and eosin (Li et. al., 1992; Aguis et. al., 1994; Dawson et. al., 1994; 
Fujitani et. al., 1994; Book et. al., 1995; MacGregor et. al., 1996b; Bramlett et. al., 
1997), and various methods for staining Nissl substance (Von Lubitz et. al., 1989, 
Von Lubitz et. al., 1994). While the increase in eosin staining intensity of damaged 
neurones is apparent in both our studies and those mentioned above, there has been 
no investigation into this phenomena. The increase in intensity may represent the 
change in pH of a compromised cell (to which eosin is sensitive) or cellular 
breakdown (e.g. of the tertiary structure of proteins, providing a larger number of 
sites for the acid stain to interact with). The cells stained are those at the later stages 
of cell death.
There is also variation between methods on the quantification of dead cells stained by 
the specific technique. The most common is a straight forward count of dead cells as
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a percentage of total cells (e.g. Fujitani et. al., 1994). This highlights another 
problem with any histological technique. As the section under examination is a 
‘snapshot’ of an ongoing situation, it takes no account of preceding or subsequent 
events. After any insult where cells are compromised, mechanisms to remove debris 
of dead cells are initiated. This results in the possibility that within an area of 
damage, the cell count of non-viable against total cell population may underestimate 
actual damage (i.e. discounts any cells that have been removed subsequent to cell 
death). Other studies overcome this by introducing a semi-quantitative system that 
covers a wider degree of damage (e.g. Berg et. al., 1993; Magloczky & Freund, 
1993). The disadvantage with this method is a loss of accuracy between damage at 
either end of the bands within the scale. Another method of determining damage by 
calculating the actual area of damage (e.g. Green & Cross, 1994), brings problems of 
determining the exact border between areas of compromised and non-compromised 
cells.
The method for determining cell death in this study is a combination of a direct cell 
count and quantitative observation. Due to the distinct morphological characteristics 
of the hippocampus it allows both an accurate calculation of the percentage of dead 
cells as well as the ability to discern easily areas of neurone depletion. The resultant 
percentage scale used in this study (in stages of five), is therefore an indication of 
percentage cell death which takes in to account areas where there is an obvious 
depletion of visible neurones. Figure 3 shows how the above method correlates with 
damage calculated using with actual cell counts. While in most experiments there is 
a high degree of correlation between the two methods, our more versatile protocol 
gives a more accurate value in instances where a proportion of the hippocampus is
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devoid of cells. The method used therefore represents a reliable and reproducible 
indication of neuronal death within the discrete populations of the hippocampus.
The TUNEL Stain as an Indicator o f Apoptosis
As mentioned above staining for cell death (whether apoptotic or necrotic), is not 
without compromise. Specific for apoptosis are a number of features which can be 
observed using a variety of techniques. While these markers (such as induction of 
immediate early genes (IEGs)) are an indication of apoptotic mechanisms, they occur 
before the onset of terminal cell death (i.e. cells can recover after the induction of 
IEGs). As both necrosis and apoptosis share a similar final pathway, discriminating 
between the two after the ‘point of no return’ may be difficult. Methods identifying 
apoptotic markers, therefore, do not quantify cell death per se, but highlight the 
mechanism by which cell death is occurring. This definition still has a problem in 
that a cell may be identified as undergoing apoptosis, before being overcome by 
necrotic mechanisms. Further complications arise from the evidence that apoptosis 
may encompass a number of discrete variations. For example, studies of T-cells 
from p53 knockout mice have found both the dependence and independence of 
apoptosis on p53 protein (which modulates the expression/induction of genes and 
proteins believed important in apoptosis; e.g. c-fos) in glucocorticoid and y-radiation 
induced apoptosis respectively (Clarke et. a l , 1993; Lowe et. al., 1993).
Controversy is also apparent in the use of marker methods such as the TUNEL 
method used in this study, or examination of DNA laddering using gel 
electrophoresis. Studies have shown that while endonuclease activity is usually
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present in models of apoptosis, blockade by DNA-degrading enzyme inhibitors does 
not affect the final outcome of the cell (Sun et. al., 1994). The TUNEL method for 
identifying apoptotic cells is also controversial, with a number of studies disputing 
the specificity of TUNEL to identify only those cells undergoing apoptosis (Van 
Lookeren Campagne & Gill, 1996; Nishiyama et. al., 1996), suggesting that DNA 
nick end labelling can also stain positive for necrosis.
DISCUSSION OF RESULTS  
K ainate Neurotoxicity, i.p.
In the above study 10 mg. kg' 1 kainate was enough to result in extensive damage to 
selected regions in the rat brain. Our experiments showed a large amount of neuronal 
degradation within the hippocampus, and specifically within the CAl, CA3a and 
CA2 regions. This correlates well with other studies, where percentage degradation 
in the CAl is similar to the CA3a regions (MacGregor et. al., 1996a; Schwob et. al 
1980). Although other reports have shown a similar increase in damage in the CA2 
region to the present study (22 %) after systemic injections of kainate (MacGregor et. 
al., 1996a observed CA2 pyramidal cell damage of -18 %), only this study found this 
increase significant. This could be due to a difference in the number of animals 
tested or in variation of kainate damage between individual experiments distorting 
any significance in the other reports. In agreement with other studies, no damage due 
to kainate was observed in the CA3b or CA4 region.
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Damage to the CAl region of the hippocampus is known to be dependant on the dose 
of kainate since Balchen et. al. (1993) observed that while the typical CAl and CA3a 
regions were damaged at 10 mg. kg'1, there was no discernible neuronal loss in CAl 
after a higher dose of 20 mg. kg'1. At 10 mg. kg '1, in our own study and that by 
Balchen et. al. (1993), it is probable that kainate acts on the CA3a neurones directly 
(the CA3a region has the highest population of kainate receptors; Wisden & Seeburg,
1993), innervating the CAl region via the Schaffer collaterals. This may result in 
indirect distal damage along these fibres to the CAl region in a manner discussed 
later.
At 20 mg. kg '1, Balchen et. al. (1993) postulated that kainate compromised the CA3a 
neurones before they were able to stimulate the collateral pathway. Arguing against 
this view is the fact that after 2 0  mg. kg' 1 kainate, over half the neurones still 
remained (only 15 % less than remained after 10 mg. kg'1). The speculation that 
kainate damages selective neurones within the CA3a area (possibly those responsible 
for innervating the CAl region), cannot be ruled out. Indeed Strain et. al. (1991), 
showed that even at 32 mg. kg'1, kainate only damaged 58.8% of the neurones in the 
CA3 region. Both DPMA and the low dose of CGS 21680 gave preferential 
protection of the CAl over the CA3a region. While this was more obvious in the 
DPMA injected animals, where there was no significant protection of the CA3a 
region, 0.01 mg. kg' 1 CGS 21680 displayed a greater reduction in CAl neuronal 
damage than in the CA3 region. This may imply a difference between binding sites 
within these areas (e.g. in density or affinity), or a difference in the mechanism of 
toxicity. The latter may be explained by neuronal loss in the CA3a being a direct 
toxic action of kainate, while CAl degeneration relies on innervation from the CA3
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region. Cells which do not undergo direct toxicity may therefore have a lower 
threshold for protection.
In our study, extrahippocampal damage was observed in the pyriform cortex and 
regions of the amygdala. These finding are in agreement with other studies, which 
have also observed neurodegeneration in the olfactory cortex, the thalamus and 
neocortex (Schwob et. al., 1980; Sperk et. al., 1983). It is interesting to note that in 
our study, distal damage to the pyriform cortex significantly correlated with damage 
to the CA3a region of the hippocampus, but not to the CAl region, suggesting that 
pyriform damage is linked to that of the CA3a area.
Protection by A 2a Receptor Agonists, i.p.
In this study both A2a adenosine agonists, CGS 21680 and DPMA, proved protective 
against 10 mg. kg' 1 kainate, suggesting that the A2 receptor has a far larger role than 
was previously assumed. DPMA, which is 13-fold selective for the rat brain A2 
versus the Ai receptor (Hutchison et. al., 1989), protected pyramidal cells in the CAl 
and CA2 region, but not in the CA3a region. This protection was only observed at a 
high concentration of 1 . 0  mg. kg' 1 and not at 0 . 1  mg. kg'1, suggesting that the 
protective effects were mediated not by A2, but by Ai receptors. On the other hand 
CGS 21680, showed protection at a concentration of 0.01 mg. kg'1, and even partial 
protection as low as 2pg. kg'1. CGS 21680 is much more selective than DPMA for 
the A2a subtype (140-fold versus the Ai receptor).
While protection has been observed in a number of models with an Ai receptor 
agonist (MacGregor et. al., 1993; Arvin et. al., 1989), a similar result with an A2a
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agonist was not predicted. As Ai and A2a receptors exert a number of opposing 
effects (e.g. on glutamate release (Poli et. al., 1991; O’Regan et. a l,  1992) and 
cAMP production (Lupica et. al, 1990)), it was assumed that administration of A2a 
agonists in a model of excitotoxicity or ischaemia would be detrimental. This belief 
was further strengthened by evidence that A2a receptor antagonists were 
neuroprotective (Phillis, 1995; Von Lubitz et. al., 1995). Few reports actually 
studied the effects of A2a agonists themselves, even though discrete populations of 
A2a receptors are located in the brain (Jarvis & Williams, 1989), including the 
hippocampus (Cunha et. a l, 1994).
Von Lubitz et. al. (1995), showed that chronic pre-operative administration of the 
weakly selective A2a agonist APEC improved cortical blood flow and survival of 
hippocampal neurones. More recently, Sheardown and Knutsen (1997) displayed 
protection by CGS 21680 in a model of temporary forebrain ischaemia in gerbils. 
The study found protection in the CAl with CGS 21680 injected post-operatively (30 
and 120 minutes) at a concentration of 2  x 10 mg. kg'1, but not at 2 x 3.0 mg. kg'1. 
Effects in other regions of the hippocampus were not reported. Contrary to the belief 
of Sheardown and Knutsen (1997), it is possible that CGS 21680 may exert some Ai 
receptor binding at this high concentration, although due to the lack of investigation 
using any antagonists, it is difficult to substantiate this proposal for any A]-mediated 
protection.
The time of drug administration may also be important, with post-operative 
injections requiring a higher concentration to be effective. Unlike our own results, 
DPMA did not protect the hippocampus in the study of Knutsen and Sheardown 
(1997). This is possibly due to the concentration not reaching levels required to
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protect the hippocampus (in our study, DPMA was protective only at a dose 10-fold 
greater than that of CGS 21680).
Adenosine A2A receptor stimulation has a number of effects, both beneficial and 
detrimental. As the overall effect of CGS 21680 was to protect the hippocampus, the 
increase in the excitotoxic amino acids aspartate and glutamate release by A2A 
receptors (O’Regan et. al., 1992, Popoli et. al., 1995) may not play an important part 
in kainate-induced excitotoxicity. It seems likely that any further rise in glutamate 
levels by A2A receptor activation may not have a substantial effect in the excitotoxic 
brain. Levels of release of the excitotoxin are already elevated by kainic acid, and 
even increasing the dose of the glutamate analogue does not appear to increase 
toxicity above a threshold (Strain et. al., 1991).
Effects o f the Addition of Adenosine Antagonists, i.p.
The effects observed with 0.1 mg. kg' 1 CGS 21680 on kainate excitotoxicity were 
modulated by the addition of either the A| receptor antagonist CPX or the peripheral 
adenosine antagonist 8 -PST. CPX, highly selective for the Ai receptor (700-fold 
over A2 receptors), was administered at a dose known to exacerbate kainate-induced 
neurotoxicity (MacGregor & Stone, 1994). When combined with CGS 21680, no 
alteration in the previous A2A agonist protection was observed in the CAl or CA2 
region of the hippocampus. In the CA3a there was an increase in pyramidal cell 
damage to a value of 30 % of that seen with kainate alone. These results show that 
the beneficial effects of CGS 21680 were mostly due to the A2A receptor, with only a 
small amount due to Ai receptor activation. The lack of enhancement of kainate
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damage in the CAl and CA2 regions, suggests the possibility of an inhibitory action 
of A2A receptors on A\ receptors. As kainate itself induces the release of adenosine 
(Carswell et. al., 1997), there should be activation of adenosine Ai receptors by 
endogenously released adenosine. With the introduction of CPX, damage should 
therefore increase due to the inhibition of the protective effects mediated by the Aj 
receptor. Alternatively, the protection by the A2A agonists may be such that any 
decrease in A 1-mediated protection is arbitrary.
In contrast, the addition of 8 -PST did exacerbate damage in all three regions. 8 -PST, 
which is highly charged, has been shown not to cross the blood-brain barrier 
(Baumgold et. al., 1992). It was therefore used as a peripherally acting adenosine 
antagonist. The decrease in CGS 21680-mediated protection suggests that a large 
proportion of it’s effects on neuronal death are mediated in the periphery. Binding 
studies have shown that 8 -PST given alone increased kainate-mediated damage to 
175 % of kainate alone (MacGregor & Stone, 1994). It therefore remains unclear 
whether our decrease in CGS 21680 protection (to 73 % of kainate) represents the 
combined effects of CGS 21680 protection and 8 -PST toxicity via different pathways 
or by the direct antagonism of 8 -PST on the A2A agonist.
Protection with ZM 241385, i.p.
This modulation of kainate excitotoxicity by a purine analogue was investigated 
further, with the introduction of a selective A2A antagonist, ZM 241385. ZM 241385 
is 80-fold selective for the A2A receptor versus the A2B and 400-1000 fold selective 
for A2 versus A| (Palmer et. al., 1995; Poucher et. al., 1995), with low affinity for the
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A] receptor. We observed protection with ZM 241385 against excitotoxic 
neurodegeneration in all of the hippocampal regions damaged by kainate. While 
other studies have observed similar effects in different models with A2A antagonists 
(Phillis, 1995; Von Lubitz et. al., 1995), our study is the first to use a compound 
which is selective for the A2A receptor with no known activity at the adenosine Ai 
receptor. The high degree of selectivity and specificity of ZM 241385 for the A2A 
receptor suggests that the effects observed with the A2A antagonists are via a direct 
action on the A2A and not the Ai receptor. When given in conjunction with CGS 
21680, ZM 241385 completely protected all the pyramidal neurones from kainate 
damage. This increase in protection above that seen with either CGS 21680 or ZM 
241385 alone, may suggest an additive effect, although this is hard to substantiate 
because of the high degree of protection with either compound alone.
The addition of the adenosine Ai antagonist CPX completely negated the protection 
observed with ZM 241385. As ZM 241385 itself has no discernible action on the A] 
receptor, this strongly suggests an interaction between the A2A adenosine receptor 
and the Ai subtype. Such an interaction has been speculated by Cunha et. al. (1994) 
and O’Kane and Stone (1997), who suggested that activation of A2A receptors 
inhibits the action of Ai receptors. Using electrophysiological studies, A2A receptor 
activation by CGS 21680 was shown to reduce the inhibition of population spikes 
induced by the Ai agonist, CPA (Cunha et. al., 1994). Indeed, interaction between 
the two receptors has since been shown to be a requirement in the potentiation of 
cAMP in cultured astrocytes stimulated by a metabotropic glutamate receptor agonist 
(Ogataet. al., 1996).
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This theory of A2A activation resulting in Aj receptor inhibition, would explain why 
both A2A agonist and antagonists, as well as A] agonists are protective and should not 
be entirely surprising, due to the high degree of co-expression and co-localisation 
between the two adenosine receptor subtypes in the hippocampus (Cunha et. al.,
1994).
In the pathophysiology of excitotoxicity and ischaemia, there is a release of 
adenosine. This endogenous adenosine activates both Ai and A2A receptors. If the 
above theory is correct then a proportion of Ai receptors will be inhibited. With the 
further addition of an A2A agonist, a higher degree of protection is observed, 
mediated by A2A receptors. A selective A2A antagonist, such as ZM 241385, would 
inhibit A2A receptors, allowing for the activation of Ai receptors by endogenous 
adenosine. Subsequent addition of CPX would therefore decrease the protection of 
ZM 241385. Ai agonists themselves are protective by overcoming the blockade by 
A2A receptors.
Further evidence is provided in studies of populations of neurones where both Ai and 
A2A receptors co-exist (Correia-De-Sa & Ribeiro, 1994; Cunha et. al., 1996). 
Corriera-De-Sa and Ribeiro (1994) first showed that at the neuromuscular junction, 
A2A receptor-facilitated neurotransmitter release predominated over A] inhibition. 
Similarly Cunha et. al. (1996), observed that endogenously formed adenosine 
preferentially activated A2A receptors in the hippocampus, enhancing synaptic 
transmission.
Microdialysis and high pressure liquid chromatography (HPLC) studies have also 
revealed an interesting phenomenon relevant to this theory. Carswell et. al. (1997)
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showed that kainate induces the release of adenosine by increasing the 
depolarisation-dependent release of glutamate. When the levels of evoked glutamate 
release were decreased by 3,4-Dichloro-A-methyl-jV-[2-(l-pyrrolidinyl)-cyclohexyl] 
benzeneacetamide (U50,488H), the subsequent endogenous adenosine concentration 
declined. Subsequent experiments showed no such decrease in extracellular 
adenosine after the injection of R-PIA, which is also known to decreases the release 
of glutamate. The possibility that the A| receptors were already fully activated before 
that introduction of R-PIA was dismissed owing to the lack of increase of adenosine 
following the addition of an Ai antagonist. One suggestion not examined was the 
possibility that the lack of effect at the A| receptor was due to an inhibition by 
endogenous adenosine mediated via the A2A receptors.
CPX, which blocks A] receptors with high selectivity, has been shown to inhibit the 
cerebral protection exerted by R-PIA in the kainate treated brain (MacGregor et. al., 
1993). Yet when given at the same concentration without the addition of R-PIA, 
there was no increase in damage (MacGregor & Stone, 1993), even though adenosine 
released endogenously would be sufficient to activate a proportion of the Aj 
receptors. At a concentration at which it has been speculated that CPX would inhibit 
both A2A receptors and Ai receptors (MacGregor & Stone, 1993; Simpson et. al., 
1992) there is an increase in toxicity. Similar results were obtained by Phillis (1995), 
who showed that CPX-enhanced neurotoxicity only occurred at 1.0 mg. kg'1, but not 
at the lower dose of 0.1 mg. kg'1. Although this effect was explained as Ai-mediated, 
this concentration was greater than that shown previously in the same experimental 
model to inhibit the depressant action of A2 receptors (Lin & Phillis, 1991) and much
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higher than the 50(j.g. kg’ 1 required to prevent R-PIA protection (MacGregor & 
Stone, 1993).
Further evidence for the inhibition of A2 receptors by CPX at 0.1 mg. kg' 1 (i.p.) 
comes from a study examining the effects of the Ai antagonist on extracellular 
glutamate detected by microdialysis and HPLC (Simpson et. a l,  1992). CPX, which 
had no effect on glutamate release at an i.p. dose of 0 . 0 1  mg. kg’1, decreased the 
release of glutamate after an injection of 0.1 mg. kg’1. The speculation was that CPX 
inhibited the A2-mediated increase in glutamate efflux.
In the same study (Simpson et. al., 1992), CPA (an A] receptor agonist) decreased 
the level of ischaemia-evoked glucose. 5’-A-ethyl-corboxamindoadenosine (NECA) 
which acts at both Ai and A2A receptors, inhibited the release of glutamate at a low 
dose. This was reversed at a higher dose. The authors speculated that NECA was 
acting only on Ai receptors at the lower dose and both subtypes at the increased dose. 
Therefore at the higher dose A2A receptor-mediated effects predominated over those 
of the A 1 receptor. A similar (albeit less dramatic) effect was observed with CPA, at 
a high dose which would activate A2A receptors. At this high dose, CPA would still 
be acting upon A\ receptors with greater selectivity and potency, and therefore the 
expected effect on glutamate release would be a net effect of A| inhibition and A2a 
release. As the actual result was a very pronounced reversal of the inhibition which 
occurred at the lower dose (to control levels), this suggesting that Ai receptor 
activation does not assume such a large role as would be expected. This would be 
explained by A2A-mediated inhibition of A] receptors.
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Behavioural studies also strengthen this theory. Depression of locomotor activity is 
believed to be a property of the A2A receptor (Jain et. a l 1995). In contrast neither 
the stimulation of A| receptors by CPA nor inhibition of both Ai and A2A receptors 
by caffeine, induced any change in locomotor activity. A subsequent increase in 
activity was observed after the combination of caffeine and CPX. This suggests that 
A 1-induced stimulation of locomotor activity requires the inhibition of A2A receptors. 
This again, would be explained by the inhibition of A] receptors by the activation of 
A2A receptors by endogenous adenosine.
Importantly the above hypothesis questions the role of the Ai receptor in the 
neuroprotection afforded by endogenously released adenosine. If Ai receptor 
inhibition does not affect the protection mediated by the kainate (or ischaemically) 
released adenosine, then there may be no Ai receptor mediated element in the 
endogenous situation. Alleviation of damage by Ai agonists occurs only after the 
exogenously administered analogue overcomes this inhibition of the Ai receptor by 
endogenously activated A2A receptors. In contrast, very high doses of Ai agonists 
may actually inhibit the actions of the Ai receptor by stimulating A2A receptors (i.e. 
after maximal A] receptor stimulation, there would be a proportional increase in A2A 
activation). This is indeed the case in study by Simpson et. al. (1992) described 
above, where a high dose of CPA did not display the inhibition of glutamate release 
which was observed at a lower dose.
Discussion
Kainate Toxicity, i.h.
Damage associated with intrahippocampal injections of kainate differed considerably 
from that of intraperitoneal administration. High concentrations of kainate (10 nmol) 
resulted in complete destruction of the entire pyramidal cell layer (CA1-4), while 
lower concentrations (1 and 0.25 nmol) gave near complete damage in the CA3a and 
a moderate amount in the CA3b region. In contrast to intraperitoneal injections, no 
significant neuronal degeneration occurred in the CA1 region. The near complete 
toxicity of the high dose of kainate agrees with Schwob et. al. (1980) who showed 
that almost all neurones within the CNS are sensitive to intracerebral injections of 
kainate toxicity, provided the local concentration reaches a certain level. The sparing 
of the dentate gyrus may represent the apparent higher threshold to kainate toxicity of 
the granule cells (Schwob et. al., 1980).
With the lowest dose (used throughout the remaining experiments), the lack of 
apparent damage in the CA1 region of the hippocampus is in agreement with a 
number of studies (Jorgensen, 1993; Magloczky & Freund, 1993; Schwob et. al., 
1980). Magloczky & Freund (1993) and Schwob et. al. (1980) only found a small 
proportion of CA1 neurones succumbed to kainate excitotoxicity after 
intrahippocampal injections, although a degree of cell death was observed in the CA4 
region. This slight discrepancy is probably due to the difference in the dose of 
kainate, as a dose comparable to our own produced a similar lack of CA1 
neurodegeneration (Magloczky & Freund, 1993). These results are also consistent 
with evidence from binding studies, as [ H] kainate is known to have a high degree 
of binding to the CA3 region, but a lower number of binding sites in the CA1
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(Kataoka et. al., 1993). Higher doses of kainic acid produced increasing damage 
within the CA1 region, although always lower than within the CA3 region 
(Magloczky & Freund, 1993), as indeed in our own study where 10 nmol kainate 
destroyed the entire pyramidal cell layer. Comparable results were obtain^ with
■7
kainate displacement of [ H]glutamate from binding sites within these regions 
(Kataoka et. al., 1993).
Apart from a difference in dose, another reason may be the age of the animals under 
study. Kesslak et. al. (1995) have shown that in young mature animals (3 months 
old) damage is apparent in both the CA1 and CA3 regions after intrahippocampal 
injections of kainate, while in older rats (14-20 months) only the CA3 region stained 
for damage. Again the dose used (0.5 pi of a solution of 0.5 mg kainate in 0.5 ml) 
was 10 times higher than our own. A difference in age is probably only a very minor 
factor as, although the ages of the animals were not given, their weights are 
comparable with (or only slightly lower than) our own (e.g. 190-210 g for Magloczky 
& Freund, 1993).
A final possible explanation could be the use of different anaesthetics. 0.47 nmol 
kainate (approximately twice that used in our study) was found to produce less 
damage in the CA1 region after pentobarbital anaesthesia than after halothane or 
ketamine (Lees, 1992). Whether similar effects are observed with Equithesin 
(phenobarbital based) have yet to be determined.
Contralateral damage after kainate injection was not observed in any of the 
hippocampal subfields. While conflicting with the higher doses used in the 
Magloczky & Freund (1993) study above, who observed contralateral damage in the
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CA1 (but not CA3) region, a similar result was observed with comparable doses. 
Magloczky & Freund, 1993) also reported that the use of Equithesin as an anaesthetic 
during surgery prevented contralateral damage. This may be representative of the 
duration of anaesthetic, which is known to affect kainate (but not NMDA) 
neurotoxicity (Lees, 1992).
Examination of extrahippocampal areas revealed no other areas of damage on the 
same plane of section. This is in contrast with both our results obtained after 
systemic kainate injections, and previous studies. Damage after intrahippocampal 
kainate has previously been observed in the pyriform, entorhinal and amygdaloid 
cortices (Sperk, 1994). One reason for the absence of distal damage may be that 
after kainate injection the pattern is known to be dependant on needle positioning (for 
example 2  nmol kainate injected into the posterior pyriform cortex results in distal 
damage to the CA1 and dentate gyrus fields of the hippocampus, whereas the same 
dose into the anterior pyriform cortex failed to produce any damage to these 
hippocampal regions (Schwob et. a l,  1980). This would not explain the difference 
between our study and others where intrahippocampal injections are used, as 
positioning the needle at the point does provide reproducible patterns of damage 
(Magloczky & Freund, 1993; Schwob et. al., 1980). The lack of distal damage is 
therefore more likely to be dependent on the differences in dose, as Schwob et. al. 
(1980) showed that distal damage increases with dose. Higher doses have been 
linked with both a non-specific binding to NMDA receptors and an inhibition of 
glutamate transport (Deupree et. a l, 1996), both of which would increase 
neurotoxicity. Our study may therefore represent a more accurate model of selective
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kainate toxicity, which when combined with i.p. studies may reveal a more complete 
picture of excitotoxicity.
M echanism  of Kainate Toxicity
The neurotoxic reaction to kainate and glutamate is a complex sequence of events 
with a number of contradictions that have yet to be elucidated. The pathophysiology 
is biphasic, involving an initial acutely toxic phase followed by apparent recovery 
before a further loss of neuronal integrity. The initial stage is believed to be 
mediated by non-NMDA receptors. Evidence for this is the absence of characteristic 
cell swelling after glutamate addition to cortical cell cultures in the presence of Na+- 
free medium (Choi, 1987), suggesting that the accumulation of intracellular Na+ 
(through non-NMDA receptor-associated channels) is responsible. Whether the 
initial phase is neurotoxic per se or requires the later, delayed phase (which may be 
more dependent on the NMDA glutamate receptors), is unclear. Evidence suggests 
that the early phase is not excitotoxic as cell death was not observed in the presence 
of NMDA antagonists, which selectively inhibit the late NMDA-dependent but not 
the initial non-NMDA-dependent phase (Deupree et. a l,  1996). Under culture 
situations, both the non-NMDA glutamate analogues, kainate and AMP A, require a 
more sustained exposure than NMDA to produce toxicity (Choi et. al., 1988; Hartley 
et. al., 1993; Koh et. al., 1990). This further suggests that the delayed phase is 
NMDA receptor mediated. This simple observation is complicated by the evidence 
that DL-2-amino-5-phosphonovalerate (AP-5), which both inhibits the NMDA 
receptor and NMDA toxicity, does not prevent neuronal degeneration by either of the
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non-NMDA receptor compounds (Choi et. al., 1988; Koh et. al., 1990). Similar 
evidence is observed with MK-801, which could not completely block kainate or 
AMPA toxicity at a dose effective against NMDA (Hartley et. al., 1993; Koh & 
Choi, 1991). This was not substantiated by our in vivo results where MK-801 was 
found to protect the hippocampus completely from intrahippocampal kainate toxicity, 
even at a dose as low as 0.01 nmol. Our results were further substantiated by an in 
vitro study where MK-801 did show a complete reduction in the damage marker, 
lactate dehydrogenase (LDH) release (Deupree et. al., 1996). The discrepancy 
between studies may therefore reflect a difference in methodology. NMDA toxicity 
is believed to be dependent on the influx of Ca2+ via the NMDA-associated Ca2+ 
channel. The relationship between kainate and AMPA and Ca2+ levels is more 
ambiguous. While the kainate receptor can increase the influx of Ca2+ directly, the 
AMPA receptor has shown no such mechanism of action (Berdichevsky et. a i, 
1983).
Although glutamate toxicity has been shown to be significantly reduced in neuronal 
cultures incubated in calcium-free buffer, some incidence of neuronal degeneration 
still remained (Deupree et. al., 1996). This suggests that a proportion of glutamate 
toxicity is Ca2+-influx independent. This hypothesis is complicated by the same 
study (and our own) which found that the addition of the NMDA antagonist MK-801
• 4^*(which inhibits the NMDA receptor-associated Ca channel) is completely 
protective. As no calcium chelating agent was added to the culture system, the 
conflict between the results obtained by Deupree et. al. (1996) and ourselves may be 
due to the release of calcium from intracellular stores and across the plasma 
membrane in the period before the addition of glutamate. This increase in levels of
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calcium may therefore be responsible for the limited neurotoxicity. Alternatively, 
cells compromised in the early calcium-independent phase may also release calcium 
across disrupted membranes.
While some studies have not observed a relationship between the amount of calcium 
present within neurones and damage (e.g. Dubinsky, 1993; Dubinsky & Rothman, 
1991; Michaels & Rothman, 1990), a correlation between the total amount of 
calcium influx and neuronal death has been observed in hippocampal cultures (Lu et.
! al., 1996), which is independent of the route of influx. With the variety of
mechanisms within a cell available to maintain calcium homeostasis, the lack of 
correlation between intracellular calcium levels and toxicity is not surprising. 
Another argument against presynaptic-dependent excitotoxicity is the apparent 
contradiction in effective concentrations. In vitro studies have observed kainate 
| toxicity at low nanomolar concentrations, yet intracellular calcium increases only in
the presence of millimolar kainate (Berdichevsky et. a i,  1983; Garthwaite &
i
j  Garthwaite, 1983; Pastuszko et. al., 1984). The release of glutamate and inhibition
i
of glutamate uptake by kainate also occur only at a millimolar concentration (Poli et. 
al., 1985). While this implies that the toxicity o f kainate is due to postsynaptic 
effects and not alterations in extracellular glutamate, it may be due to limitations of 
in vitro studies. Kainate may display a direct toxicity at low levels in culture that 
does not manifest in the more complicated system of the whole brain, possibly due to 
the existence of other cells (e.g. glia, which take up glutamate) which influence the 
environment. There is also controversy over the origin of kainate-induced glutamate 
efflux. A number of studies have found that the release is dependent on the levels of 
intracellular calcium in the presynaptic ceU and that glutamate efflux is exocytotic
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from intracellular vesicles. Pocock et. al. (1988) challenged these findings by 
showing in a synaptosomal system that kainate inhibited the excitatory amino acid 
Na+ co-transporter, allowing a net calcium-independent leakage of glutamate across 
the plasma membrane. The glutamate would be from a metabolic rather than 
vesicular origin. They found no evidence to support the calcium-dependent 
exocytotic release of glutamate. Due to the large number of studies professing 
calcium-dependence in glutamate release, it seems unlikely that glutamate release is 
entirely independent of the dication. The possibility still remains that kainate- 
induced glutamate release relies on both calcium-dependent and independent 
mechanisms. The initial calcium- (and ATP-) dependent glutamate exocytotic 
process being short lasting due to receptor desensitisation and depletion of ATP by 
kainate (Carver et. al., 1996). The non-receptor-dependent leakage from the 
cytoplasm may provide a more sustained release over a period of time. A 
comparable picture of glutamate levels has been observed during cerebral ischaemia 
(Phillis & O’Regan, 1996), with an initial sharp rise in glutamate concentration, 
followed by a longer lasting slow decrease over a period of hours. Due to the rapid 
uptake of glutamate, this slow decline represents a sustained release of the amino 
acid (although at an ever decreasing rate).
More recently a study has characterised the calcium-dependent release of glutamate 
and found that high micromolar kainate inhibited 4-aminopyridine (4-AP) stimulated 
[ H] glutamate release in synaptosomes via an action on the kainate receptor 
(Chittajallu et. a i,  1996). The response was biphasic in that the inhibition was 
preceded by an initial enhancement of release. This could be explained by an inward 
depolarising calcium current through the kainate-linked ion channel, exciting the
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presynaptic cell, before a long-lasting desensitisation of the channels and subsequent 
inhibition. AMPA receptor stimulation was shown to enhance [ Hjglutamate release. 
As the net effect of kainate is known to be an increase in the release of glutamate, 
this release (as shown by Chittajallu et. a l , 1996) is likely to be due to the activation 
of AMPA and not kainate receptors. The release of glutamate by kainate is therefore 
a combination of enhancement via AMPA receptors and inhibition through 
interaction of kainate receptors. As the kainate receptor is desensitised by kainate, 
the less kainate-sensitive AMPA receptor-induced glutamate release is likely to 
predominate.
Further evidence suggesting that kainate-induced glutamate release is mediated by 
AMPA receptors on the presynaptic neuronal population, is that AMPA inhibitors 
and AMPA desensitisation blockers attenuated and potentiated kainate-induced 
glutamate release respectively (Patel & Croucher, 1996). The lack of complete 
inhibition with AMPA inhibitors and the presence of glutamate release without the 
addition of the desensitisation blocker, suggests that activation of the AMPA receptor 
is not the only mechanism involved. Both these results would be explained by the 
observation above, that kainate, aside from direct receptor activation, can increase the 
net leakage of glutamate into the extracellular space. Low concentrations of kainate
9+may inhibit glutamate release by desensitisation of the Ca channel, but at a higher 
(millimolar) concentration induce the leakage of glutamate, thus explaining why 
kainate is still toxic even though it inhibits calcium influx. Kainate has an action on 
AMPA receptors, increasing the influx of K+ and Na+, (removing the Mg2+ block of 
NMDA receptors), as well as this glutamate leakage. As kainate does not desensitise
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AMPA receptors, the influx of ions through the AMPA-linked ion channels is likely 
to be more sustained.
The complete protection of MK-801 against kainate toxicity implies that calcium 
influx through the kainate-associated ion channel may not constitute a significant 
role. Excitotoxicity may therefore be dependent on NMDA-induced calcium influx. 
Indeed the toxic mechanism of kainate may not depend on its interaction with the 
kainate receptor at all, but from the evidence above, rely more on the ability of 
kainate to release glutamate from the cytosol. This glutamate may then act on 
NMDA receptors (with the Mg block removed) increasing intracellular calcium, 
further release of glutamate and subsequent calcium cell death.
An alternative explanation is that kainate may interact directly with the NMDA 
receptor. Direct non-specific binding by the non-NMDA agonists on NMDA 
receptors has been speculated (Deupree et. al., 1996). This speculation was again 
fuelled by the necessity of high concentrations of kainic acid (1 mM), much more 
than required to saturate kainate receptors, to produce neurotoxicity. This can now 
be explained by the toxicity of kainate not being dependent on it’s association with 
the kainate receptor, but with the inhibition of the glutamate co-transporter and direct 
activation of NMDA receptors, especially at higher doses of kainate.
Oedema, resulting from the diffusion of water into the extracellular space, may also 
play a role in kainate toxicity (Sperk et. al., 1983). The subsequent constriction of 
vessels in the vicinity may cause slight alterations in local environment (such as 
blood flow). Although this is a non-specific effect mediated by kainate it may 
compound the already poor situation.
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H istological Consequences o f Kainate Toxicity
The appearance of the brain after kainic acid injection has been well characterised 
(Jorgensen et. al., 1993; Magloczky & Freund, 1993; Schwob et. al., 1980; Sperk et. 
al., 1983). Shortly after systemic kainate administration, the hippocampal regions 
showed a swelling of gliotic cells or postsynaptic dendrites, which was not observed 
(or greatly reduced) 13 hours later (Schwob et. al., 1980). In the same time period 
many neurones underwent marked swelling or shrinkage. Interestingly the swelling 
was associated with glutamate toxicity, while the argyrophilic appearance was 
associated more with status epilepticus (Schwob et. a l, 1980). This stresses that 
kainate and glutamate do not have identical mechanisms of action. In the 
hippocampus, damage in the CA3 regionjs prominent after 8  hours, but damage to 
the CA1 region does not appear until a later time point (24 hours). Thus either CA1 
neurones are more resistant to excitotoxic damage than CA3 neurones (possibly due 
to a lower density of kainate binding sites) or the CA1 neurones degenerate by a 
different mechanism from those of the CA3 region. As shown by our results using a 
low dose of CGS 21680 or DPMA i.p., the latter appears more likely. One of the 
speculative mechanisms by which the CA1 and other neurones distal to the CA3 
region succumb to both i.p. and i.h. administered kainate is by direct innervation 
along axonal pathways.
Another post-intrahippocampal injection characteristic of kainate is an induction of 
glial cells in the brain. Within the damaged regions there is an increase in both small 
rounded macrophages and microglia (identified by a rod-shaped nucleus; Araujo & 
Wandosell, 1996; Jorgensen et. al., 1993). Both cell types are present by day 2 and
128
Discussion
maximal at 7 days. This general gliosis was apparent in the CA3 region, dentate 
hilus and entorhinal cortex. Consistent with a lack of substantial neurodegeneration 
to the CA1 subfield, no major influx of gliotic cells was apparent (Jorgensen et. al., 
1993). This invasion of blood-borne macrophages was not just dependent on 
neurodegeneration or blood brain barrier degeneration, as none were observed after 
lesioning of the dorsal hippocampus, suggesting a more specific response to the 
kainic acid insult. This is further substantiated by the same report which observed 
differences between the gliotic response to kainate and AMPA. The gliotic response 
may be of considerable importance in the overall toxicity of kainate as a mechanism 
of removing cellular debris and their release into the extracellular environment of a 
large number of molecules (including free radicals, nitric oxide and neurotrophins; 
Korsching, 1993). Aside from their role in the short term mediation of 
excitotoxicity, which is discussed below, these molecules have a long term effect on 
the environment of the damaged brain. Immediately after the hippocampal insult, 
astroglial processes extending towards the pyramidal cells of the CA3 region can be 
observed. A network is formed by day 21. Gliotic cells are still apparent 6  months 
later (Jorgensen et. al., 1993).
Distal Damage
There is now a large amount of research to suggest that kainate exerts neurotoxic 
effects to distal regions via afferent fibres. This hypothesis relies on the highly 
selective pattern of toxicity by kainic acid. Kainate is known to be toxic in areas of 
high kainate receptor density (e.g. CA3a region), but is also toxic in areas where
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there is not such a high degree of kainate binding (e.g. the pyriform; Unnerstall & 
Wamsley, 1983). Studies of kainate damage have found that areas linked by axonal 
connections tend to display linked damage. For example, Schwob et. al. (1980) 
observed from differing injection regimens that structures in the thalamus (such as 
the mediodarsal thalamic nuclei) and cortex (such as the agranular areas), which are 
linked neuronally, did not show damage independent of each other. Either both 
regions showed signs of neurodegeneration, or both were undamaged.
A simple experiment by Moncada et. al. (1991b), using both NMDA and non- 
NMDA antagonists after focal injections of kainate, AMPA and NMDA revealed a 
number of irregularities. Both kainate and AMPA were injected at a dose which 
caused near complete neuronal death in the subfields CA1-4. The non-NMDA 
antagonists 2,3-dihydro-6-nitro-7-sulphamoyl-benzo(f)quinoxaline (NBQX) and L- 
(amino)phenyl-4-methyl-7,8-methylendioxy-5H-2,3benzodiazepine HC1 (GYKI 
52466) both protected neurones in the CA1 and CA2 from kainate-induced 
neurotoxicity. There was neither protection of the CA3 region after kainate, nor any 
hippocampal region after either AMPA or NMDA injection. The NMDA antagonist 
(E)-4-(3-phosponoprop-2-enyl)-piperazine-2-carboxylic acid (D(-)-CPPene) 
protected against kainate and NMDA in the CA1 and CA2 regions. The lack of 
protection observed against AMPA with the non-NMDA antagonists was put down 
to the dose of the antagonist being such that it inhibited the binding of the less 
selective ligand (kainate), but was not high enough to compete with AMPA, which 
has a greater affinity for it’s own receptor. This may also explain why no protection 
was observed in the CA3 against kainate. As both the non-NMDA receptor 
antagonists used have a greater affinity for AMPA over kainate receptors (Honore,
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1991; Ouarduoz & Durand, 1991), it seems unlikely that, if the dose used cannot 
block AMPA receptors against AMPA, it can inhibit kainate receptors binding 
kainate.
This study highlighted the concept that the mechanism for kainate toxicity in the 
CA1 was not the same as for the CA3 region. It suggests that for the CA1 region the 
toxicity of kainate is dependent on both AMPA and NMDA receptors, while for the 
CA3 region, kainate excitotoxicity is more dependent on the kainate receptor. This is 
in stark contrast to our results obtained with MK-801 which showed complete 
protection in the CA3a region after intrahippocampal kainate injection. Again the 
deciding factor on the mechanism may be dependent on dose. In the study of 
Moncada et. a l (1991b) the dose used was both higher than our own and sufficient to 
cause extensive damage throughout the hippocampus (including the less sensitive 
dentate gyrus). The higher dose of kainate might be enough to activate both AMPA 
and NMDA receptor populations in the CA1 region to cause direct toxicity, while in 
our own study, kainate may not be at a concentration high enough to bind 
indiscriminately to NMDA receptors. In the CA3 region, the high dose of kainate 
may result in cell death by the activation of a large number of kainate receptors, 
while our lower dose may require the activation of NMDA receptors (e.g. by kainate- 
induced glutamate release). A further possibility may be that kainate can activate 
post-synaptic neurones only over a certain threshold concentration (either directly or 
by releasing glutamate), resulting in distal CA1 toxicity.
Three speculative mechanisms have been suggested to explain this damage along 
axonal connections (Schwob et. al., 1980). The first is that either kainate itself or a 
toxic metabolite is transported the length of the axon. This product then exerts a
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toxic effect at the distal population of neurones. As far as is known kainate (or 
metabolite) is neither taken up by the postsynaptic cell nor incorporated into 
macromolecules necessary for transport facilitation. This mechanism would also 
require the presence of binding sites in the distal region for kainate (or the 
speculative metabolite) to exert the toxic effect. As one of the peculiarities of distal 
damage is that there is not an abundance of kainate receptors, it seems unlikely that 
even if kainate were transported it would be unable to exert an effect.
Another possibility is that neuronal degeneration at the primary site results in the 
production of transneuronal effectors which mediate distal damage. This would 
suggest that a non-specific mechanism is responsible for the production of distal 
damage. As physical lesions which damage primary sites do not reproduce distal 
toxicity in other sites which are linked by neuronal connections, this mechanism is 
unlikely.
The third and most likely scenario is that kainate acts postsynaptically to initiate 
neuronal excitability, which is propagated along axons to populations removed from 
the primary location of kainate action.
Actions of Adenosine Agonists and Antagonists Against Kainate, i.h.
In complete contrast to the effects observed after intraperitoneal injections, CGS 
21680 did not appear to protect against kainate excitotoxicity if administered 
intrahippocampally. This lack of protection was observed using a range of doses, the 
uppermost of which is believed to activate Ai receptors (Zhang et. al., 1994a). The 
lack of protection by the A2A agonist suggests that the beneficial effects are not
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mediated locally at the hippocampus. While not measured, it is unlikely that the drug 
solution would diffuse far from the injection point. It has been observed previously 
that a 5 pi solution of 10 nmol kainate injected over 10 minutes diffused a radial 
distance of only 1.5 mm from the tip of the cannula (Schwarcz et. al., 1978). 
Although the injection volume used in the above experiments was five times greater 
than our own, the speculated diffusion distance for our study would only be ~0.9 mm 
(using the assumption that kainate diffuses in a spherical manner). Even considering 
differences in drug attributes (e.g. lipophillicity), it remains unlikely that any of our 
compounds injected would diffuse throughout the whole rat brain. The i.h. 
experiments do not therefore rule out a global centrally-mediated mechanism. 
Combining these results with the i.p. experiments involving 8 -PST, suggests that the 
effect of CGS 21680 is mediated most within the periphery. The lack of complete 
reversal of the CGS 21680 protection with the peripheral adenosine antagonist 
suggests that some of the protection may be due to a central effect, which, as just 
stated, is likely to be an effect mediated throughout the brain, without any specific 
localisation to A2A receptors in the hippocampus.
While no protection was observed after central administration of CGS 21680, 
intrahippocampal injection of the A2A antagonist, ZM 241385 did dramatically 
reduce kainate-induced toxicity in the CA3a and CA3b regions. This further 
substantiates the theory of A2A-mediated inhibition of the A] receptor, especially 
when considering that the addition of the Ai receptor agonist R-PIA, did not protect 
the CA3a region to any degree. While the inhibition of detrimental effects mediated 
by the A2A receptor in the hippocampus may account for some of the protection 
afforded by ZM 241385, combined with i.p. experiments, the evidence suggests the
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involvement of the A| receptor. Further evidence comes from the lack of protection 
following the administration of adenosine itself (which would activate both the Ai 
and A2A receptor subtypes). While not protecting the CA3a region, R-PIA, at a low 
dose did protect a different subsection of the hippocampus (the CA3b region). This 
effect was not observed with a higher dose. Differences between the two cellular 
sub-populations (CA3a and CA3b), including different A 1/A2A receptor ratio, may 
account this protection. Alternatively, as peripherally administered kainate 
selectively damages the CA3a region, while sparing the CA3b area, damage to the 
CA3b region by intrahippocampally injected kainate may be by a different 
mechanism to that of the CA3a area.
M echanism o f Adenosine A 2a Receptor-M ediated Protection
Adenosine, normally present at 0.05-2 pM in the extracellular fluid, increases 
dramatically in the presence of kainate. The pattern of adenosine increase is bell 
shaped, increasing shortly after kainate administration and peaking at 40 minutes 
(Carswell et. al., 1997).
Adenosine, by A2A receptor stimulation, has been shown to exert effects on blood 
flow (Phillis, 1989; Torregrossa et. al., 1990), phagocytosis, free radical generation 
and neutrophil adhesion (Cronstein et. al., 1994).
The vasodilatory effects of adenosine via nitric oxide modulation have also been 
attributed to the A2A receptor, with little or no implication of any A\ receptor- 
mediated interaction. Stimulation of L-arginine transport (system y+) and a rise in 
cGMP in endothelial cells, indicative of an increase in nitric oxide synthesis, are
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apparent in foetal endothelial cells after A2A, but not Ai receptor stimulation and are 
inhibited by ZM 241385 (Sobrevia et. al., 1997).
Adenosine A2A receptors modulate the activity of cells involved in the inflammatory 
response, by a variety of mechanisms. The adhesion of neutrophils to the 
endothelium, important for effective invasion of leukocytes, is prevented by A2A 
agonists, as is the priming of neutrophils by macrophages and monocytes by the 
release of tumour necrosis factor-a (TNF-a; Cronstein, 1994). While the former is 
mediated by the A2A receptor (Cronstein et. a l, 1985), it is unclear if the latter is due 
to any receptor-induced changes (Parmely et. a l, 1993). Generation of superoxide 
radicals by neutrophils is enhanced by an action of chemoattractant molecules, e.g. 
A-formyl-methionyl-leucyl-phenylalanine (FMLP), on their receptors (Cronstein et. 
a l, 1990). Coupling of these receptors to the cytoskeleton, increased by the 
stimulation of A2A receptors, results in receptor desensitisation (Cronstein et. a l, 
1990). The A2A receptor therefore results in a decrease in neutrophil radical 
production. The combination of these properties of the A2A receptor suggests the 
presence of another protective mechanism in the modulation of the inflammatory 
response, decreasing the overproduction of damaging molecules. To determine how 
much effect the inhibition of this response has on cells within the compromised 
areas, it is first necessary to assess any increase in toxicity due to this response. No 
study has directly measured the leakage of damaging molecules (such as the 
superoxide radical, hydrogen peroxide and possibly BDNF) into the extracellular 
space and the effects of released neurotrophic factors have yet to be fully determined.
The above results suggest that A2A agonists work by a mechanism that is not local to 
the hippocampus. If the inhibition of the local inflammatory response was of major
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importance, then it would be expected that intrahippocampal injections of CGS 
21680 would retain the protective abilities observed by systemic injections. While 
the inhibition of adhesion of neutrophils to endothelial cells may not occur due to the 
limited distance that the adenosine analogue diffuses through the brain, the remaining 
properties would still be apparent. It therefore appears that the production of 
neurotoxic effectors by this route may not play an important role in increasing 
excitotoxic damage. There are a number of explanations to this.
The first is simply that the amount of leakage of molecules such as superoxide 
radicals, may not be substantial enough to induce damage. As mentioned in the 
Introduction, cells have an array of different molecules to neutralise toxins (such as 
glutathione), and it is only after the volume of metabolites overcomes these defences 
that cellular death occurs. Alternatively, due to the release of large amount of toxic 
molecules from other sources during excitotoxicity, the leakage of damaging 
compounds into the extracellular environment by the inflammatory response may be 
surplus to that required to cause neurotoxicity (such that their removal would make 
little impact on the survival of neurones). As inflammatory cells are only apparent in 
areas of damage, the leakage of these molecules will only occur in areas where large 
amounts of toxic metabolites are already present (e.g. superoxide radicals released by 
disrupted mitochondria). The reduction or increase in damaging effectors may be 
offset by an opposite effect of beneficial molecules (such as FGF). As shown in the 
above experiments, glial cells were only present when accompanied by cellular 
damage. It is possible, therefore, that the gliotic response occurs after the onset of 
damage and is concerned with the long-term maintenance of the damaged
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environment, with very little involvement in mediating kainate-associated 
excitotoxicity.
A further explanation for the lack of protection of CGS 21680 after central 
administration, even though it inhibits potentially detrimental inflammatory effects, 
involves the route of drug penetration. After i.p. injections the build up of kainate is 
more gradual than i.h., where the compound is applied directly into the hippocampus. 
Neuronal degeneration after centrally administered kainate was apparent 1 hour post­
lesion (Liu et. al., 1996), while peripheral injections required 3-5 hours to display 
damage (Schwob et. a l, 1980). The speculative reason for a lack of A2A effect may 
therefore be that the inflammatory response does not contribute to i.h. kainate 
toxicity, whereas it plays an important role in toxicity after i.p. injections.
With reference to the protection of CGS 21680 (as well as the other compounds) the 
protective mechanism occurs before the onset of the inflammatory response, 
preventing it’s initiation. This is shown by the absence of any cells involved in the 
response in the hippocampal environment of undamaged brains.
A2A agonists also have a number of effects on transmitters other than glutamate. A2A 
receptor stimulation by CGS 21680 enhances the expression of the gene coding for 
tyrosine hydroxylase in cultured PC 12 cells (Chae & Kim, 1997). This in turn 
modulates the catecholamine biosynthesis pathway, of which tyrosine hydroxylase is 
the rate limiting enzyme (Nagatsu et. al., 1964). The activation of the A2a receptor 
can also facilitate dopamine synthesis and release in striatal cell systems (Onali et. 
al., 1988; Zetterstrom & Fillenz, 1990) and reduce both the affinity of D2 agonists 
for the D2 dopamine subtype receptors (Ferre et. al., 1991), and the resultant effect of
137
Discussion
the receptor (Ferre et. al., 1993). Acetylcholine release from cholinergic neurones 
can also be increased by CGS 21680 (Cunha et. al., 1995).
Intravenous CGS 21680 has been shown to depress cerebral energy metabolism in a 
large number of areas in the brain, including the hippocampus (Nehlig et. al., 1994). 
Regions that displayed this reduction in glucose utilisation included areas of cortex, 
hypothalamus, thalamus as well as the limbic system. Therefore, there was no 
correlation between known A2A receptor binding sites and pattern of depressed 
metabolism. While this lack of conformity between effect and receptor localisation 
is unusual, it is not unique. Similar mismatched results have been obtained for 
GABA (Palacios et. a l 1982), dopamine (Brown & Wolfson, 1981) and muscarinic 
agonists (Dow-Edwards et. al., 1981). The effect is therefore either due to a non­
specific interaction or specific action mediated at a location distal to the area of 
effect. Whether CGS 21680 acts via an adenosine receptor subtype (such as the A2b) 
receptor or other binding sites dissimilar to adenosine Ai, A2a/b and A3 receptors 
(Johansson et. a l,  1993), could not be determined by the use of co-injected 
antagonists. The profile of the location of these sites (the non-adenosine receptor 
sites were localised mainly to cortical regions) did not correspond to the regions 
where glucose depression was observed, suggesting that this effect was not mediated 
by any known binding site of CGS 21680.
Depression of the metabolism of glucose is unlikely to be mediated by the A2B 
receptor, as at the dose used (0.01 mg. kg'1) CGS 21680 does not appear to 
significantly bind to the receptor subtype (Jarvis & Williams, 1989; Johansson et. a l, 
1993; Lupica et. a l, 1990). The participation of Ai adenosine receptors was
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dismissed by the lack of duplication of the CGS 21680 depression by an Aj selective 
agonist (Nehlig et. al., 1994).
It is conceivable that this non-adenosine receptor-mediated depression of glucose 
utilisation may be protective against kainate-induced excitotoxicity (where there is a 
depletion of ATP - Lothman & Collins, 1981; Retz & Coyle 1980) and similarly 
ischaemia. By decreasing the demand for a limited (and depleted) resource (ATP), 
CGS 21680 could decrease cellular stress and related damage. Glucose utilisation 
during ischaemia is decreased in all areas except those areas that are susceptible to 
damage (Choki et. a l, 1983; Jorgensen et. al., 1990; Pulsinelli et. al., 1982). Due to 
the kainate-mediated action in vasodilatating cerebral blood vessels, any effect CGS 
21680 may have is likely to have more importance on peripheral vessels. 
Unfortunately, while studies have shown the advantage of vasodilatation in 
ischaemia (where blood flow is restricted; ), none have investigated this within the 
kainate model of excitotoxicity. Therefore whether increasing peripheral blood flow 
(without the increase of nitric oxide radicals observed with kainate-induced central 
vasodilatation) is protective is not known. Alongside increasing the nutrient supply 
to compromised areas, vasodilatation may also increase the washout of kainate (and 
therefore potentially decrease the toxic effects). This is less likely when considering 
that Sheardown and Knutsen (1997) showed protection with CGS 21680 when given 
30 minutes post-operatively.
In conclusion, the evidence presented suggests that A2A receptor mediated protection 
is an effect that is not mediated by A2A receptors in the hippocampus. The most 
likely candidate for this protection is the vasodilatory action on both peripheral and 
central blood vessels. While this is probably the major beneficial influence, other
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factors that may contribute to a lesser degree are those which influence glucose 
utilisation and the inflammatory response.
In the physiological situation (without external influences) it is unlikely that the 
adenosine released would have a large effect on peripheral vasodilatation. Therefore 
the protective mechanisms of endogenously released adenosine would rely on a more 
locally mediated mechanism. As it seems probable that A2A receptors inhibit the 
action of Aj receptors, this mechanism would have to be mediated by A2A receptors. 
The lack of protection by A2A agonists after i.h. injection (which is more equivalent 
to the normal physiology of excitotoxicity as there are no peripheral effects), would 
question the neuroprotective role of endogenously released adenosine. The release of 
adenosine during kainic acid insults may not, therefore, be an endogenously released 
neuroprotectant, but simply a part of the excitotoxic pathway. This is more probable 
when considering evidence that adenosine release is not unique to the brain, but has 
been shown after stimulation of a number different of preparations, including the 
stomach, heart, vas deferens, blood vessels, bladder, lung and ileum (see Fredholm & 
Hedqvist, 1980). Adenosine release may simply be a consequence of the ionic fluxes 
across the membrane. Further evidence for this comes from our own study where 
adenosine, given intrahippocampally, did not alleviate kainate-induced excitotoxicity 
even at a dose of 2.5 nmol. This concentration of adenosine is greater than the 2 pM 
levels observed after twin pulses of 1 mM kainate (Carswell et. a l,  1997).
This does not discount the use of adenosine agonists and antagonists in the 
prevention of kainate induced excitotoxic damage, but suggests that in the normal 
physiology of the insult, endogenously released adenosine may not have the 
protective role previously assumed.
140
Discussion
Origin of Adenosine Release
Both in vivo and in vitro studies have shown an increase in extracellular adenosine 
after kainate administration and ischaemia (Carswell et. al., 1997; Latini et. al., 
1995). Carswell et. al. (1997) showed that the 2-fold increase induced by a 5 minute 
pulse of 1 mM kainate was due to the activation of non-NMDA receptors, as an 
inhibition of this rise by a non-NMDA antagonist (CNQX), was not observed after 
NMD A antagonists (MK-801 and (±)-AP-5). In vivo, the Na+ channel blocker 
tetrodotoxin (TTX) also prevented the kainate-induced change in adenosine levels, 
implying that neuronal excitation and subsequently generated action potentials are 
the important mediators. Due to the rapid desensitisation of kainate receptors, 
excitation (via an influx of Na+ and/or Ca2+) is likely to be mediated through the 
kainate-insensitive AMPA receptors. As kainate receptor stimulation may even be 
inhibitory (Chittajallu et. al., 1996), the net release may represent an aggregation of 
opposing effects mediated by both non-NMDA receptors. Further release may be a 
property of subsequently released (or leaked) glutamate, which may involve 
metabotropic receptors (Carswell et. al., 1997). Inhibition of glutamate release by 
U50,488H decreased the amount of extracellular adenosine detected by microdialysis 
after kainate administration (Carswell et. al., 1997).
Exactly how adenosine is formed is not yet entirely clear. Although the purine can be 
formed by a number of different enzymatic routes, the most common is 
dephosphorylation by ecto-5’-nucleotidase of 5’adenosine monophosphate (5’AMP). 
The enzyme is not unique to either the cytosol or the extracellular space and exists 
within membranes of glial, and the soma and axons of neuronal cells (Newby et. al.,
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1987). ATP is known to be released from nerve terminals. Release of ATP has been 
observed from some nerve fibres both in conjunction with (Burnstock, 1976), and 
independently of (Abood et. al., 1962), neurotransmitter release, implying that most 
or all of ATP release is not dependent on exocytotic mechanisms. ATP release has 
been shown to accompany neuronal depolarisation in some nerve systems, implying 
that such a release during excitotoxicity may increase extracellular adenosine 
concentrations. In contrast, in other systems (e.g. non-myelinated nerves), activity is 
coupled with intracellular indications of ATP breakdown (e.g. increases in phosphate 
levels), before the rise in the extracellular purines, with no release of ATP. While 
extracellular adenosine concentrations may be dependent on both ATP release 
followed by extracellular degradation and intracellular breakdown of ATP with 
subsequent adenosine release, evidence favours the latter as the most important 
(Fredholm & Hedqvist, 1980). While this appears to be the major route of adenosine 
formation, a small amount of adenosine may be formed by the S- 
adenosylhomocysteine hydroxylation of S-adenosylhomocysteine (Schrader et. al., 
1981) or from the breakdown of cAMP (Newman & Mcllwain, 1977).
Levels of adenosine can be controlled by both intra- and extracellularly located 
degrading enzymes, as well as adenosine transport systems. Adenosine deaminase 
(present mostly in the intracellular environment) and adenosine kinase, both 
breakdown adenosine to inosine or ATP respectively, with the kinase enzyme being 
most significant (Fredholm & Hedqvist, 1980).
There are also numerous transporter systems for adenosine, increasing adenosine 
movement to and from the extracellular space. A degree of regional variability in 
transport, systems is indicated by both a difference between distribution of
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transporters inhibited by nitrobenzyl-mercatopurine riboside (NBMPR) and 
dipyridamole in the brain (Deckert et. al., 1988), and a higher affinity for adenosine 
of neuronal uptake systems over those of glial cells (Thampy & Barnes, 1983). This, 
coupled with evidence of variable affinity and selectivity between cell types, suggests 
there is discrimination in regional uptake.
Unlike adenosine which is rapidly metabolised or taken up (plasma half life of 
approximately 1 second; Camm et. al., 1991), CGS 21680 is not broken down in the 
presence of adenosine deaminase, nor does it appear to be taken up (e.g. by blood 
cells). After an intravenous dose, CGS 21680 shows rapid clearance in an unchanged 
form (Camm et. al., 1991).
The Role o f Apoptosis W ithin Excitotoxicity
While an earlier chapter opened the discussion on the validity of the research tools 
used to establish the presence of apoptotic cells, the argument below concentrates on 
evidence directly linked to excitotoxicity. A large amount of research has linked 
kainate damage with a mechanism of apoptotic cell death (e.g. Nishiyama et. al., 
1996; Pollard et. al., 1994; Simonian et. al., 1996; Weiss et. al., 1996). After an i.p. 
dose of kainate identical to that used in our study, DNA fragmentation was observed 
after 18 hours and was apparent after 72 hours in regions that displayed kainate- 
induced damage (e.g. hippocampus; Filipkowski et. al., 1994). Using a slightly 
higher dose, Weiss et. al. (1996) observed TUNEL detectable fragmentation in the 
thalamus, amygdala, cortex and the CA1 region of the hippocampus. The staining 
remained at similar levels for at least 7 days, suggesting a long lasting, dynamic
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process. The CA3 and CA4 regions only displayed TUNEL staining if the animal 
exhibited severe seizures. Nuclear run-on assays have shown that glutamate, by 
stimulating NMDA-receptor mediated calcium influx, increases the transcription of 
IEGs (Bading et. al., 1995). Similarly, kainate induced the expression of c-fos, fns B, 
c-jun, jun  B, zif/268 and nur/77 in hippocampal culture. While this mechanism was 
believed to involve the NMDA receptors (Bading et. al., 1995), calcium influx 
through kainate-linked L-type calcium channels effects similar results in cortical and 
dentate gyrus cells (Lerea et. al., 1992). The response was biphasic, with the initial 
expression limited to highly susceptible regions such as the hippocampus and 
entorhinal cortex, before a delayed, more widespread induction (Kasof et. al., 1995a;
I Willoughby et. al., 1997).
i
Although many IEGs are believed necessary for the apoptotic pathway, it has beenj
i
| suggested that c-fos induction may be a mechanism of protection. While the majority
i
; of pyramidal cells expressed fos-lacZ, only limited numbers succumbed to
excitotoxic damage (Kasof et. al., 1995a). Further evidence comes from the 
observation that, during the delayed period of expression, almost the entire forebrain 
shows an increase in expression, even though not all of the structures undergo 
apoptosis (Willoughby et. al., 1997). The neurotrophin bFGF, which protects against 
kainate toxicity in vivo (possibly by maintaining calcium homeostasis; Lui et. al., 
1993), increased the induction of c-fos in vitro (Simpson & Morris, 1994). Evidence 
suggests that although IEGs may constitute a significant link of the apoptotic 
pathway, apoptotic cell death is determined by the pattern of IEG expression rather 
than IEG expression per se (Kasof et. al., 1995a). Cells that express c-Fos, but do
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not proceed to die by apoptosis, may therefore not be exhibiting a pattern of 
expression necessary for the initiation of apoptosis.
In our own study, i.p. kainate induced damage in both the CA1 and CA3a regions 
(from haematoxylin and eosin staining), but only induced positive staining for 
TUNEL in the CA1 region. The CA3a region remained devoid of any positively 
stained cells. This is in agreement with other studies. Wiess et. al. (1996) observed 
this phenomenon of apoptotic cells localised only to the CA1 region. The disparity 
mentioned above, where apoptosis occurred in the CA3 and CA4 regions after 
seizures, may be due to the higher dose used in that study (15 mg. kg'1). Similar 
results have been obtained in ischaemic models. Honkaniemi et. al. (1996) reported 
a high density of TUNEL-positive cells in the CA1, and a low amount in the CA3a 
(although none were obviously apparent from the photomicrographs).
From this data it is tempting to suppose that cells which contain a high density of 
kainate binding sites (such as the CA3a region of the hippocampus) undergo necrosis 
due to the rapid excitotoxicity of the compound, whereas those sites which are distal 
(CA1 and pyriform regions) succumb to apoptosis. Ankarcrona et. al. (1995) showed 
that, following glutamate exposure, an initial subset of cells lost mitochondrial 
function and died by necrosis. Cells which restored mitochondrial homeostasis 
underwent delayed apoptosis. The ability of cells to recovery shortly after glutamate 
addition and therefore the route by which cells died, was determined by the 
concentration of glutamate. Therefore, after i.p. injections, it is probable that cells of 
the CA3a region do not recover from the original kainic acid insult and die by a 
necrotic mechanism. Cells distal to the CA3a population die by both necrosis and
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apoptosis, as the percentage of TUNEL stained cells in this study was always below 
the total percentage of damaged neurones.
Brain sections which were stained for both TUNEL-positive cells and eosin, showed 
that cells of the CA1 region which were stained for TUNEL, also stained bright pink 
(indicating non-viability), whereas not all of the pink cells were TUNEL-positive. 
This suggests that the majority of distal cells appeared to follow the apoptotic 
pathway, and therefore, that in these areas kainate was not exerting a direct toxic 
effect (such as was observed in the CA3a region).
While some studies which examined neurones at the electron microscopic level after 
i.p. injection of kainate, suggested that many of the cells stained positive for TUNEL 
did not share apoptotic morphology (e.g. chromatin condensation), there still 
remained a proportion o f these cells within the population which did display 
structural apoptotic signatures (Nishiyama et. al., 1996). In contrast, an in vitro study 
did observe chromatin condensation (via the use of a DNA intercalating dye), but 
showed a lack of either protein or RNA synthesis (Simonian et. al., 1996). The latter 
observation may help to clarify how apoptosis, generally an energy requiring process, 
can occur in an ATP depleted environment.
The reliability of chromatin condensation as a marker for apoptosis has been 
questioned, as it’s presence has been observed without other ultrastructural features 
associated with apoptosis (Sun et. al., 1994). In studies of cortical cells after middle 
cerebral artery occlusion (MCAO) with NMD A injections in 7 day old rats, DNA 
fragmentation and nuclear chromatin condensation was observed alongside 
characteristics not consistent with apoptosis (such as leakage of chromatic material
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across the nuclear membrane). 24 hours after NMD A injection, there was a mixture 
of both TUNEL positive cells which did not display all of the apoptotic criteria with 
cells which appeared to die by classical apoptosis. This study highlights a major 
difference between the mechanisms of excitotoxic and ischaemic cell death. As 
excitotoxic neuronal death appears to require the binding of glutamate analogues to 
receptors which are located within specific regions, the toxicity is mediated directly 
within this region or indirectly via neuronal fibres to distal regions. Ischaemic insults 
achieve a similar mechanism of neuronal death by inducing the release of the 
excitatory amino acid itself, but also restrict blood flow through a proportion of the 
brain. It is therefore possible that while both excitotoxic and ischaemic insults 
initiate a similar sequence of events (inducing apoptosis at distal sites), in ischaemic 
models, the extra complication of reduced blood flow ensures that the majority of 
cells do not complete the apoptotic cell death cycle, but are overtaken by necrotic 
mechanisms. Even within excitotoxic cell death there are three apparent subclasses. 
The first are those cells which stain bright pink for eosin, indicating cell death, but do 
not stain for TUNEL; these cells presumably died by necrosis. The second are cells 
which stain positive for TUNEL, but do not show all the characteristics necessary for 
apoptotic cell death. These may be neurones where necrosis has overtaken an 
initiated program of apoptosis. The last are cells where all the criteria of apoptosis 
are met.
In contrast to our systemic results, central injections of kainate induced TUNEL- 
positive staining throughout the CA3a region. In agreement with the lack of any 
distal damage, no other area was found to contain cells that stained by the TUNEL 
method. The obvious reason for apparent apoptotic damage in a region where only
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necrotic damage was observed after i.p. injections, was that the dose was such that 
cells were not compromised by the initial excitotoxic insult, recovering before 
undergoing apoptosis. Similar results were observed after kainate was injected at a 
higher dose (1.2 pg in 0.3 pi) into the amygdala, although in this case the CA3 
damage is distal to the injection site (Pollard et. a l,  1994). Apoptosis (measured by 
staining and morphological techniques) also occurred in the amygdala, in the 
presence or absence (after diazepam treatment) of damage to the CA3. Kainate can 
therefore initiate local (i.e. non-distal) apoptotic cell death. As this study used higher 
doses than our own, the difference in mechanism may not, therefore, be related to 
differences in central concentrations.
Another possibility may be the route of administration. A peripheral injection of 
kainate, due to the time taken to penetrate the brain, may therefore induction 
mechanisms that are not initiated by central injections. One of these mechanisms 
may be the inflammatory response. Due to the more gradual build up of peripherally 
over centrally administered kainate, cells of the inflammatory response could be 
stimulated by stressed cells before the extracellular levels of kainate reach toxic 
levels. The presence of the inflammatory mediators may then induce necrosis in a 
proportion of cells (e.g. those already stressed), but protect the remainder. After i.h. 
injections the levels of kainate within the hippocampus are immediately high. 
Without the presence of any immediate inflammatory response, cells recover from 
the initial insult, but subsequently undergo apoptosis. This may also explain why 
even after a high systemic dose of kainate, a population of approximately 40 % of the 
cells in the CA3a survived (Strain et. a l,  1991), while after i.h. administration nearly 
100 % succumbed to excitotoxicity.
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Our study also showed that the mechanism of protection observed with the i.p. 
administered adenosine compounds, did not selectively inhibit either necrotic or 
apoptotic cell death. No unexpected increase or decrease in TUNEL staining was 
evident. In the CA1 region of animals given an i.p. injection of kainate, the degree of 
apoptosis correlated with damage such that there was always a high proportion of 
TUNEL staining in cells where damage was observed. In conjunction with the 
experiments with kainate alone, no drug administered, induced TUNEL staining 
within the CA3a region. This is entirely consistent with the proposed mechanism of 
action for protection by either A2A or Ai agonists, which suggests that protection is 
mediated at a point much earlier along the neurodegenerative pathway, before cells 
have undergone necrosis. Ankarcrona et. al. (1995) suggested that apoptosis only 
occurs after a population of cells, which failed to recover mitochondrial integrity, 
underwent necrosis. If the mechanisms of protection with any of the above 
compounds involved mediating against this delayed apoptosis, we would expect to 
observe a high degree of damage without the presence of apoptotic cells.
The introduction of antagonists revealed a slight discrepancy in this relationship 
between apoptosis and necrosis. In i.p. experiments, the slight induction of apoptosis 
in the CA3a after the administration of ZM 241385 or 8-PST, suggests that inhibition 
of the A2A receptor may increase apoptosis. That both antagonists have a similar 
effect suggests that it is not mediated by hippocampal A2A receptors. Speculatively, 
the antagonists may increase apoptosis by preventing the A2A-mediated induction of 
the inflammatory response. As discussed more fully below, the inflammatory 
response may increase necrosis while preventing apoptosis. Any inhibition o f this
Discussion
response may therefore increase the proportion of apoptotic cells within the non- 
viable cell population.
This increase in apoptosis is not observed after the injection of ZM 241385 in the 
intrahippocampal model. This may be due to the lack of involvement of the 
inflammatory response in this regimen. That there is a complete absence of apoptosis 
in the CA3a region after co-injection of ZM 241385 with kainate, is suggestive of a 
role for the A2A receptor in the promotion of apoptosis.
The A2A receptor may therefore play an important role in determining the pathway by 
which certain populations die during kainate-induced excitotoxicity, although this 
role may be dependent on experimental conditions.
The Role o f Growth Factors
The role of growth factors is both diverse and not yet fully understood. As the 
hippocampus itself contains the highest central mRNA levels of NGF, BDNF, NT-3 
and NT-4/5, it does not seem much of a presupposition to assume that the family of 
neurotrophic factors exerts some effects during periods of neuronal insult. Many of 
the neurotrophins appear to be protective in various models of cerebral damage 
(Boniece & Wagner, 1995; Cuevas et. al., 1994; Kromer, 1987; Lui et. al., 1993b; 
Pringle et. al., 1996).
Levels of BDNF mRNA increase after kainate administration (Guilhem et. al., 1996; 
Rudge et. al., 1995; Suzuki et. al., 1995; Zafra et. al., 1990), with peaks shortly after 
i.h. kainate administration and after 7 and 60 days. The highest peak was that of 7
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days which reached levels of -270% of control (Suzuki et. al., 1995). The increase 
in mRNA is apparent in all regions of the hippocampus, with the most dense levels in 
the dentate gyrus. The possible protective mechanisms of BDNF may explain why 
the dentate gyrus is less sensitive to the excitotoxicity of kainate, although whether 
BDNF is protective is still in debate. Amongst the reports of protection by BDNF 
(Beck et. al., 1994; Lindholm et. al., 1993; Schabitz et. al., 1997) are a few that 
disagree with these observations (Koh et. a l, 1995; Fernandez-Sanchez & Novelli, 
1993). Glutamate neurotoxicity was enhanced in the presence of BDNF in cerebellar 
neuronal cultures (Koh et. al., 1995). This enhancement is believed to be mediated 
through the NMDA glutamate receptor. Koh et. al. (1995), speculated that the 
detrimental effects of BDNF are constrained to necrotic cell death, with the 
protective potential reserved for cells following the apoptotic pathway of neuronal 
death. As many of the effects mediated by BDNF and other neurotrophins are 
regulated in the embryonic and neonatal developing stages, it would not be surprising 
if the protective effects were directed mainly against the apoptotic process.
BDNF and other neurotrophic proteins are expressed in both neurones and glia 
(Rudge et. a l,  1995; Korsching, 1993). Under normal conditions in co-cultures of 
hippocampal neurones and astrocytes, only the neurones appear to be responsible for 
mediating the levels of BDNF. Upon application of kainate, the protein levels of 
BDNF dramatically increased, in both neurones and reactive astrocytes peaking at a 
level 2-3 fold larger at 18 hours (Rudge et. al., 1995). While this increase 
corresponded with mRNA levels, the experiment did not proceed beyond 3 days. 
Therefore the possibility of further peaks at 7 or 60 days was not investigated. As 
BDNF may mediate detrimental or protective effects on cells depending on the
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mechanism of cell death (whether necrotic or apoptotic), this increase in BDNF 
protein levels in astrocytes after activation by kainate, may explain the differences in 
CA3a damage between i.h. and i.p. administered kainate. Following i.p. 
administered kainate, the activated inflammatory response and resultant increase in 
BDNF protein could exacerbate necrotic damage while preventing delayed apoptotic 
neuronal death. After central administration of kainate, BDNF may not be an 
important factor in determining the outcome of cells. This speculated absence of 
interference of BDNF after i.h. kainate may be due to a lack of coincidence in the 
onset of damage with induction of BDNF. Alternatively, due to the limited sphere of 
influence of central (as compared with peripheral) injections, the inflammatory 
response may be more limited than after i.p. injections. Any such decrease in 
neurotrophic influence on excitotoxic cells after centrally administered kainate, may 
result in a decrease in the number of neurones recovering from the early excitotoxic 
shock, but exaggerate the population undergoing apoptosis.
Highlighting the difference in time taken to induce either BDNF protein or mRNA, 
intrahippocampal injection of kainate does not show an induction of BDNF mRNA 
until 7 hours after the injection (Ballarin et. al., 1991). After i.p. injections, kainate 
induced the expression of BDNF mRNA after only 1 hour (3-4 fold), peaking at 3 
hours (9-10 fold ; Lee et. al., 1997). From this, it appears that local injections of 
kainate may not induce the inflammatory response in the same manner as systemic 
administration. BDNF induction by i.h. kainate injection (mostly from a neuronal, 
not inflammatory source) does not therefore, appear before the onset of damage. 
After i.p. kainate, a coincidence of damage and BDNF mRNA increase occurs.
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Systemic administration, due to a more extensive diffusion, has the opportunity to 
induce a much larger inflammatory response.
The time dependence of BDNF protection was highlighted in a hippocampal slice 
model of ischaemia (Pringle et. al., 1996). Pre-incubation of cultures with BDNF 
protected the CA1 and CA3 pyramidal cells of the hippocampus, whereas addition of 
BDNF after the insult did not. In the study by Pringle and co-workers (1996) study, 
significant protection of CA3 neurones was achieved at a lower dose than that 
required for neurones in the CA1 region. Even so, at the dose required to 
significantly protect the CA3 region there was a decrease in percentage damage from 
-34 % to -10  %. In the CA1 region the same dose decreased damage from - 6 8  % to 
-42 %. Therefore in both regions -25 % of neurones were protected. This may 
imply that a similar subset of cells were protected in each region. Without 
examination of the mechanism of cell death (apoptotic or necrotic), it is impossible to 
tell if BDNF is selectively protecting against one mechanism over the other.
Basal levels of BDNF mRNA in vivo, were almost 3 - fold greater in the CA3 than in 
CA1 region (Kokaia et. al., 1996). After ischaemia an increase in the CA3 region to 
a 3-fold control levels was observed after 2 hours, coupled with a 131 % increase in 
protein after 7 days. In contrast, the CA1 region displayed no transient increase in 
mRNA, but displayed a 25 % reduction in protein levels after 24 hours. The 
difference in mechanism of cellular death in the CA3 and CA1 region may therefore 
be due to a difference in level of BDNF protein and/or mRNA expression. In the 
CA3 region, the higher level may induce necrosis, but restrict apoptotic death. In the 
CA1 area, the level may not be enough to influence necrosis, nor to prevent 
apoptosis.
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Our own immunohistochemical studies with kainate suggest that after 7 days, the 
only cells that stained for the presence of BDNF protein were neuronal, with very 
little, if any cells of the inflammatory response apparent. This is the case after either 
centrally or systemically administered kainate. This would imply that after 7 days 
any increase of BDNF is from a neuronal source. In i.h. experiments, this correlates 
with the study above (Ballarin et. al., 1991), with no role for inflammatory response- 
mediated increase in BDNF. After i.p. injections, this similarly suggests that BDNF 
protein is increased after 7 days exclusively in neurones. The initial increase in 
mRNA after i.p. kainate (Lee et. al., 1997) is unlikely to be due to the hippocampal 
neurones, as no such increase was observed at a similar time point (1  hour) after i.h. 
kainate (Ballarin et. al., 1991). The early response to i.p. kainate may therefore be 
due to inflammatory cell increases. By day 7, any inflammatory mediated effects on 
BDNF protein levels have disappeared, leaving a neuronal response.
There appeared to be no direct correlation between damage and extent of BDNF 
protein after 7 days. Due to any sustained levels in BDNF probably being concerned 
with long-term maintenance, and not a defence against acute toxicity, 7 days after the 
initial insult may be too late to determine any direct relationship.
Evidence from Rudge et. al. (1995) suggests that the degree of upregulation of BDNF 
protein may not be enough to mediate protection/degradation as there is no evidence 
of the phosphorylation of the TrkB receptor necessary for signal transduction. 
Similarly, from in vivo experiments, there was no apparent correlation between 
BDNF mRNA and that encoding the full-length TrkB receptor protein (Falkenberg 
et. al., 1996) after the central administration of the non-NMDA receptor agonist 
quisqualate. There was however, a correlation observed between BDNF mRNA and
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components of the TrkB receptor (e.g. a 145-kDa glycoprotien, gpl45trkB). Due to 
gene splicing and the resultant variation of receptors (two different classes of 
receptors made from at least eight different transcripts; Barbacid et. al., 1994), a lack 
of correlation between BDNF and full-length TrkB mRNA expression is not 
surprising. BDNF itself may not have to act on the TrkB receptor, as while 
neurotrophins have a receptor to which they most commonly bind, there is evidence 
suggesting that this relationship is not exclusive (Korsching, 1993). This diversity 
amongst binding sites may account for the suggested opposing roles of neurotrophic 
factors under different experimental conditions. Due to the interrelationships 
between growth factors (e.g. BDNF mRNA stimulation by FGF; Kwon, 1997), it is 
probable that both the protective and detrimental effects of the neurotrophic factors 
are mediated through a complex mechanism involving a number of different 
receptors and receptor subtypes.
From our experiments the adenosine compounds may have an effect on the kainate- 
induced increase in BDNF protein expression at 7 days. In our i.p. studies, the A2A 
antagonist ZM 241385 appeared to increase the levels of expression. This is 
noticeable when given with CGS 21680, but is more startling when given alone, 
before kainate. In contrast R-PIA did not show any increase in BDNF protein at 7 
days, even in damaged hippocampi, while BDNF protein was apparent in CGS 21680 
injected animals that were damaged. After i.h. administration, kainate alone showed 
a high degree of BDNF expression. Co-injection of kainic acid with CGS 21680, 
ZM 241385 or adenosine resulted in the inhibition of this BDNF induction, even 
when damage was comparable. Co-administration of kainate with R-PIA did show
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BDNF protein levels comparable to those after kainate alone in hippocampi that were 
severely damaged.
The response of neurones at day 7 may very well depend on a number of other 
influences in the period after the initial insult. Different effects of the adenosine 
compounds on effector systems (such as the inflammatory response) early during 
excitotoxicity may affect how neurones behave subsequently. For instance, 
differences in levels after i.p. R-PIA and ZM 241385 (both of which should directly 
or indirectly activate Ai receptors), may be due to effects on different populations of 
receptors. For example, the increase in BDNF after ZM 241385 may be due more to 
inhibition of A2 effects on the inflammatory response than allowing the activation of 
A| receptors. Without the interference of the inflammatory response (e.g. after i.h. 
injections), the effects on the neuronal increase in BDNF by the adenosine 
compounds may alter, with either inhibition or stimulation of the A2A receptor 
decreasing BDNF levels. While the interactions between adenosine receptors and 
BDNF levels results in a complex relationship, BDNF levels at 7 days appear to have 
no effect on the outcome of the neuronal population. This is shown by a lack of 
correlation between protection/degradation and day 7 protein levels. Therefore these 
increases may be more relevant to the longer-term repair and maintenance of the 
hippocampus.
The Dual Role o f Nitric Oxide
Nitric oxide has been shown to occupy a double edged role, both to attenuate or 
exacerbate excitotoxic damage. Kainate, via an interaction with the kainate receptor,
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stimulates NO production (Balcioglu & Mather, 1993, Garthwaite et. a l , 1989). This 
release may be further exacerbated by a similar reported action for the NMDA 
receptor (East & Garthwaite, 1991; Faraci & Brian, 1995). An increase in diameter 
of cerebral arterioles is also apparent, although only after topical exposure of the 
blood vessels to 100 pM kainate for 3 minutes (Faraci et. al., 1994). This neuronal 
NO production was inhibited by the addition of nitric oxide synthase-inhibitors 
(NOS-I). In our study two NOS-Is were administered systemically 10 minutes prior 
to kainate. L-NAME is a general NOS inhibitor, while 7-NI is specific for the 
neuronal subtype (i.e. does not prevent the actions of eNOS which include cerebral 
vessel dilatation; Faraci & Brian, 1995). In both cases marked protection against 
kainate-induced excitotoxicity was observed. This suggests that the effects mediated 
by NO are more harmful than protective in this model, which is in agreement with a 
large number of other studies (see Introduction). L-NAME at 20 mg. kg' 1 inhibits 
almost 50 % of NOS activity (Iadecola et. al., 1993). Our experiments observed 
protection at a quarter of this lower dose, suggesting that even limiting a small 
proportion of NO production is highly protective.
As free radical-associated cell death is considered important in excitotoxicity, the 
prevention of the conversion of NO to toxic metabolites (ONOO’ and *OH), may 
represent the most important mechanism by which NOS-Is protect against cerebral 
insults. As well as decreasing free radical production, NOS inhibition by L-NAME 
has also been shown to decrease the extracellular glutamate concentration during 
seizures after a systemic injection of 10 mg. kg' 1 kainate (Rigaud-Monet et. al., 
1995). This was presumably by the prevention of the presynaptic augmentation of 
glutamate release by postsynaptically released NO (O’Dell et. al., 1991; Lawrence &
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Jarrott, 1993; Sergovia et. al., 1994). The inhibition by L-NAME of the NO-induced 
inhibition of glutamate uptake may also account for a proportion of the reduction in 
extracellular glutamate levels (Pogun et. al., 1994).
While the above mechanisms of the NOS inhibitors may confer protection, the role 
of NO in glutamate release is probably more complex. Other evidence suggests that 
NO mediates an inhibition of the NMDA receptor, limiting the activity of the 
glutamate analogue (Manzoni et. al., 1992). While NO may have different actions on 
the various glutamate receptors, it is more likely that NO has a conflicting role that is 
dependent on environmental conditions. Both the functional state of the receptor and 
the local glutamate concentration have been implicated (Rundfelt et. al., 1995). 
While of possible importance in seizure related activity, the mediation of glutamate 
release by NO may not be of significance in enhancing neurotoxicity. Overall, the 
beneficial effects of NOS inhibition on the compromised brain appear to overcome 
any possible detrimental actions.
The dose of NOS-I appears to be important in determining the outcome of 
compromised neurones (Rundfelt et. al., 1995). Low doses of NOS-I exert a 
protection against cerebral insults, which was not apparent (or was even reversed), 
when administered at higher levels (Carreau et. al., 1994; Shapira et. al., 1994). 
While the dual role of NO on glutamate release may account for this effect (i.e. at 
higher doses NOS-Is prevent the NO-mediated inhibition of the NMDA receptor), 
this is unlikely, as low doses L-NAME enhance NMDA convulsive activity (Buisson 
et. al., 1993). Low concentrations of the NOS-I have also been shown to increase 
extracellular glutamate levels in vivo (and enhance NMDA-mediated release), but 
again at a higher concentration, this effect was not observed (Segieth et. al., 1995).
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As modulation of glutamate does not appear to correlate with damage, it is unlikely 
to contribute to excitotoxic insults. The increase in damage by.high doses of NOS-I 
is probably due to the inhibition of blood vessels .
Within an ischaemic model, the time course of nNOS mRNA expression has been 
correlated with neuronal damage in vivo, although NOS containing neurones 
appeared to be slightly more resistant to degeneration themselves (Zhang et. al., 
1994b). This may be accounted for by the ability of nitric oxide to upregulate 
intracellular antioxidant systems (e.g. glutathione; Nicotera et. al., 1997), whereas 
conversion in the extracellular space to toxic oxygen radicals initiates the injurious 
pathway.
CONCLUSIONS
This study has investigated the mechanism of both kainate-induced excitotoxicity and 
protection mediated by a number of compounds. Evidence from both our 
experiments and other studies suggest that kainate toxicity is not dependent on the 
kainate receptor, but relies on activation of AMPA, NMDA receptors and leakage of 
glutamate across the plasma membrane. We observed an improvement in neuronal 
survival after kainate-induced excitotoxicity following the administration of A2A 
agonist. Further investigation suggested that this protection was mediated from the 
periphery, and not by A2A receptors localised to the hippocampus. Results with the 
A2A antagonist ZM 241385, provided more evidence for an inhibitory action of the 
A2A receptor on the Ai receptor. Importantly, these results suggest that adenosine, 
released endogenously during the cerebral insult, does not protect the pyramidal cells 
of the hippocampus.
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The role of nitric oxide within this model was examined and although NO has a 
variety of diverse functions, it was shown that inhibition of a small proportion of NO 
synthesis prevented a large percentage of neuronal cell death.
The role of both necrotic and apoptotic cell death in excitotoxicity was investigated. 
Apoptosis was limited to discrete regions of the hippocampus and displayed different 
patterns of expression dependent on the route of administration. A link between the 
outcome of cells and the inflammatory response (with particular emphasis on BDNF) 
has also been postulated.
While the above study focuses on a whole animal model, an attempt was made to 
correlate this with data obtained from hippocampal studies (see Appendix I). This 
would have helped to provide further information on the exact mechanism of CGS 
21680 protection as well as clarify the relationship between the A2A and Aj adenosine 
receptors without the complexity of in vivo interactions. Much more work needs to 
be focused on the role of the inflammatory response and in particular growth factors 
in excitotoxicity. While it is clear that some neurotrophins mediate protection, our 
study shows that BDNF may occupy different roles dependent on the situation (and 
therefore on the model used). A multiple approach (combining both in vitro and in 
vivo techniques) would therefore benefit our understanding. Other in vitro studies 
(such as electrophysiology) would also define the interaction between the two 
adenosine receptor subtypes, Ai and A2A. Clinically, if adenosine compounds are to 
be used to alleviate the cerebral damage associated with excitotoxicity, then the 
importance of this interaction cannot be overlooked.
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APPENDIX I
DISSOCIATED HIPPOCAMPAL CULTURE
Hippocampal cell culture has been used widely to elucidate a number of different 
areas in various fields of science. This scope extends from examining the effects of 
free radical scavengers on hypoxic cultures (Rosenbaum et al., 1994), to 
electrophysiological recordings of ion currents (Wann et al., 1994; Garcia et al., 
1994), as well as numerous investigations into neurite growth (Brinton, 1994; 
Femaud-Espinosa, et al., 1994; Kobayashi et al., 1994).
This frequent use o f the hippocampus is deliberate and due to both specific reasons 
such as its capacity for activity-dependent changes in synaptic function (e.g. long­
term potentiation; Bliss & Collingridge, 1993), its importance in epileptic activity, as 
well as less-specific influences. These latter incentives include the hippocampus as a 
source of a relatively homogeneous neuronal population (pyramidal neurones are 
prevalent at 80-95%), which is representative of the CNS in general (Banker and 
Goslin, 1991) and its presentation of a clear defined boundary in developed embryos, 
allowing relatively easy dissection. Due to the homologous cell population, 
hippocampal cell culture provides an opportunity to examine drug effects/interactions 
on pyramidal cells without the complications of influence from either afferent input 
from other cerebral regions or different cell types (e.g. glial cells or cells of the 
inflammatory response).
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Early in this study it was decided to use hippocampal cell culture in conjunction with 
the in vivo experiments to provide a broader interpretation of the events during 
kainate-induced excitotoxicity and to elucidate mechanisms by which the adenosine 
compounds may be exerting their effects. Extensive research and experimentation 
into setting up the technique, which was novel to our laboratory, led to progress in 
establishing hippocampal neuronal cultures. Unfortunately, the cultures were to 
prove only partially successful, with inconsistent hippocampal cell survival under 
apparently identical situations. With this lack of reproducibility after nine months of 
experiments, we moved away from the in vitro approach, concentrating on the 
histological in vivo studies. The chapter below highlights problems with culture 
systems, not least the huge array of different methods used, and discusses changes 
made to our original protocol.
To establish hippocampal cultures, tissue from late foetal (E l5-18) or early neonatal 
(Dl-3) rat brains (or equivalent times for mice) are most commonly used. This 
provides the advantages of neurones being much less susceptible to damage due to 
the absence of a complicated system of axons and dendrites in the immature brain 
and a lower reliance of the neurones on innervation from other cell populations. In 
our research we used brains from both late embryonic (E l4-15) and postnatal day 1 
mice. We found that while hippocampal tissue was easier to remove from neonatal 
animals (due to a much greater size of the animal), more cultures tended to grow 
from tissue obtained from foetal animals. Unfortunately in foetal animals the small 
size of the hippocampal structure made dissection without any surrounding tissue 
more difficult. This was compounded by the use of mice rather than rats of the same 
relative age. To overcome this, dissection erred on the side of caution (i.e. removing
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all non-hippocampal tissue at the possible expense of some of the hippocampus 
itself).
In most studies the method of dissection of the hippocampal tissue from embryonic 
or neonatal brain is similar, utilising previously established methods (Lochter et al., 
1991; Banker & Cowan, 1977; Segal, 1983). In our study, pregnant CBA mice were 
killed by CO2 asphyxiation followed by cervical dislocation. Embryo sacs were 
removed and placed in a large petri-dish of Hank balanced salt solution (HBSS, a 
solution of inorganic salts, glucose and phenol red; Life Technologies Ltd.). The 
embryos were then separated from the membranous pouch, before the head was 
removed and placed into a small petri-dish of HBSS. Using sterile needles and 
forceps the skin covering the head was reflected. Under a microscope the skull was 
broken open and teased apart exposing the brain, which was subsequently removed 
and placed into another small petri-dish of HBSS. The brain was then bisected into 
two cerebral hemispheres. The easily discernible hippocampus was gently teased out 
using syringe needles. The hippocampi from 6-12 animals were placed into fresh 
sterile HBSS. The above operation was performed in an open sterile cabinet to allow 
the use of the microscope. The tissue at this point was transferred to a tissue culture 
flow hood.
Major differences in methodology appear after the hippocampus has been removed 
from the surrounding brain. Dissociation and breakdown of the hippocampus is 
usually achieved by the addition of trypsin to the tissue although some methods 
require only mechanical breakdown (Garcia et al., 1994; Brinton, 1994). The 
concentration of trypsin used varies from between 0.08 % (Kieth et al., 1994; Louis
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et al., 1993) to 0.25 % (Brinton, 1994; Lochter et al., 1994; Kleiman et al., 1994). 
DNase (0.01-0.07 %) is often added to hydrolyse any released DNA and prevent its 
agglutination (Kobayashi et al., 1994; Lochter et al., 1994).
In our own study the hippocampi were diced using sterile needles before transfer, 
with as little of the surrounding HBSS as possible, to a sterile test tube, where the 
tissues were allowed to settle in fresh buffer. The buffer was replaced to wash the 
tissue further, before the tissue was transferred to a sterile pre-warmed test tube of 1 
ml 0.25 % trypsin + EDTA (Life Technologies Ltd.) and incubated at 37 °C. 
Originally the time allowed for the trypsin to remove membrane proteins was 15 
minutes. To reduce stress on the cells, this was reduced in later experiments to 10 
minutes. The trypsin reaction was inactivated by the addition of 1 ml foetal calf 
serum (FCS), followed by light centrifugation (500g for 3 minutes). Originally cells 
were centrifuged at 1 0 0 0  rpm, but to limit any damage or trauma to the cells this was 
reduced. The supernatant was removed and cells were washed twice in Dulbecco’s 
modified minimum Eagle’s medium (DMEM, a concoction of compounds similar to 
HBSS, but with a number of additions, including a variety of amino acids and 
vitamins; Life Technologies). Cells were titrurated through a heat narrowed Pasteur 
pipette and resuspended in fresh media for plating.
Where many laboratories appear to differ is in the formulation of the culturing 
medium. Some papers rely on a straight forward medium with only a few 
supplements while others add numerous compounds to already complex media. 
There is little correlation between the complexity of culturing media and the type of 
experiment or length of culturing. The only apparent exception is that short term
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cultures (0-2 days) often use Ham's F12 media (similar to DMEM with both essential 
and non-essential amino-acids, a wide array of vitamins, minerals and metabolites) in 
conjunction with MEM (which contains only 13 essential amino acids and 8  
vitamins) or DMEM (Lochter et al., 1994; Brinton, 1994), whereas long term 
cultures (> 2 days) tend to utilise MEM or DMEM only (Rosenbaum et al., 1994; 
Garcia et al., 1994).
Basal medium is not usually sufficient for cell growth and survival, but requires 
further enrichment. These supplements are often provided by a serum, the most 
widely used being FCS or horse serum. FCS is generally believed to enhance glial 
cell growth while horse serum promotes neurone growth (Banker & Goslin, 1991). 
This belief is not definitive as while some investigators use horse serum alone to 
culture hippocampal neurones (Garcia et al., 1994; Whitty et al., 1993), others use 
only FCS (Rosenbaum et al., 1994; Brinton, 1994; Wann et al., 1994), while a 
further contingent uses both (Louis et al., 1993).
There are disadvantages with serum in that no two batches are identical and the 
actual concentrations of nutrients and growth factors are unknown. This latter point 
has numerous consequences in that certain constituents within the serum may interact 
with the process under investigation. In 1979 Bottenstein and Satto first grew cells in 
a serum-free supplement medium (N2 supplement). Neuronal cultures have since 
been maintained in serum-free environments (Lochter et al., 1994; Kleiman et al., 
1994; Kobayashi et al., 1994), and in some instances the N2 serum free supplement 
has been used in conjunction with serum (Louis et al., 1993).
165
Appendix I
The most common antibiotic added to the medium is a mixture of penicillin (25-100 
U. ml"1) and streptomycin (25-100 pg. ml"1; Whitty et al., 1993; Okamoto et al., 
1994; Brinton, 1994). Gentamycin (10-100 pg. m l'1) gives a broader protection and 
is often used against low levels of contamination after neuronal plating (Banker & 
Goslin. 1991).
The media we used to culture the neurones was DMEM + 10 % FCS, with 
gentamycin added at a final concentration of 0.1 mg. m l'1. Due to problems with cell 
growth, the addition of gentamycin was superseded by penicillin/streptomycin (at
! 100 U. ml' 1 and 100 pg. ml' 1 respectively). In an attempt to further remove
j contamination, some experiments utilised a concentration of penicillin/streptomycin
|
| 2.5 times greater in the media used to wash the cells before plating.
I
i
I| Our protocol was also modified in respect of the FCS or penicillin/streptomycin
I
! content of the culturing medium. in some experiments FCS or
penicillin/streptomycin concentrations were doubled, either independently or within 
the same protocol. Ultraser G (a serum substitute: Life Technologies Ltd.) was also 
used in place of FCS at 2 %. None of the changes appeared to increase the reliability 
of the cultures. In experiments where the antibiotic content was increased, less 
cultures were successful. The serum substitute seemed no more reliable than FCS.
An area where there appears to be more conformity is in the coating of the culture 
plates to entice the neurones to adhere. Most protocols use poly-lysine (Brinton, 
1994; Kleiman et al., 1994; Tan et al., 1994) in varying concentrations (10 pg. ml' 1 
to 0.1 mg. ml’1). There are, of course, some modifications of this with other
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protocols preferring polyethylene (Okamoto et al., 1994) or a mixture of poly­
ornithine and laminin (Louis et al., 1993). Although the L-isomers of these amino 
acids are usually used, the D-isomers are sometimes favoured due to resilience 
against protease breakdown.
Plating density was altered throughout our experiments to attempt to achieve an 
optimum density. The density of the cultured cells should be low enough to prevent 
overcrowding and allow unrestricted growth, but not too low as this appears to be 
detrimental. 15,000 viable cells, ml' 1 of medium was the routine plating density used
; (0.8 ml added to a well of 13 mm diameter), although experiments were also
performed with half or double of this. Cell density was calculated by incubating a
I
| volume of cell suspension in 0.1 % trypan blue at 37 °C. A hoemocytometer was
Ii
| used to count the viable cell population and density before plating. Banker and
Cowan (1977) have found that the plating density was crucial to cell survival and that|
ij  ^ t
| a narrow range of 15,000 - 20,000 cells, cm was optimal. Our own limited
i
experience tended to agree with this. Cells were left in an incubator under conditions 
of 95% O2, 5% CO2 and high humidity.
One method not discussed here is the use of glial feeder layers in the culture dish 
over which the neurones are grown. This is because while the neurones may grow 
better, the glial layer introduces more variation into the experiment. The downside of 
not using feeder layers according to Banker and Goslin (1991) is that neuronal cells 
can only survive for a few days without the presence of glial cells. There is 
conflicting evidence for this throughout the literature, as, although many protocols 
allow the glial cells to propagate alongside the neurones for up to five days before
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halting their proliferation with the addition of cytosine arabinoside for 24 hours 
(Kleiman et al., 1994; Rosenbaum et al., 1994; Garcia et al., 1994), others add the 
anti-mitotic agent after only 24 hours (Tan et al., 1994). In both cases, neurones 
continue to grow after the removal of glial cells. Other studies allow the proliferation 
of glia alongside neuronal cells by not adding any agent to prevent glial growth 
(Kobayashi et al., 1994; Keith et al., 1994).
In our own experiments the substrata we used were covered in 5 or 10 pg. ml' 1 poly- 
D-lysine and left for a minimum period of 1 week before use. The solution was 
removed and allowed to dry. One area within our own experiments where we 
introduced great variety was in the plating density of the cultured cells.
We used Ara-C at a variety of concentration to determine the optimum which would 
inhibit glial growth. Ara-C was added after 24 hours to give final concentrations of 
0, 0.25 pM, 0.625 pM or 6.25 pM. In agreement with other studies which have 
found Ara-C toxic at higher doses (Orr & Smith, 1988; Wallace & Johnson, 1989), 
cultures given the uppermost concentration showed some inhibition of neuronal 
growth. At the other extreme, cultures where Ara-C was not added did not usually 
display pyramidal cell growth, although glial cells did proliferate.
Cells were left in an incubator under conditions of 95% O2 , 5% CO2 and high 
humidity.
Figures 53-58 show photomicrographs from hippocampal cultures between 6  hours 
and 48 hours after initial plating. These photomicrographs, taken down a light 
microscope, show a number of healthy neuronal cells present at all time points.
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What is apparent is that as time proceeds the amount of cellular debris increases. 
This was usually more obvious after the addition of AraC (24 hours). While most of 
the pyramidal cells appear spherical at the early (6 hour) time point, their more 
traditional ‘pyramid’ shape is obtained by 24 hours. Processes appear between 6 and 
24 hours, with very few neurite outgrowths before this (see arrow in fig. 2). 
Prominent growth cones can been seen after 24 hours (see arrows in fig. 3). At 48 
hours the origins of a neuronal network can been seen.
While a number of cultures did survive for a period of time, the inconsistency in 
maintaining hippocampal neurones proved such that obtaining meaningful results 
would not have been feasible. The study did provide a protocol to reduce this 
inconsistency, although only with limited success. Due to the seemingly 
inexhaustible number of alternate techniques, including feeder layers and co-cultures, 
and it is quite possible that it is this direction which may provide more dependable 
hippocampal cultures.
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Fig. 56 Hippocam pal cell culture 6 hours after plating. The photomicrograph is taken using phase  
contrast m icroscopy.  W hile  most ce l ls  have a sphere-like shape, so m e  (see  arrows) are  
already d e ve lop in g  processes.  Culture tissue was taken from the optimal experimental  
conditions .  2 0  mm : 30 pm.
Fig. 57 H ippocam pal culture at 6 hours. A s  above , short processes  are vis ible  (arrows).
Photomicrograph again taken from an optimal experiment (plating density o f  15000 cei ls .  
m l'1). 20  mm : 15 pm.
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Fig. 5 8 Hippocam pal cells,  1 day in vitro. 24  hours after initial plating, the more characteristic  
shape o f  the pyramidal cell  perikaryon is apparent. Num erous processes are also obvious,  as 
are growth c o n es  at the tips o f  som e outgrowths (see  arrows). 20  m m  : 15 pm.
Fig. 5 9 2 day hippocampal culture. A neuronal network is appearing with many more processes  than
after 24  hours. An increase in cellular debris is also observable.  S o m e  ce l ls  which have not 
altered from their original spherical shape, nor emitted processes are still present (arrows).  
20  m m  : 30  pm.
171
H ippocam pal culture after 48  hours. The intricate network is more apparent at this slightly  
higher magnification. 20  mm : 15 pm.
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